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Recent three decades have seen a significant progress in the protein engineering field. 
Protein engineering has not only facilitated our understanding of the sequence-structure-
function relationship of proteins, but also yielded numerous invaluable new proteins or 
protein variants for research, medical and industrial applications. The success of protein 
engineering largely relies on the ability to diversify protein sequence. Protein sequence 
diversification is usually achieved by directed or random mutagenesis technologies. This 
dissertation discusses two non-canonical protein sequence diversification techniques—
transposon mutagenesis and unnatural amino acid (UAA) mutagenesis. 
Transposon mutagenesis is based on an in vitro transposition reaction, where a 
transposon DNA randomly inserts into the gene encoding the protein of interest. Removal 
of the transposon sequence followed by subsequent manipulation generates desired 
  
mutations. By engineering transposon DNA sequence and subsequent procedures, 
random “codon” deletions and substitutions can be introduced into random positions of a 
protein sequence. This dissertation describes how this technology can be applied to 
determine the minimal domain required for the fluorescence of green fluorescent protein 
(GFP) and improve the spectral properties of GFP. 
In UAA mutagenesis, orthogonal aminoacyl tRNA and aminoacyl tRNA synthetase 
(aaRS) pairs are employed to reassign an amber stop codon (TAG) with an UAA. This 
dissertation describes how this technology can facilitate both enzymatic and 
nonenzymatic approaches to synthesize polyubiquitin chains. 
Besides, two ongoing projects are introduced in the Appendices. The first project 
describes how UAA mutagenesis technology can be potentially used to genetically 
encode a thiotyrosine in a protein sequence, which can serve as a comparison probe. The 
second project intends to develop a rapid in vitro methodology to expand the functions of 
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Chapter 1: Introduction 
1.1  Directed Evolution: Evolving Biomolecules by Mimicking Natural Evolution 
Staunch Darwinists attribute the complexity of living creatures to the natural algorithm of 
evolution—mutation and selection. Central to natural evolution is the concept of 
“fitness”—a species’ ability to survive selection and reproduce itself in a given 
environment. Fitter species have larger chance to survive and propagate their “biological 
traits” to the whole population. Billions of years of natural evolution has eventually 
created a world of “the fitter ones” at all scale, from ecosystems down to single 
biomolecules. However, the journey of evolution has not yet ended. In a simple case of a 





variants—more than all the atoms in the universe. Even with billions of years’ searching 
for the “fitter species”, nature has explored only an infinitesimal fraction of all the 
possible solutions. There is no doubt that in this enormous unexplored space many 
biomolecules with dreaming functions are just waiting to be discovered.  
    Researchers are now applying the same concept—mutation and selection— to evolve 
biomolecules (RNA, DNA and proteins) under laboratory conditions. The artificial 
evolution of biomolecules is generally achieved by creating a library of variants and then 
selecting for improved variants. The variants with desired functional improvements can 
be subjected to next round of evolution. Therefore, the evolution pathway of the 
biomolecules is directed by artificially defined selection pressure. This experimental 
approach is given the name of “directed evolution”. 
    Different from natural evolution, directed evolution experiments are no longer 
restricted to the improvement of biologically relevant functions. Instead, any function of 
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interest, as long as physically and chemically possible, can be pursued. Perhaps one of 
the best examples of artificially evolved biomolecules is green fluorescent protein (GFP). 
Roger Tsien won 2008 Nobel Prize in Chemistry for his work on engineering fluorescent 
proteins (FPs) for biological imaging (1). These FPs have been extensively engineered 
for their excitation/emission spectra, oligomerization state, solubility, pH stability, 
photostability and so on. These artificially evolved FPs may have little biological benefits 
in their native contexts but are serving as perfect biological imaging tools for research or 
medical purposes. Furthermore, laboratory evolution has dramatically shortened the time 
of molecular evolution from millions of years to decades or even years. Taking the FPs 
for example again, it took only two decades from its discovery to common laboratory use, 
and many of these FPs contain enhanced functions that nature failed to address during 











Figure 1.1. General procedure for laboratory evolution of biomolecules. The balls on 
the gene of interest represent introduced mutations 
Gene of interest 
Create a library of variants 
with random mutations 
Insert gene library into vector 
Express protein in host cells 




Laboratory evolution of biomolecules usually contains two major processes: i) creation 
of a mutant library ii) screening or selection of improved mutants (Figure 1.1). 
Numerous mutagenesis methods and screening/selection methods have been developed (2, 
3). With an appropriate screening/selection method, improved mutants can be rapidly and 
accurately detected. However, it is the employed mutagenesis methods that decide if a 
beneficial mutation can even show up or not in the library of variants. The quality of a 
mutant library is critical to the success of an evolution experiment. 
Unfortunately, there is no “single best” method to create mutant libraries for all 
purposes. Nearly all the mutagenesis methods have their own advantages and 
disadvantages. In fact, the advantage of a method under some circumstance may be a 
drawback when a different task is to be achieved. That is why a complicated evolution 
task is usually achieved by the combinatorial use of several different mutagenesis 
methods. Based on the information input, the methods of library creation can be divided 
into three types: i) rational design; ii) irrational design; iii) semi-rational design (Figure 
1.2). The development of FP variants gives good examples how these three different 
approaches can be used to accomplish different goals. Below are introduced these three 
protein design methods following the stories of FPs. 
Rational design requires considerable amount of information input (chemical, 
structural, and sometimes computational) as both the mutation positions and types need 
to be predicted. Once designed, these site-mutations can be introduced into proteins by 
site-directed mutagenesis (4). Although variations exist in different site-directed 
mutagenesis methods, most of them rely on the PCR amplification of the target gene 
using mutagenic primers carrying the desired nucleotides at the mutation sites. The 
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template DNAs (usually plasmids isolated from host cells) can be removed by digestion 
of endonuclease Dpn I, which cleaves only the plasmid DNAs with methylated adenosine 
but not newly amplified PCR product. For example, Tsien and co-workers solved the 
crystal structure of GFP in 1996, based on which they designed a T203Y mutation to tune 
the spectra of GFP (5). The introduced Y203 is in close proximity to the chromophore 
and stacks with its phenol ring, therefore stabilizing the  electons in the chromophore. 
The reduced energy gap between excited state and ground state of  electons result in the 










Irrational design requires least input of information and is particularly useful when the 
information (such as the structure of a protein of interest) is not easy to obtain, or the 
evolution task is too complicated to achieve using current knowledge. The two most 
widely used random mutagenesis methods are error-prone PCR (EP-PCR) (6) and DNA 
shuffling (7). The first technique, EP-PCR, is very similar to routine PCR process, but the 





EP-PCR or DNA shuffling 
Figure 1.2. Rational, irrational and semi-rational approaches to create a library of 
variants. In rational design, both mutation positions and types are “fixed” or selected. 
Irrational design allows random types of mutations to occur at random positions. Semi-




pairs. Although the conditions of EP-PCR may have a lot of variations, such as the ratio 
of dNTPs (8), concentration of Mn
2+
 (9) or even different types of DNA polymerases 
(10), they all rely on the natural error rate of DNA polymerases. Therefore, the 
constructed libraries are inevitably marked by the mutation bias of the polymerases. 
Nevertheless, EP-PCR is perhaps the simplest random mutagenesis method one can 
imagine and is relatively time and cost-efficient as compared with other methods. One 
successful application of EP-PCR is the engineering of chromophore maturation of YFP 
(11). Soon after its discovery, YFP was found to mature very slowly in vivo, limiting its 
application as a biological probe. The chromophore maturation of FPs is a complicated 
process consisting of cyclization, dehydration and oxidation (12). Improving the 
maturation rate of FPs may not be easily achieved using rational protein design. 
Miyawaki and co-worker successfully enhanced the chromophore maturation rate of YFP 
by more than 10 fold using EP-PCR followed by fluorescence screening. The second 
technique, DNA shuffling, is a homologous recombination-based mutagenesis method. In 
a DNA shuffling experiment, a template DNA is first randomly fragmented by DNase I 
into 50~100 bp DNAs and these small fragments are then assembled in PCR based on 
their homologous region (7). The major advantage of DNA shuffling is that different 
members of proteins in the same family can be used as the templates together and 
homologous recombination during DNA shuffling will generate chimeric DNA 
sequences with unique properties. The widely used UV-enhanced GFP variant, GPFUV, 
was the result of a successful DNA shuffling experiment (13). As this dissertation mainly 
focuses on mutagenesis methods generating “point-mutations”, these recombination-
based techniques will no longer be discussed below. 
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Semi-rational design can be seen as an “intermediate” between rational design and 
irrational design. Most semi-rational protein design experiments create mutant libraries 
using (multi-site) saturation mutagenesis (14), a derivative method of site-directed 
mutagenesis. In saturation mutagenesis, one or several mutation sites are chosen and 
defined or a mix of amino acid mutations are introduced into these positions, usually by 
PCR reactions with degenerate primers. Semi-rational design largely reduces the 
difficulty of mutation design as it no longer requires perfect prediction of mutation sites 
and types. Moreover, when these chosen mutation sites are structurally close (such as in 
the active site of an enzyme), the function of a protein can be dramatically improved. By 
using multi-site saturation mutagenesis in combination with EP-PCR, Tsien and co-
worker have successfully developed monomeric red FPs (RFPs) with a wide range of 
spectra (15). Most of the currently used RFPs are directly from or derived from this work. 
This dissertation will introduce two unique protein sequence diversification 
technologies that are very different from routine methods. The first one is transposon 
mutagenesis which relies on the random insertions of transposon DNA into a gene of 
interest in an in vitro reaction. This method can be considered as an irrational approach to 
create mutant libraries. However, it does not rely on the natural error rate of DNA 
polymerase and thus, overcomes many limitations that are usually found in a PCR-based 
random mutagenesis method. The second technology in this disseration is unnatural 
amino acid (UAA) mutagenesis which can site-specifically incorporate a UAA into a 
protein sequence. This method can be considered as a rational approach to evolve protein 
functions. However, it is dramatically different from traditional rational design methods 
because it uses UAAs as new building blocks to evolve proteins to carry out chemistries 
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beyond those contained in the 20 natural amino acids. The basis of this method is the 
application of orthogonal aminoacyl tRNA/tRNA synthetase pairs that can assign 
unnatural amino acids into the amber stop codon (TAG) in a protein sequence. 
1.2  Transposon Mutagenesis 
A transposon is a DNA element that can be transported from one location in a genome to 
another. It is a ubiquitous genetic element that exists in bacteriophage, bacteria, plant, 
animals and human. Transposon has become an indispensable genetic tool in recent years. 
Classical in vivo transposition reaction has been applied as gene tagging and mapping 
techniques (16, 17) as well as DNA sequencing tool (18). As early as in 1980s, in vitro 
transposition reaction using Mu transposon DNA was developed (19). However, early in 
vitro reactions are as complex as the in vivo reactions as they require a number of 
accessory proteins and DNA cofactors, such as host-encoded DNA bending protein, 
phage-encoded cofactor protein that affects target specificity and transpositional enhancer 
DNA that is located in the phage genome (20). 
    With modified Mu transposon DNA and appropriate reaction conditions, a minimal 
reaction set-up requires only MuA transposase, donor DNA (transposon) and acceptor 
DNA (target plasmid) as the macromolecular components (21-23). In such mini-
transposition reaction, MuA transposase first recognizes a specific sequence at each 
transposon end (transposase recognition site, R-site). This transposase-transposon 
complex, termed as transpososome, binds to the acceptor DNA (usually a plasmid), 
cleaves the double-stranded acceptor DNA and then catalyzes the joining reaction 
between donor DNA (transposon) and acceptor DNA (21, 22) (Figure 1.3A). Notably, 
the transposon DNA has been engineered such that it only needs one R-site at each end 
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for the reaction (Figure 1.3B). These two R-sites are inverted repeats or so called 
symmetric sequences. Flanking the R-sites are five nucleotides that can be modified to 
contain restriction sites without eliminating the ability of integration of Mu transposon 
(24, 25). These transposon DNAs are usually pre-cut by endonuclease Bgl II or BamH I 
to generate a 5' GATC overhang, which largely accelerates transposition (though not 
essential) by bypassing the otherwise necessary cleavage of transposon by transposase 
(23). The middle segment of the transposon is not involved in the transposition reaction 
and is usually a selection marker for selecting the target plasmids with transposon 
insertions (23, 24). Another feature of Mu transposition is that the acceptor DNA will 
have a five-basepair duplication along the transposon insertion site (26, 27). This is 




Figure 1.3. In vitro mini-transposition reaction. A) General procedure. B) Construct of 
Mu transposon. R-site sequences are shaded. C) Origin of the five-basepair duplication. 
Cyan color indicates the 5 bp sequence recognized by transposase. 
 
 9 
then inserts the transposon sequence in between of the cleaved sequence (Figure 1.3C). 
After insertion, the transposon is flanked by a five nucleotide single-stranded sequence at 
each end. When transformed into E. coli, the single-stranded gaps will be repaired by E. 
coli DNA repair system, resulting in five nucleotide duplication. The transposition 
reaction will generate a library of plasmid each containing a random transposon insertion. 
    Chapter 2 describes three applications of the Mu transposition reactions. In the first 
experiment, a previously reported Mu transposon variant (MuDel transposon) (25) was 
applied to GFP to identify amino acid deletions that can retain fluorescence (“neutral” 
deletions). MuDel transposon-based deletion mutagenesis can generate triplet nucleotide 
deletion at a random position of a DNA sequence. This experiment aimed at generating a 
size-optimized GFP that is less likely to interfere with the native function of a fused 
protein. As the MuDel transposon does not have any control of reading frame, the 
random triplet nucleotide deletions sometimes affected two neighboring residues 
resulting in unexpected mutations in addition to the desired deletions. The second 
experiment aimed to solve this problem by engineering the Mu transposon to contain a 
DNA segment for reading frame selection. The outmost five nucleotides of this new 
transposon are asymmetric to facilitate downstream manipulation. Using this transposon, 
a new deletion mutagenesis method has been developed, named as “codon deletion 
mutagenesis” (CDM). This method allows for generation of up to five consecutive, in-
frame codon deletions at a random position of a protein. CDM was performed on GFP 
and several in-frame “neutral” deletions were successfully identified. These two 
experiments together identified more than 40 residues (out of the total 238 amino acids) 
in GFP that are not essential for the fluorescence. In the third experiment, CDM approach 
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was adapted to develop a codon scanning mutagenesis (CSM) method that can generate 
up to three consecutive, in-frame amino acid substitutions at a random position of a 
protein. This asymmetric transposon-based CSM was performed on GFP. A series of 
spectra-shifted mutants were identified by screening just a small fraction of the mutant 
libraries. 
 
1.3  Unnatural Amino Acid Mutagenesis 
Proteins are the chief actors in living creatures, carrying out the majority of the 
biochemical reactions within cells. Many of the biochemical functions of proteins are 
achieved with only 20 amino acids, though in some rare cases noncanonical amino acids 
selenocysteine (28) or pyrrolysine (29) are also encoded for added functions of proteins. 
When it comes to chemistries beyond those contained in the 20 amino acids, proteins 
often require cofactors (such as metal ions, flavins and thiamine) or post-translational 
modifications (PTMs) (such as methylation, phosphorylation and glycosylation). These 
cofactor or PTMs confer on proteins new biophysical or biochemical properties to 
accomplish a broader range of biochemical reactions. 
Nevertheless, none of the naturally occurring amino acids contain side chains that are 
highly reactive under mild or neutral conditions. For one reason, these amino acids are 
sufficient to support the lives of cells as proteins usually carry out their functions under 
controlled, specified micro-environment. Another reason is that highly reactive groups 
such as ketones, aldehydes and thioesters, if frequently present in the side chains of 
proteins, will possibly “over-heat” cellular machinery. 
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Although nature evolves proteins to achieve their functions with just 20 amino acids, 
researchers are not satisfied with the chemistries contained in this limited number of 
amino acids. Given the importance of proteins in chemistry, biology, medicine and 
pharmacy fields, it is desirable to be able to manipulate proteins with new building blocks 
for better understanding and application of proteins in vivo and in vitro. Unlike the first 
protein sequence diversification technology introduced above, the second technology, 
unnatural amino acid (UAA) mutagenesis diversifies protein sequence by adding new, 
artificial building blocks rather than randomizing protein sequence with the canonical 20 
amino acids. In fact, a number of approaches are being pursued to incorporate unnatural 
amino acids (UAAs) into proteins. Below are introduced several different techniques for 
UAA incorporation. 
One of the early methodologies is solid-phase peptide synthesis (SPPS) (30) which 
allows automated polypeptide synthesis by coupling the C-terminal carboxyl group of 
one amino acid with the N-terminal amine group of another. Using SPPS, UAAs can be 
incorporated into any position of a protein sequence just like natural amino acids. This 
method, however, is subject to size limitation. Peptides of 50~100 amino acids are 
difficult to synthesize in large quantities. This limitation can be partially alleviated by 
using native chemical ligation, where a small peptide containing C-terminal thioester can 
react with another peptide with N-terminal cysteine to assemble a larger peptide (31). 
Alternatively, the peptide containing C-terminal thioester can be produced by intein-
mediated cleavage of recombinant proteins expressed from bacteria cells. The 
recombinant proteins containing C-terminal thioester can then be ligated with a synthetic 
peptide containing UAA at the desired position. This intein-based method, referred to as 
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expressed protein ligation (EPL) (32), largely facilitates the synthesis of long peptide 
chains using SPPS. Concerns about the incorporation of UAAs using SPPS and EPL 
includes the repeated protection and deprotection process and the non-native (in vitro) 
conditions of peptide synthesis, which may disrupt the native structures or functions of 
proteins (some proteins, for example, require chaperones to fold properly). 
Another powerful yet technically challenging technique is based on tRNAs that are 
“pre-charged” with desired amino acids. In this method, truncated tRNAs are 
enzymatically ligated with chemically aminoacylated nucleotides (33-35). The “charged” 
tRNA is then used in cell-free translation system to incorporate UAAs into a specific 
position in response to a nonsense or frameshift codon. This method has also been 
adapted to inject or transfect the “charged” tRNA directly into living cells (36, 37). 
Although methods are potentially powerful, they are limited by the large-scale synthesis, 
instability and discontinuous supply of the aminoacylated tRNAs. 
A third approach relies on natural or engineered aminoacyl tRNA synthetases to 
globally replace one amino acid in proteins with a close structural analog (38-41). In this 
method, a host strain auxotrophic for the amino acid to be replaced is first grown to mid-
log phase as usual and then transferred to a minimal medium lacking the amino acid to be 
replaced but containing the analog amino acid of interest. Newly expressed proteins from 
the existing cells will have global incorporation of the desired amino acids. The 
drawbacks of this method are that the incorporated UAAs are limited to close structural 
analogs and that the UAA incorporation is not site-specific. 
The UAA mutagenesis described in this dissertation is based on genetically encoded 
UAAs during translation process. In this method, an orthogonal tRNA and aminoacyl 
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tRNA synthetase (aaRS) pair is expressed from a plasmid in a host organism and then 
assign a UAA in response to a nonsense or frameshift codon in the gene of interest 
(Figure 1.4). Importantly, the orthogonal tRNA/aaRS pair can incorporate UAAs 
independent of endogenous tRNAs and aaRSs. That said, host tRNA is not aminoacylated 
with UAAs by orthogonal aaRS nor orthogonal tRNA is aminoacylated with any of the 
20 canonical amino acids by endogenous aaRSs. The orthogonal tRNA/aaRS pairs are 
usually taken from another species, for example, Escherichia coli tyrosyl tRNA and aaRS 
pair is orthogonal in Saccharomyces cerevisiae (42) and Methanococcus jannaschii 
tyrosyl tRNA and aaRS pair is orthogonal to E. coli (43). This strategy allows UAAs with 
various properties to be site-specifically incorporated into proteins in different organisms. 
So far, more than 70 UAAs have been successfully incorporated into E. coli, yeast and 





























Figure 1.4. Site-specific incorporation of UAAs into proteins in response to amber 
stop codon (UAG). 
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Chapter 3 shows how UAA mutagenesis technologies can facilitate the enzymatic and 
nonenzymatic synthesis of polyubiquitin (polyUb) chains. In collaboration with Dr. 
Fushman’s group, we have developed two approaches for synthesis of polyUb chains. 
Both of these two approaches rely on an orthogonal pyrrolysyl tRNA (PylT) and tRNA 
synthetase (PylRS) pair to incorporate 

N-tert-butyloxycarbonyl-L-lysine (BocLys) into a 
targeted lysine position in Ub. The first method focuses on synthesis of homogeneous 
polyUb chains that require a linkage-specific Ub conjugating enzyme E2 (enzymatic 
approach). The second method does not involve E2 enzymes (non-enzymatic approach) 
and can generate polyUb chains of any linkage composition. Also included in this chapter 
is a simple yet highly efficient technique to improve protein production yield per unit 
UAAs used. This technique is particularly useful for large-scale production of Ub or 
other proteins containing UAAs. 
Two ongoing projects are also included in this dissertation as appendices. Experiments 
in Appendix I aim to develop a general method for site-specific incorporation of 
thiotyrosine into proteins in E. coli. Tyrosine residues play important roles in the 
functions of many proteins. Besides serving as catalytic center, they can also act as 
regulatory signals. The ability to incorporate thiotyrosine will provide a convenient 
means to install a comparison probe at a desired tyrosine position in a protein. 
Experiments in Appendix II aim at developing an in vitro system for the evolution of 
tRNA synthetases. In vivo evolution of tRNA synthetase is usually labor-intensive and 
requires considerable amount of UAAs. Moreover, the in vivo evolution does not allow 
the development of aaRSs for incorporating cytotoxic or impermeable UAAs whereas the 
in vitro approach is cell-free and thus, completely bypasses this limitation. 
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Chapter 2: Transposon Mutagenesis for Diversifying Protein 
Sequences 
2.1  Introduction 
This chapter shows how transposon mutagenesis technology can be used to diversify 
protein sequences and facilitate our understanding of proteins. The first two methods, 
MuDel transposon mutagenesis and codon deletion mutagenesis (CDM), share the same 
concept that removal of the random transposon insertions simultaneously deletes extra 
nucleotides from the target gene. The difference lies in that MuDel mutagenesis utilizes 
restriction digestion to remove the transposon (Figure 2.1A) whereas CDM relies on 
PCR process followed by digestion (Figure 2.1B). Another major difference is that CDM 
transposon (MuCDM) bears a reading-frame selection marker rather than simply a 
traditional selection marker as in the MuDel transposon. The third method, codon 
scanning mutagenesis (CSM), can be seen as advanced CDM where the process not only 
deletes codons from the target gene but also delivers new codons to fill in the codon 
“scar” (Figure 2.1C). Sections 2.1.1~2.1.3 will introduce the rationales of each 
mutagenesis method. 
2.1.1 Rationale of MuDel deletion mutagenesis 
MuDel deletion mutagenesis requires an engineered Mu transposon (MuDel) that 
contains an Mly I recognition site at each end. Mly I is a type IIS endonuclease and its 
cleavage site is four nucleotide away from its recognition site (Figure 2.2A). Other type 
IIS endonucleases used in the following experiments included Bsg I and Bpm I (Figure 
2.2A). Type IIS restriction enzymes differ from the orthodox type II restriction enzymes, 
which are classified as type IIP enzymes (46), in that their recognition sites are 
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asymmetric rather than palindromic (see examples of type IIP enzymes in Figure 2.2B) 
and that their cleavage sites are located outside of their recognition sites. As mentioned in 
Chapter I, the five nucleotides flanking the R-sites of transposon can be modified to 
contain any restriction sites. Jones (25) has engineered these five nucleotides to contain 
an Mly I recognition site (Figure 2.3A). Mly I digestion removes the inserted transposons 








Figure 2.1. General procedures of transposon mutagenesis. A) MuDel transposon-




a net deletion of three nucleotides (5 bp duplication minus 4 bp deletion from each end). 
The digestion product is a library of linearized plasmids each containing a random triplet 
nucleotide “scar”. Subsequent re-ligation gives back a library of circular plasmids with 


























































Figure 2.3. MuDel transposon-based deletion mutagenesis. A) Mu transposon and 
MuDel transposon with Mly I sites (italic letters) at the two ends. The selection markers 




2.1.2 Rationale of codon deletion mutagenesis (CDM) 
During the MuDel deletion mutagenesis, the importance of the control of reading 
frame was realized. To avoid unexpected mutations, we sought to develop a random 
mutagenesis method for generation of codon deletions. This method, named as codon 
deletion mutagenesis (CDM), allows for generation of up to five consecutive, in-frame 
codon deletions at a random position (Figure 2.1B). As compared with the MuDel 
mutagenesis, the major advantages of CDM are that 1) the deletions occur in frame and 
do not introduce unexpected mutations and that 2) up to five consecutive codons can be 
deleted from a random position. Key to this method is the development of an “all-in-one” 
Mu transposon (MuCDM) that contains asymmetric end sequences and a reading-frame 
selection element in the middle segment. The asymmetric end sequences serve as unique 
primer pairing sites for the downstream enzymatic inverse PCR (EI-PCR) (47) (see below 
for details). The reading-frame selection segment in transposon contains an intein-based 
dual reporter system (48, 49) which ensures that only in-frame transposon insertions can 
result in colonies on ampicillin plate (see below for details). 
In CDM experiment, a gene of interest is first cloned into a transposon-targeting 
plasmid (pTT). A Tat signal peptide (which directs fused peptide into periplasm) and a 
Saccharomyces cerevisiae vacuolar membrane ATPase intein N-terminal domain 
(VMAI-N) are fused upstream to the gene of interest (Figure 2.4A). The C-terminal 
domain of VMA intein (VMAI-C) is carried by the MuCDM transposon, upstream fused 
to TEM-1 –lactamase gene (bla, ampicillin resistance gene) (Figure 2.4B). VMAI-C 
and bla fusion genes do not bear a start codon such that their expression stringently 
depends on the insertion of transposon into an open reading frame (ORF). Only when the 
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MuCDM transposon is inserted in the same reading frame with the gene of interest, will 
VMAI-N and VMAI-C be present in the same reading frame and self-splice to assemble 
Tat signal peptide and TEM-1 –lactamase, resulting in ampicillin resistance (Figure 
2.4C). Therefore, the transformed cells containing in-frame transposon insertions can 
survive on plates supplemented with ampicillin. All the out-of-frame transposon 
insertions are purged from the library. The advantage of intein-based “head-and-tail” dual 
reporter system lies in that the function of -lactamase will not be interrupted by N-
terminal fusion peptide (48) (Figure 2.4C). Importantly, the ability to control the reading 
frame of transposon insertions guarantees that primers annealing to the transposon ends 
can install type IIS restriction sites in the correct reading frame for codon deletions.  
Figure 2.4. Construction of transposon-targeting plasmid (pTT) and asymmetric 
transposons MuCDM and MuCSM. A) pTT. B) Asymmetric transposons. C) 









The library of pTT plasmids with random, in-frame transposon insertions will serve as 
the template in the subsequent EI-PCR, where two primers anneal to the asymmetric ends 
of transposon in a back-to-back manner and amplify the whole plasmid except the 
transposon sequence (Figure 2.5). The PCR product is a linearized DNA where the 
majority of the transposon sequence no longer exists. The 5' sequence of each primer 
Figure 2.5. Detailed procedure of CDM. The asymmetric end sequences are 




introduces a unique Bsg I (type IIS endonuclease) recognition site. The cleavage site of 
Bsg I locates 16 nucleotides away from its recognition site. By placing the Bsg I site 
closer to or further away from the 3' of the primers, various number of nucleotides can be 
removed from the gene of interest. After Klenow treatment to blunt the 3' overhang and 
re-ligation, the plasmids become circular again and each will contain in-frame codon 
deletions in the gene of interest. 
2.1.3 Rationale of codon scanning mutagenesis (CSM) 
    CSM adapts the approach described in CDM and aims to generate codon substitutions 
rather than deletions. CSM can replace up to three consecutive, in-frame codons at a 
random position of a protein with any desired codons. The Mu transposon for CSM 
(MuCSM) is nearly the same to MuCDM with only one nucleotide difference. MuCDM 
has a four nucleotide difference as the asymmetric ends whereas MuCSM contains a five 
nucleotide difference at the two ends (Figure 2.4B). This is designed so to reduce the 
non-specific binding of primers in the EI-PCR (see Results and Discussion section for 
details). Additionally, CSM has one more EI-PCR step than CDM. This is because new 
codons need to be delivered to the gene of interest. In the first EI-PCR, one primer 
introduces a Bsg I or Bpm I site that will remove in-frame codons from the gene of 
interest. The other primer delivers new codons to the gene of interest. Importantly, the 
sequence of this codon-carrying primer (“anchor” sequence) cannot be removed by Bsg I 
digestion and remains in the gene of interest. In the second EI-PCR, two primers anneal 
to the “anchor” sequence and each introduces a unique Bsg I site. Upon Bsg I digestion, 
all the foreign sequences will be removed, leaving only the new codons to fill in the 















Figure 2.6. Detailed procedure of CSM. The asymmetric end sequences are 
highlighted in red. Bsg I sites are in italic letters. Green boxes indicate the new 
codons to be delivered. Di-NDT codon substitution is shown as a demonstration. In 
the first EI-PCR, an “anchor” sequence and the new codons are introduced by one 
primer and the other primer introduces a Bsg I site which removes the 5 bp 
duplication (from Mu transposon insertion) and additional 6 in-frame nucleotides. 
The second EI-PCR removes all the foreign sequences, leaving behind only the 
“NDTNDT” codons to fill in the 6 bp deletion gap. Note that the 2 bp 3' overhangs 
created by Bsg I is removed by Klenow treatment 
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2.1.4 Generation of size-minimized GFP using MuDel mutagenesis and CDM 
This experiment aims to generate a size-optimized GFP that is less likely to interfere 
with the native function of a fused protein. Aequorea victoria GFP is generally 
considered as a size-minimized protein (50-52). Wild-type A. victoria GFP is a 27 kDa 
protein containing 238 amino acids. GFP and all its known variants adopt a β-can 
structure assembled by 11 antiparallel β-strands (5, 53). Most of the strands are connected 
by small loops consisting of one to four amino acids. Two larger loops appear at positions 
129~143 and 189~197. The top and bottom “lids” composed mainly of residues 74-91 
and 128-145, respectively (5, 54). The chromophore is located at the central α helix, 
surrounded by β-strands. The chromophore of wide-type GFP (wtGFP) is formed by 
residues Ser65, Tyr66 and Gly67, requiring no cofactors from host systems (54, 55). 
Despite that GFP has become a commonly used laboratory tool, characterization of the 
functions of a target protein fused with GFP tag is not necessarily a simple task. GFP is 
usually considered as innocuous tag as it can fold independently and autocatalyze to form 
matured chromophore when fused to other proteins. However, GFP is, after all, a protein 
consisting of more than 200 amino acids. Fusion with GFP is still risky at disrupting the 
folding, native functions or intracellular locations of a target protein. Although rarely 
reported in literatures, some evidence exists that high level of GFP expression in certain 
locations is detrimental to cells (56-58) and that GFP fusion could change the 
intracellular location of a target protein (59-61). This problem could be alleviated by 
using a size-minimized GFP. Ideally, the flexible loops (which are very likely to interfere 




GFP is well tolerant to deletions at N or C terminus (50, 51). The minimal domain 
required for the fluorescence of wtGFP is 2~232 (50). An enhanced version of GFP 
(EGFP, mutation F64L/S65T) can still fluoresce with 5 amino acids deleted from N 
terminus or 10 amino acids deleted from C terminus (51). However, GFP is very sensitive 
to deletions at internal positions. Deletions of residues 132~139 or 191~195 in the two 
larger loops eliminated the fluorescence of EGFP (51). A targeted deletion analysis of the 
longest loop (129~143) in SuperGlo GFP (sgGFP, containing mutations 
F64L/S65C/I167T) showed that only two single deletions I128 and D129 could retain 
the fluorescence of GFP (52). 
It is worth mentioning that previous deletion studies of GFP were all based on the 
whole-cell fluorescence. The underlying reason for the loss of fluorescence is still 
unclear. The intensity of whole-cell fluorescence of GFP reflects the overall contributions 
of expression level, folding robustness, efficiency of chromophore formation and intrinsic 
brightness (quantum yield and extinction coefficient) (12). One possibility is that those 
deletion mutants have lost considerable amount of conformational stability such that 
proteins cannot fold properly to catalyze the formation of chromophore. If this is the case, 
the lost fluorescence of the deletion mutants may be restored by folding-enhancing 
mutations (62). To understand if the deletions destroy the fluorescence of GFP by 
compromising its conformational stability, MuDel deletion mutagenesis (25) was 
performed on a UV-optimized GFP variant (GFPUV) (13). The mutant library was 
screened for deletions that could retain GFP fluorescence (“neutral” deletions). Detailed 
characterization of these “neutral” deletions, indeed, suggested that the fluorescence loss 
was largely due to the compromised stability of proteins. Furthermore, incorporation of 
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folding-mutations largely recovered the fluorescence of these mutants and the 
fluorescence of the mutants with combined “neutral” deletions. 
Encouraged by this experiment, we then set out to apply CDM to identify more 
“neutral” codon deletions. In total, more than 40 “neutral” deletions were identified using 
MuDel deletion mutagenesis and CDM. These results strongly indicated that GFP can be 
minimized, as opposed to the previous conclusion that GFP is a naturally size-optimized 
protein (50-52). Although CDM was developed in our experiment for minimizing GFP, it 
could have potential applications for engineering other proteins. Some protein functions 
can be improved by deleting certain regions or residues. In the case of streptavidin (159 
amino acids), high affinity to biotin (Kd ~10
-15
 M) is only seen in the truncated or “core” 
streptavidin (residue 13~139) because the N- and C-terminal regions prevent its ligand, 
biotin, approaching the binding pocket (63). Another example is that site preference of 
MuA tranposase can be reduced by truncating its N-terminal sequence (64). Additionally, 
amino acid deletion is a general mechanism of sequence variation in immunoglobulin 
variable domain (65). Thus, CDM can be used as a general method for engineering 
protein functions. 
2.1.5 Development of spectral variants of GFP using CSM 
Traditional methods for diversifying protein sequences usually generate mutations at 
the nucleotide level. This largely compromises the diversity of a mutant library because 
of codon redundancy and the rarity of consecutive nucleotide mutations. A statistic 
analysis of the existing random mutagenesis methods have suggested that many of them 
are highly biased due to the limitation of generating mutations at the nucleotide level (66). 
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An ideal random mutagenesis method would allow one to substitute every amino acid of 
a protein sequence in a statistically equivalent manner. 
Random insertion and deletion (RID) mutagenesis (67) is perhaps the first attempt to 
generate mutations at the amino acid level. RID allows random deletions of an arbitrary 
number of nucleotides from a gene of interest followed by insertions of any desired 
sequences. This method, however, requires multiple inter-molecular DNA ligations and 
can be difficult to employ in generating large libraries. Another important progress was 
made by Jones and co-workers, where they developed a MuDel transposon-based method 
to generate random triplet nucleotide substitutions (68) (referred to as TriNEx for triplet 
nucleotide exchange) or random domain insertions (69). 
    While both RID (67) and TriNEx can generate mutations in the unit of triplet 
nucleotides, our interest was to generate “codon mutations” in which the reading frame of 
the mutation is defined. In a previous study, we reported a process for replacing single, 
random in-frame codons with a new codon of choice (49). This method employs the same 
MuDel transposon described in the TriNEx method (25, 68) and integrates an intein-
based “dual reporter” reading-frame selection system (48). This codon-based random 
mutagenesis method limits unwanted out-of-frame mutations resulting in a “pure” library 
and was perhaps the closest to achieve a non-redundant mutagenesis method (68). 
However, this method can generate only one mutation per round of mutagenesis and 
contains a technically challenging manipulation step (inter-molecular blunt-end ligation). 
Hence, construction of a large mutant library using this method may be difficult. 
To overcome these problems, we developed an asymmetric transposon-based codon 
scanning mutagenesis (CSM) (70). Compared to the MuDel transposon-based single 
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codon mutagenesis method (49), the current method 1) can scan up to three consecutive 
codons rather than only one, 2) has user-friendly process of manipulation, and 3) has 
been largely optimized for high efficiency of mutagenesis. These features enable the 
construction of large-scale libraries. The major advantage of this method is that the 
mutant library is highly diverse so that beneficial mutants can be identified by screening 
just a small fraction of the mutants in the library. As a demonstration of this approach, we 
generated three libraries that scanned single, di- or tri-NDT degenerate codons (71), 
respectively, throughout the gene encoding superfolder GFP (sfGFP) (72). By screening 
only 500 clones from each library, we successfully identified several mutants that showed 
altered spectral properties. 
2.2  Results and Discussion 
2.2.1 Random deletion mutagenesis of GFPUV using MuDel transposon 
Since early deletion analysis on GFP suggested that it is sensitive to amino acid deletions 
especially at internal positions (50-52), it is necessary to investigate the effect of amino 
acid deletions on GFP to answer the question if it is possible at all to generate a 
minimized GFP. A size-minimized GFP is most likely to be produced by incorporation of 
“neutral” deletions, amino acid deletions that can retain fluorescence. Therefore, MuDel 
transposon-based random deletion mutagenesis followed by fluorescence screening was 
performed on GFPUV to identify such “neutral” deletions first. These “neutral” deletions 
were then characterized to determine if the fluorescence loss was caused by compromised 
protein stability. This is particularly important because if this is the case, impaired GFP 
fluorescence may be restored by folding-enhancing mutations. 
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2.2.1.1 Construction of deletion library and identification of “neutral” deletions 
The transposon reaction resulted in 38,000 individual colonies, sufficient for a full 
coverage of all the possible insertion sites. The collected pGFPUV-MuDel transposon 
library was digested by Kpn I/EcoR I to isolate those transposon insertions inside the 





















Figure 2.7. Isolation of transposon insertions inside GFPUV gene. A) EcoR I/Kpn I 
double digestion to isolate transposon insertions inside GFPUV. B) 1% agarose gel 
showing the four DNA fragments resulting from EcoR I/Kpn I digestion. A purified 
library can be obtained by gel purification and subsequent re-ligation of the DNA 
bands “vector backbone” and “GFPUV gene + transposon” 
vector backbone + transposon 
vector backbone 







To screen the fluorescence of these mutants, cells were grown on plates for 48 h at 23 
ºC. The in-plate fluorescence was then monitored under UV lamp by visual inspection. In 
total, 40 fluorescent mutants and 24 non-fluorescent mutants were picked from the plates 
and sequenced. Ninteen unique mutants were obtained from the 64 sequenced clones as 
some mutants carried identical deletions. A detailed analysis of the sequences of the 














To verify the in-plate fluorescence, the identified 19 mutants were grown at 23 ºC for 
24 h in liquid culture. The results revealed that 12 of the deletion mutants were 
fluorescent and the other 7 were not (Figure 2.8). Of the 12 fluorescent mutants, 7 
contained deletions at N- or C-terminus (S2/K3R, G4, E5/D6E, F8/T9S, 
Figure 2.7. Deletion maps of GFPUV. The displays are arrows for strands, cylinders for 
helices and star for chromophore. The numbers indicate the starting and ending positions 
of secondary structures. Deletions resulting in fluorescent and non-fluorescent 
phenotypes are indicated by white and black triangles, respectively. The fluorescent 
mutants include S2/K3R, G4, E5/D6E, F8/T9S, C48, P75/D76H, P75, 
E172, S175/V176F, A225/A226A, G228 and G228/I229V. The non-
































A225/A226A, G228 and G228/I229V) and 5 had deletions at internal positions 
(C48, P75/D76H, P75, E172, S175/V176F). The internal deletions were all at 
the border of helices and strands. Of the 7 deletions that eliminated GFP fluorescence, 
one was found in the N-terminal region (G10), one in the middle of a -strand (T203) 
and the other five mutants at the border of helices and strands (D21, G24, E34, 
P58, P89/E90Q). Interestingly, mutant G10 could restore trace fluorescence after 
prolonged incubation (>48 hours) at 23 ºC. These results were consistent with previous 
analysis (73) and the general expectation that deletions within the secondary structure 
were unfavorable for retaining protein functions. 







A size-minimized GFP could be most easily generated by sequential incorporation of 
these “neutral” deletions into wtGFP. However, characterization of these deletion 
mutants showed that their in vivo whole-cell fluorescence was all decreased when 
expressed at 37 ºC (Figure 2.8). Interestingly, the reduced whole-cell fluorescence can be 
largely recovered at reduced temperatures (30 ºC and 23 ºC). Some of these mutants were 
only fluorescent when expressed at 23 ºC. Importantly, the GFP fluorescence under 




Figure 2.8. Whole-cell fluorescence of 12 mutants with “neutral” deletions under 
three different temperatures. 
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mutant was compared to the fluorescence of wtGFPUV under the same temperature. This 
“normalized” fluorescence was used to dissect the effect of these deletions on GFP 
fluorescence. The dramatic recovery of the fluorescence at low temperatures indicated 

























Figure 2.9. Characterization of in vivo expression and fraction soluble of deletion 
mutants. A) Quantification method using Image J. S: supernant; L: crude cell lysis. B) 
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    To further understand the cause of fluorescence loss, we characterized the in vivo 
expression and solubility of the 12 fluorescent mutants. For each mutant, the GFP overall 
expression (in crude cell lysis) and soluble portion (in supernatant of cell lysis) were 
analyzed by SDS-PAGE. The amount of protein present in each sample was estimated by 
comparing with an internal standard BSA of known concentration (Figure 2.9A). The 
quantification was carried out using Image J (http://rsbweb.nih.gov/ij/). The protein 
expression was presented in the unit of g protein produced per OD600 per mL culture. 
Overall expressions of wtGFPUV and mutants were generally within 50% variation under 
the same temperatures (Figure 2.9B). The fraction soluble was the ratio of supernatant 
GFP and overall protein in whole-cell lysis. Remarkably, the soluble fraction of each 
mutant underwent a dramatic increase when the temperature was reduced, especially for 
those carrying internal deletions (Figure 2.9C). These results further indicated that these 
“neutral” deletions may disrupt protein folding at high temperatures. 
To better understand the effect of these deletions on GFP, the mutants carrying internal 
deletions were purified and further characterized (Figure 2.10). These mutants were of 
particular interest, because only two internal deletions (I128 and D129were known to 




 Figure 2.10. Purified mutants with internal deletions. Lane 1~6: mutants C48, 
P75+D76H, P75, E172, S175+V176F, respectively, expressed at 23 ºC 
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GPFUV has a major excitation (Ex) peak at 397 nm and a minor Ex peak at 475 nm. 
When excited at 397 nm or 475 nm, the emission spectra of wtGFPUV and mutants were 
superimposable (Figure 2.11A). The excitation spectra of these mutants were very 
similar with the only difference being the ratio of the major and minor peaks (Figure 
2.11B), which represents the relative abundance of the two ionization state of the 
chromophore. The neutral chromophore is responsible for the 397 nm peak whereas 
anionic chromophore gives 475 nm peak (12). The mutations that can alter the ratio of the 
two chromophore species have been observed before (74). For example, mutation S65T 
in EGFP (F64L/S65T) completes the ionization of the chromphore in the ground state and 














    The above results indicated that the chromophores of the five deletion mutants could 
be chemically similar to that of wtGFPUV. To further characterize the properties of the 
chromophore, we determined the extinction coefficient at 397 nm (397) and 475 nm (475) 
and the quantum yield of each mutant (Table 2.1). While some deletions, such as 
S175/V176F, had obviously altered 475, most deletions did not result in significant 
change in 397. Furthermore, the quantum yield of these mutants was nearly the same as 
that of wtGFPUV. These results strongly supported the idea that these deletions did not 
disrupt the chemical structure of the chromophore. Therefore, decreased fluorescence loss 
observed in this study, presumably as well as those in previous studies (50-52), is very 






























(ex=397 nm, %) 
GFPUV 29,600 7,500 0.79
[b]
 
C48 31,600 8,500 0.80 
P75+D76H 29,700 6,800 0.79 
P75 29,400 7,100 0.79 
E172 29,300 7,600 0.81 
S175+V176F 30,900 5,000 0.79 
Table 2.1. The effect of internal deletions on extinction coefficient and quantum yield 
Note: [a] SD of each value is generally within estimated instrumental error (±2%) 
          [b] Patterson et al, 1997 
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In GFP, chromophore maturation and protein folding are coupled as the autocatalysis 
of the chromophore formation requires the residues involving in the chemistry to be in 
structural proximity (12). One result of the disrupted folding process is that the 
maturation of chromophore could be slowed down. In fact, the above results strongly 
supported this hypothesis because the five mutants had the same quantum yield values to 
wtGFPUV but decreased whole-cell fluorescence (Figure 2.8). These results suggested 









    To verify this conclusion, the efficiency of chromophore maturation of each sample 
was determined using the “based denatured” method (75). Under “based denatured” 





(75). The concentration of matured chromophore can thus be obtained by Beer’s Law 
using the experimentally determined absorbance (see Materials and Methods for 
details). Efficiency of chromophore maturation is equal to the ratio of matured protein 
and overall protein (see Materials and Methods for equations). In the current study, the 
efficiency of chromophore maturation for wtGFPUV was lower than the reported value of 
Wavelength (nm) 
Figure 2.12. Efficiency of chromophore formation. A) Absorbance of 7 M protein 
under “base denatured” condition. B) Calculated efficiency of chromophore formation. 
SDs are within instrumental error of ±2%. 









1.0 (76). This was probably due to different expression conditions. Importantly, when 
compared with wtGFPUV, all the five deletion mutants showed clearly reduced efficiency 
of chromophore maturation (Figure 2.12). 
2.2.1.3 Restore fluorescence by incorporation of folding-enhancing mutations 
As shown above, the “neutral” deletions reduced GFP fluorescence most likely by 
disrupting protein folding (as well as chromophore maturation). Next question would be 
if the decreased fluorescence can be recovered. Previous protein folding studies have 
shown that compromised protein stability can be rescued by incorporation of global 
folding-enhancing mutations (62). Being one of the most engineered proteins, GFP has 
many known folding mutations identified in previous study (15, 72, 77). Herein, we 
chose a central folding mutation F64L (76) and a distant folding mutation S30R (72) to 












Figure 2.13. Folding-enhancing mutations F64L and S30R and the five internal 






























F64L and S30R mutations were introduced into each of the five mutants individually. 
The whole-cell fluorescence at 37 ºC was assayed for each new construct. Mutation S30R 
did not result in obvious fluorescence increase whereas F64L restored partial 






Figure 2.14. Folding-rescued whole-cell fluorescence. A) F64L and S30R rescued 
whole-cell fluorescence at 37 ºC. The rescued fluorescence of mutants is normalized 
to the fluorescence of wtGFPUV with corresponding folding mutations. B) F64L 
rescued the fluorescence of mutants with combined deletions at 23 ºC. The 
fluorescence of mutants is normalized to that of GFPUV-F64L. Three individual 
replicates were performed for each sample. 
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a central folding mutation and may have larger impact on folding process than the distant 
folding-mutation S30R. Next was examined if the folding mutation F64L could rescue 
the fluorescence of mutants with combined deletions. This is particularly important 
because generation of a size-minimized GFP may require sequential incorporation of pre-
determined “neutral” deletions into the same protein. All the possible mutants with 
double internal deletions were generated and tested for F64L folding-rescue. Remarkably, 
combination of any two of the five deletions eliminated GFP fluorescence at 23 ºC and 
incorporation of F64L mutation successfully restored the fluorescence loss on all the ten 
double deletion mutants (Figure 2.14B). To the best of our knowledge, these mutants are 
the only known GFP variants that can retain fluorescence with multiple deletions 
incorporated at internal positions. However, mutation F64L was neither capable to rescue 
their fluorescence at 37 ºC nor the fluorescence of any triple deletion mutants. This 
suggested that triple deletions may have overwhelmed the folding-rescue ability of F64L. 
Additional folding mutations may be necessary to recover the fluorescence of mutants 
with three or more deletions. 
2.2.2 Codon deletion mutagenesis of GFPUV using MuCDM transposon 
MuDel deletion mutagenesis has two limitations that prevent rapid identification of 
“neutral” deletions. First, it lacks control of reading frame and thus some deletions were 
found with accompanying mutations. Second, each mutant in the library contains only 
one amino acid deletion. This motivated us to develop a novel random deletion 
mutagenesis that can generate multiple, random “codon” deletions, referred to as codon 
deletion mutagenesis (CDM) below. The Mu transposon used in this method is named 
MuCDM in the following section for convenience. 
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2.2.2.1 The development of an “all-in-one” asymmetric Mu transposon 
Previously, transposons have been successfully employed to mutate sequence with 
foreign segments of DNA, therefore we hypothesized that they could also be used to 
generate new annealing sites for primers within a plasmid. The Mu transposon is known 
to accommodate nucleotide changes outside of the MuA transposase recognition sites (R-
sites). These outside sequences are always symmetrical inverted repeats, however, and to 
the best of our knowledge there has been no attempt to generate asymmetric transposons. 
The forward and reverse ends of asymmetric transposon were designed to contain a four 
nucleotide difference with the outermost 3' nucleotide remaining symmetrical (Figure 
2.4B). These asymmetric ends can force two different primers to be specifically used for 
whole-plasmid PCR amplification. As demonstrated in the following expeirments, a 4 bp 
difference in MuCDM transposon is sufficient for the specific annealing of carefully 
designed primers (see next section for details). The transposition efficiency of MuCDM 
was estimated to be ~1% by comparing a test plate supplemented with ampicillin and 
kanamycin to a control plate with only kanamycin. This efficiency is comparable to other 
Mu transposon variants, suggesting that the nucleotides flanking the transposase 
recognition sites need not be identical.  
Another interesting observation was that MuCDM transposon could insert in the 
VMAI-N region on the pTT plasmid, as far as 60 residues upstream to GFPUV. In these 
cases, the self-splicing of intein is disrupted by transposon insertions, but -lactamase 
may still, though less likely, function with an N-terminal fusion peptide. Assuming that 
60 residues of VMAI-N and 238 residues of GFPUV were the allowed positions for 
transposon insertions, 3,000 colonies were collected from the transposition reaction to 
 
 40 
ensure a >95% chance of full coverage (78). In general, 1 L of the transposition product 
could yield 1,500 colonies. Therefore, a single 20 L transposition reaction should 
provide sufficient colonies to cover the full library of a very large protein. 
    The randomness of the transposon insertions was verified by EcoR I/ Mly I digestion of 
20 randomly picked colonies (Figure 2.15). The transposon insertions were found to 
distribute throughout the GFPUV gene with colonies 13, 15, 17 and 19 containing N-
terminal insertions and colonies 5, 10 and 11 bearing C-terminal insertions (the smaller 
band was difficult to visualize). Notably, transposon were inserted in VMAI-N in 
colonies 3, 8 and 18 (with a >780 bp smaller band). To investigate the distribution of 
transposon insertions, we did not purify the transposon library in this experiment. In any 
further applications, however, the library can be purified to isolate the transposon 












Figure 2.15. Verification of randomness of transposon insertions. Twenty random 
colonies from the transposition reaction were digested by Mly I/EcoR I. M1,  Hind III 
DNA ladder; M2, NEB 100 bp DNA ladder. MuCDM transposon carries a Mly I site at 
the 3' end and pTT-GFPUV plasmid bears an EcoR I site at the C-terminus of GFPUV. 
Upon Mly I/ EcoR I digestion, the N-terminal insertion of MuCDM transposon in 
GFPUV will result in 780/ 4,400 bp bands whereas the C-terminal insertion will result in 
70/ 5,000 bp bands. If the transposon is inserted in the N-VMA sequence, >780 bp/ 
<4,400 bands are expected. 







2.2.2.2 Optimization of conditions for enzymatic inverse PCR (EI-PCR) 
In EI-PCR, two primers will specifically anneal to the transposon ends in a back-to-back 
manner and amplify the whole plasmid, except the transposon sequence, in an inverse 
direction (Figure 2.5). The starting and ending position of the PCR product were 
randomly distributed in the GFPUV gene, depending on the position of transposon 
insertions. Therefore, the “head” of a PCR product could overlap with the “tail” of 
another product, resulting in “side product” with extended size (Figure 2.16A). This 
problem, however, was solved by simply reducing template concentration and cycling 
number (79). As a crude estimation, side product became predominant once the 














Figure 2.16. Testing template concentrations and cycling numbers of EI-PCR. A) 
Smeared PCR product occur when regular template concentration and cycling number 
are used. Lane 1, no template control; Lane 2, 0.1 ng/L template. The cycling number 
is 30 for both. B) Optimization of template concentration. Lane 1~4: 5, 25, 125 and 250 
pg/L template, respectively. The cycling number is 18 for these four reactions. DNA 
gel is analyzed by Image J to determine the relationship between the concentration of 
desired product and the appearance of side product. Side product is indicated by arrow.  














Another challenge of EI-PCR is that the primers need be carefully designed to prevent 
non-specific annealing (Figure 2.17). This is because MuCDM transposon has only four 
nucleotide asymmetric sequence at the two ends. The majority of the forward and reverse 
primer annealing sequence is symmetrical (Figure 2.5). That said, the four nucleotide 
difference provided the only basis for the primers to specifically anneal to one end but 
not the other. It was found that the length of these primers is very important. On one hand, 
the longer the primer is, the less weight this 4 bp difference will have in the whole primer. 
On the other hand, PCR process also requires primers to have sufficient nucleotides 
pairing with the template. Hence, the primer design must balance between efficient 
annealing and specific annealing. A variety of primers have been tested and the best ones 













Figure 2.17. PCR reactions for testing primer design. Lane 1, no template control; 
lane 2, forward primer A only; lane 3, reverse primer B only; lane 4, reverse primer C 
only; lane 5, reverse primer D only; lane 6, A+B; lane 7, A+C; lane 8, A+D. Note that 
in lane 5, primer D non-specifically anneals to both ends of the transposon and results 
in a side product. 





Table 2.2. List of primers for the EI-PCR of CDM 

















2.2.2.3 Optimization of conditions for restriction digestion and Klenow treatment 
Bsg I cleavage was >95% efficient under optimized conditions, with several final mutants 
containing uncut Bsg I sites. Fresh SAM and incubation of reaction in a PCR 
thermocylcer were critical for the complete cleavage of Bsg I. Klenow digestion was also 
>95% efficient following NEB’s instructions. Short incubation time (~15 min) and 
quenching with EDTA before heat-inactivation were important to avoid overdigestion. 
Four nucleotide deletion and two nucleotide deletion were also observed in the sequenced 
mutants, which were presumably caused by overdigestion and incomplete digestion of 
Klenow, respectively. 
Note: 1. Asymmetric sequences highlighted in red. 
 2. Bsg I sites are underlined. 
3. “FWD” and “REV” indicate forward and reverse primers, respectively. 
4. The number in the primer names indicate the number of nucleotides that can 
be removed from target gene by Bsg I digestion. For examples, FWD8N 
means that 8 bp will be removed from the forward end of PCR product upon 
Bsg I digestion, including the 5 bp duplicate. 
5. To delete a desired number of codons, more than one combination of primer 
pairs may exist. For example, a two codon deletion library can be generated 
using either the primer pair FWD8N/REV3N or FWD11N/REV0N. 
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2.2.2.4 Overall efficiency of CDM 
Five deletion libraries of GFPUV were constructed by CDM, containing one to five 
consecutive codon deletions, respectively. To characterize the library quality, ~20 
colonies were randomly picked from each library and sequenced (Appendix V). More 
than 90% of mutants in the library contained seamless, in-frame deletions, including 
those deletions occurring in the VMAI-N region (Table 2.3). The 8% undesired mutants 
were the results of incorrect Bsg I/ Klenow digestion as stated above. This mutagenesis 
efficiency is advantageous over many other approaches and is sufficient for any further 
applications. Importantly, the reproducibility of CDM was illustrated because the five 
deletion libraries were constructed following essentially the same procedure, with the 
only difference being the primer pairs used in EI-PCR. 
Table 2.3. Quality of the five deletion libraries 
Deletion Libraries One Two  Three  Four  Five Overall 
Total sequenced 20 21 21 20 22 104 
Incorrect 2 1 2 1 2 8 (7.7%) 
Correct in VMAI-N
[a]
 4 1 0 1 5 11 (10.6%) 






Next the distribution of the 96 correct deletions was examined. This information is 
very important as large-scale deletion mutagenesis expeirments demand the coverage of 
the entire protein sequence. Strong site preference, if any, will be undesirable for the 
application of CDM. In Figure 2.18, the cumulative fraction of deletions is plotted with 
the deletion positions. In such a plot, uniform distribution should present a linear 
Note: [a] As the pTTGFPUV-MuCDM library was not purified to isolate 
transposon insertions inside GFPUV gene, the final deletions may 
occur in the upstream leading peptide. 
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relationship, because if deletions are evenly distributed throughout the entire protein 
sequence, the total number of deletions (cumulative deletions) should increase 
proportionally with the amino acid positions. If these deletions do not follow uniform 
distribution, experimental curves will deviate from the straight line. From Figure 2.18, 
the distribution of deletions from the five libraries was generally consistent with the 
uniform distribution with minor bias observed. This site preference of deletions may 
result from the intrinsic bias of MuA transposase as previously observed (24). 
Fortunately, recent studies have suggested that the site preference of MuA transposase 
can be reduced by truncating its N-terminal sequence or changing its working buffer (64). 
Another possible reason is the “dual reporter” reading-frame selection marker. Although 
the intein-splicing mechanism guarantees an identical “Tat+BLA” reporter regardless of 
the position of transposon insertions, the folding of VMAI-N and VMAI-C may be 
problematic depending on the peptide sequence between these two domains. Nevertheless, 
previous studies of this intein-mediated reading-frame selection system revealed a non-








           
 
 
Figure 2.18. Distribution of deletions in GFPUV and VMAI-N, based on the 96 
correct deletions. The first residue of GFPUV is numbered as 1. The straight and 
curved lines represent uniform distribution and experimental results, respectively. 
























2.2.2.5 Identified “neutral” deletions 
The five deletion libraries were cloned into pET expression vector and screened for GFP 
fluorescence. In total, 24 non-fluorescent mutants and 12 fluorescent mutants were 
identified (Figure 2.19). The 12 fluorescent deletion mutants included 20 “neutral” 
deletions at internal positions (Figure 2.20). To the best of our knowledge, none of these 
residues have been reported before, nor can they be easily identified using traditional 
methods. Consistent with the results from MuDel deletion mutagenesis, these “neutral” 
deletions were located either in the loop structure or at the border region of 
helices/strands. These “neutral” deletions are usually expected to occur in the longest 
loop (51, 52), but our results suggested that small loops were well tolerant to deletions, as 
demonstrated in mutants D117, G51/K52, E90/G91 and G189/D190. 
Surprisingly, multiple deletions G51/K52, E90/G91, G189/D190, 
A154/D155/K156, A226/A227/G228/I229 and 
A226/A227/G228/I229/T230 could also retain GFP fluorescence. This result has 
largely expanded our knowledge of the tolerance of GFP to deletions as such consecutive 
amino acid deletions were usually thought to be very destabilizing to the compact -can 
structure of GFP. 
 
 
Figure 2.19. Identified deletions in GFPUV.  strands and  helices are displayed as 
arrows and cylinders, respectively. The deletions that can retain fluorescence are 















The liquid culture whole-cell fluorescence of the “neutral” mutants was also 
determined. These mutants showed little fluorescence when expressed at 37 °C but their 
fluorescence was significantly restored when expressed at 23 °C (Table 2.4). This is 
consistent with the conclusion from MuDel deletion experiment that fluorescence loss at 
higher temperature was probably caused by the disrupted folding process and/or 
chromophore maturation of GFP. Remarkably, by using MuDel deletion mutagenesis and 
CDM, more than 40 “neutral” amino acid deletions (from separate mutants) have been 
identified. These results strongly suggest that GFP can be minimized, as opposed to the 
















Figure 2.20. Structure of GFPUV, showing the “neutral” deletions identified by CDM. 
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wtGFPUV 1.00 ± 0.13 
V11 0.36 ± 0.07 
H25 0.09 ± 0.00 
D117 0.17 ± 0.05 
T118 0.05 ± 0.00 
N135 0.10 ± 0.01 
H139 0.14 ± 0.00 
G51/K52 0.05 ± 0.00 
E90/G91 0.07 ± 0.00 
G189/D190 0.22 ± 0.06 
A154/D155/K156 0.08 ± 0.00 
A226/A227/G228/I229 0.17 ± 0.01 
A226/A227/G228/I229/T230  0.26 ± 0.01 
 
2.2.3 Codon scanning mutagenesis of sfGFP using MuCSM transposon 
Codon scanning mutagenesis (CSM) is a non-redundant random mutagenesis method that 
allows generation of up to three consecutive, random codon substitutions within a protein 
sequence. This method advances the strategy used in CDM and, instead of generating in-
frame deletions, it generates in-frame mutations. As generation of substitutions demands 
delivery of new codons into the gene of interest, one additional EI-PCR/digestion step is 
necessary. We further engineered asymmetric transposon, optimized the conditions of EI-
PCR and restriction digestion to accommodate the changes in CSM. As a proof of 
principle, CSM was performed on superfolder GFP (sfGFP) (72), a highly stabilized GFP 
Note: Fluorescence was determined in the context of pET28b(+) vector. The 
fluorescence assay was performed after induction at 23 ºC for 18 hours. 
The fluorescence of mutants has been normalized to that of wtGFPUV. 
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variant (containing the following mutations as compared to wild-type jellyfish GFP: 
S30R/Y39N/S65T/F64L/F99S/N105T/Y145F/M153T/V163A/I171V/A206V). We 
created three mutant libraries, containing one, two or three consecutive, random codon 
mutations, respectively. 
2.2.3.1 Optimization of asymmetric transposons, EI-PCR and digestion 
In CDM, primers in EI-PCR may sometimes anneal non-specifically to both ends of 
transposon due to lack of asymmetric sequences (Figure 2.17). Hence, in CSM, 
transposon end sequence is further engineered to contain five asymmetric nucleotides 
(Figure 2.4B). This new transposon DNA, named as MuCSM, indeed alleviated the non-
specific annealing problem as we found later in the EI-PCR. This MuCSM transposon 
has an insertion efficiency (~1%) similar to that of MuCDM transpson. This MuCSM 
tranposon again, demonstrates that the sequences flanking the R-sites need not be 
symmetrical. To verify the randomness of transposon insertions, 23 colonies were 
randomly chosen from the pTTsfGFP-transposon library and digested with EcoR I/Mly I 
(Figure 2.21). It is clear from the DNA gel that transposon insertions occurred 
throughout the entire sfGFP gene, suggesting that the asymmetric terminal sequences do 
not alter the randomness of transposon insertions. After transposition reaction, the 
pTTsfGFP-MuCSM transposon library was digested with Nhe I and EcoR I (which flanks 
sfGFP gene) to shuffle the sfGFP gene with transposon insertions into an expression 
vector pTrcHisA. This shuffling process allows isolation of transposon insertions inside 
sfGFP gene and also sets up the final mutant libraries in the context of an expression 
vector for direct functional assay. 
 
 50 
The cleaned transposon library was used as the template in EI-PCR. The detailed 
procedure of CSM is shown in Figure 2.6. CSM has one additional EI-PCR/digestion 
step than CDM, because new codons need be delivered into the gene of interest. In the 
first EI-PCR, the forward primer introduces a Bsg I or Bpm I restriction site (see Figure 
2.2 for detailed information) that cleaves one or two codons from sfGFP gene (Bpm I site 
is only used in the forward primer in the first EI-PCR of one codon mutation. For some 
unknown reason, replacing this Bpm I site with Bsg I site caused PCR failure). The 
reverse primer supplies up to three new codons and an “anchor” sequence that will serve 
as the primer binding region for the second EI-PCR. Importantly, this “anchor” sequence 
remains in the target gene and can not be removed by digestion. Hence, Bsg I or Bpm I 
digestion of this PCR product followed by re-ligation yields a library of plasmids each 
containing a random codon “scar” filled by new codons and an “anchor” sequence. To 
remove the “anchor” sequence, the library from the first EI-PCR is subjected to a second 
EI-PCR where two primers anneal to the “anchor” in a “back-to-back” manner and 
amplify the whole plasmid (Figure 2.6). Subsequent Bsg I digestion, Klenow treatment 
and re-ligation generates a mutant library where each clone has up to three consecutive, 
random codon mutations. The primers used in CSM are summarized in Table 2.5.  
We chose to deliver NDT degenerate codons (N= adenine (A)/cytosine (C)/guanine 
(G)/thymine (T); D=A, G, T) to sfGFP. NDT codon includes 12 codons, encoding 12 
unique amino acids (Phe, Leu, Ile, Val, Tyr, His, Asn, Asp, Cys, Arg, Ser, Gly). This 
combination represents a balanced mix of polar and nonpolar, aliphatic and aromatic, and 
positively charged and negatively charged amino acids, excluding most of the structurally 
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similar amino acids. Hence, NDT codon can increase the chance of positive hits in 
screening by reducing the number of variants with identical or similar mutations (71).  
In comparison with the previous MuDel transposon-based single codon mutagenesis 
(49), one of the most important advances of the current CSM method is that the number 
of codons to be mutated can be easily adjusted by using different primer pairs. This is 
achieved by precise placement of the type IIS resctriction sites in primers such that a 
certain number of nucleotides can be removed from the target gene. Moreover, 
challenging DNA manipulation steps, such as inter-molecular blunt-end ligation, are 
excluded from the current method. 







First PCR, Fwd 
remove one codon.  
FF2 TTTTTCGTGTGCAGTCGGA 
First PCR, Fwd 
remove two codons. 
FR1 AHNAATCAACGACTTTGCGCCGCTAAG 
First PCR, Rev 
introduce one codon. 
FR2 AHNAHNAATCAACGACTTTGCGCCGCTAAG 
First PCR, Rev 
introduce two codons. 
FR3 AHNAHNAHNAATCAACGACTTTGCGCCGCTAAG 
First PCR, Rev 
introduce three codons. 
SF0 TAACGTGCAGTTACAAGTCGTTGATT 
Second PCR, Fwd 
cleave to new codons. 
SF1 CATCGTGCAGATGCGCCGCTAAG 
Second PCR, Fwd 
remove one codon. 
SR CTTCGTGCAGTAAATGCGCCGCTAAG 
Second PCR, Rev 





Note: [a] More than one primer pairs may exist for generation of a certain mutation. 
For example, two codon mutation can be achieved using either FF2/FR2 
in the first PCR and SF0/SR in the second PCR or FF1/FR2 in the first 
PCR and SF1/SR in the second PCR.  
       [b] Bsg I and Bpm I sites are underlined. Asymmetric sequences are 
highlighted in red 
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2.2.3.2 Overall efficiency of CSM 
To assess the quality of the library, 50 colonies were randomly chosen from each library 
and sequenced (see Appendix V for sequencing results). The frequency of clones 
containing seamless, in-frame mutations in single, di- and tri-NDT library was 47.6%, 
65.0% and 63.6 %, respectively (Table 2.6). This suggests that CSM has sufficient 
mutagenesis efficiency for constructing large-scale libraries. The incorrect mutations 
generally arose from incomplete Bsg I/Bpm I digestion (resulting in uncut primer 
sequence) or overdigestion of Klenow (resulting in one additional nucleotide deletion). 
Table 2.6. Mutagenesis Efficiency of CSM 
Library One Two Three 
Total sequenced 50 50 50 
Incorrect 21 20 28 
Correct 29 30 22 
% Correct  58.0 60.0 44.0 
 
To analyze if these mutations were distributed uniformly along the sfGFP, the 
cumulative fraction of correct mutations were plotted against amino acid positions of 
sfGFP (Figure 2.21). The distribution of mutations in these three libraries shows similar 
trends. While mutations occur in all regions of the sfGFP protein, there is a mild 
preference for the N-terminal mutations, likely the result of transposon target sequence 
bias. Next was examined the amino acid composition of the introduced codons. The 
degenerate sequence “NDT” (12 codons/12 amino acids) is a balanced mix of codons 
(71). Ideally, these 12 codons can be delivered into a protein sequence with equal 
probability. In this study, however, we observed a bias of the introduced codons (Figure 
2.22). The 81 correct mutants introduce 155 new codons. Thus, the expected average 
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number of each of the 12 amino acids is 13. The mutants in the current study are rich in 
Arg and His mutations and short of Ile and Phe mutations. This codon bias most likely 





















Figure 2.21. Distribution of mutations in sfGFP, based on 81 correct mutations. For 
consecutive mutations, positions of the first mutations are chosen for plotting the curve. 
Figure 2.22. Introduced codon types in sfGFP, based on 81 correct mutants 
(introducing 155 new codons). The amino acids encoded by NDT codons are Gly 
(GGT), Val (GTT), Leu (CTT), Ile (ATT), Cys (TGT), Ser (AGT), Arg (CGT), His 
(CAT), Asp (GAT), Asn (AAT), Phe (TTT) and Tyr (TAT). 
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2.2.3.3 Identification of spectra-shifted mutants of sfGFP 
As a proof of principle, CSM was performed on sfGFP to search for variants that 
exhibited altered spectral properties. Several spectra-shifted mutants were successfully 
identified by screening only 500 colonies from each library (Figure 2.23). The excitation 
peaks of these mutants shifted up to 15 nm to blue and up to 25 nm to red as compared to 
the 490 nm peak in original sfGFP (Figure 2.23A). For the emission peaks, up to 6 nm 
blue shift and up to 12 nm red shift were observed (Figure 2.23B). Interestingly, among 
those identified spectral mutations is a red-shift mutation S203Y, which has been 
reported in yellow fluorescent protein (YFP) (5). This tyrosine mutation at position 203 
introduces an aromatic ring that overlays with the phenol ring in chromophore and thus 







Figure 2.23. Normalized excitation and emission of spectra-shifted mutants. For 
excitation spectra (A), the emission wavelengths are 530 nm for mutant S203Y, 520 
nm for mutants S205C and Q204L/S205V/V206D, and 515 nm for all other 
mutants. For emission spectra (B), the excitation wavelengths are 505 nm for S203Y 
and 490 nm for all other mutants. Note that all the mutations are referred to as in the 




More interestingly, a S205D mutant was found to be 7-fold more fluorescent than the 
original sfGFP when excited under UV light but non-fluorescent when excited under 
visible light (Figure 2.24). Characterization of the excitation spectra showed that the 
S205D mutant bears a single peak at 395 nm as compared to the original sfGFP that has a 
minor peak at 395 nm and a major peak at 490 nm. The 395 nm and 490 nm excitation 
peaks are known to arise from the different ionization states of the chromophore (80). 
The neutral/protonated chromophore is responsible for the 395 nm peak. Upon light 
irradiation, the chromophore becomes deprotonated and can absorb light in the visible 
region (80). The enhanced fluorescence under UV light and the elimination of 
fluorescence under visible light in S205D mutant are likely due to the change of 
ionization states of the chromophore. The S205 residue in the sfGFP structure (PDB entry 
2B3P) (72) projects toward the chromophore and the S205D mutation may alter the pKa 







Figure 2.24. Normalized excitation and emission of S205D mutant. For excitation 
spectra (A), the emission wavelengths are 510 nm for both original sfGFP and S205 
mutants. For emission spectra (B), excitation at either 395 nm or 480 nm was used. 
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    In the current study, three factors play important roles in the successful identification 
of these spectra-shifted mutants. First, the highly stabilized template protein sfGFP (72) 
provides extra stability space for beneficial mutations to appear (81). Second, the NDT 
degenerate codon (12 codons/12 aa) increases the chance of a positive hit in screening by 
reducing codon redundancy (as compared to the conventional NNK codon, 32 codons/20 
amino acids). Third and most importantly, our approach allows the direct construction of 
mutant libraries with high diversity on the amino acid level, bypassing the problems of 
codon degeneracy and rare chance of consecutive nucleotide mutations in traditional 
random mutagenesis methods that usually compromise the diversity of mutant libraries. 
 
2.3  Conclusion and Future Applications 
2.3.1 Generation of a size-minimized GFP 
MuDel deletion mutagenesis and CDM experiments have determined more than 40 
“neutral” deletions in GFP, suggesting that GFP is not a “naturally minimized” protein. 
Furthermore, the fluorescence loss caused by these “neutral” deletions can be restored by 
incorporation of folding-mutations. These results have pointed to the way to generate a 
size-minimized GFP: stepwise incorporation of “neutral” deletions followed by folding 
rescue. However, there are several general considerations (see Figure 2.25 for proposed 
procedure). First, it is desirable to start with a stabilized template, such as sfGFP, which 
already has several folding mutations incorporated. Second, terminal deletions can be 
incorporated before internal deletions as GFP is known to tolerate terminal deletions (51). 
Third, folding rescue can be achieved by either adding a known folding mutation or 
globally optimizing the folding state of the truncated GFP by random mutagenesis. Last, 
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the final mini-GFP may require further optimization for oligomerization state and other 








2.3.2 Application of CDM 
CDM is advantageous over many other random deletion mutagenesis methods because it 
i) generates random, in-frame codon deletions, ii) allows up to five consecutive codon 
deletions per round of mutagenesis and iii) is technically efficient (no challenging DNA 
manipulations). It can be used to engineer not only GFP but also many other proteins 
which have not been extensively explored for deletion engineering. Perhaps one of its 
most interesting applications is to study how length variations affect protein functions. 
Antibodies, for example, are known to have length variations in the complementarity 
determining regions (CDRs) and are thus good target for CDM. Another good reason of 
applying CDM on the CDRs of antibodies lies in that CDRs usually contain flexible loop 
structures which are responsible for antigen-binding specificity. As compared with  
sheets, these loops may have less structural constraints and therefore, be more tolerant to 











Figure 2.25. Proposed procedure for generation of a size-minimized GFP. The green 
and grey colors indicate fluorescent and non-fluorescent constructs, respectively. 
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create a “mixed” library of mutants carrying one to five codon deletions. Outlined below 











2.3.3 Application of asymmetric transposon-based CSM 
CSM is a very powerful random mutagenesis method. It generates codon mutations and 
the number of codons to be mutated can also be easily adjusted using different primer 
pairs in the EI-PCR. These two features enable CSM to achieve complicated tasks. 
Shown below are several potential applications of CSM. 
2.3.3.1 Single, di- and tri- alanine scanning mutagenesis  
Traditional alanine scanning mutagenesis (82) requires synthesis of different primer pairs 
for alanine mutations at different positions. This method is basically to perform site-
directed mutagenesis on several sites of choice. Although this method is generally 
successful, it requires predicting a specific region for scanning. The information beyond 







Figure 2.26. Proposed experiments of antibody engineering using CDM. The red 
color represents variable region while the blue color stands for constant region. 
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may be very difficult as it requires tremendous effort to synthesize the primers and 
generate all the mutants in individual reactions. CSM overcomes this problem as it allows 
full-length alanine scanning and can generate all mutants in a single reaction (Figure 
2.27). With a proper screening/selection method, alanine mutants with interesting 
property changes can be identified rapidly. Furthermore, CSM can also generate two or 
three consecutive alanine mutations at once. This allows one to perform regional alanine 











2.3.3.2 Semi-rational twin-cysteine scanning mutagenesis 
CSM can be also used to scan reactive amino acids throughout a protein sequence. One of 
such applications is twin-cysteine scanning mutagenesis to introduce disulfide bonds into 
proteins. Disulfide bonds play important roles in protein folding and stability, especially 
to those proteins secreted to the extracellular medium (83). Rational approach to stabilize 
protein with disulfide bonds may be very difficult as the two cysteine residues involving 
Figure 2.27. Alanine scanning mutagenesis using CSM. The red spheres represent 
alanine mutations. 








in the disulfide bond need to be spatially close to each other with their side chains 
oriented properly. Furthermore, appropriate micro-environment (oxidizing conditions) is 
also an important consideration. CSM bypasses these limitations as it can randomly 













Perhaps the easiest and most efficient way to perform twin-cysteine scanning is a semi-
rational approach with the combinatorial use of site-directed mutagenesis and CSM 
(Figure 2.28). First, several variants of a target protein can be generated using site-
directed mutagenesis (rational design) to introduce the first cysteine at several preferred 
sites. This pool of variants can then be used as the starting template in CSM to introduce 
the second cysteine. This semi-rational approach has two advantages versus the irrational 




Figure 2.28. Semi-rational twin-cysteine scanning mutagenesis using CSM. The 
red spheres represent rationally introduced cysteine mutations by site-directed 
mutagenesis while the blue sphere represent randomly introduced cysteine 
mutations by CSM. 
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knowledge and thus may increase the chance of disulfide bond formation and the chance 
of having a beneficial disulfide bond. Second, this semi-rational approach can create a 
library with more mutants containing desired mutations. CSM has a mutagenesis 
efficiency of ~50% (Table 2.6), meaning that two rounds of CSM will give a library 
where only ~25% of the mutants contain desired mutations. This is an important 
consideration especially when high-throughput screening methods are not available. 
2.3.3.3 Generation of an “ultimate” mutant library 
The most interesting feature of CSM is that the number of mutated codons can easily be 
adjusted by using different primer pairs. Although we reported the generation of up to 
three codon mutation, four or five codon mutations are also possible if proper primers can 
be designed. Significantly, these primers can be used separately as shown above or 
combined as a mix. For example, when primers FF1, FF2, FR1 and FR2 (Table 2.5) are 
used together in the first EI-PCR, four possible combinations can occur (Figure 2.28A). 
The combination of primer pairs allows generation of an ultimately diversified library 
that contains random codon deletions, insertions and substitutions (Figure 2.28B). To the 
best of our knowledge, such versatile libraries can not be easily constructed by any 
existing mutagenesis method. These libraries will largely expand our knowledge as it will 
provide the direct comparison of the effects of codon deletions, insertions and 
























2.4  Materials and Methods 
2.4.1 Random deletion mutagenesis of GFPUV using MuDel transposon 
2.4.1.1 Construction of deletion library of GFPUV 
pGFPUV vector (Clontech, Mountain View, CA) was used as the transposon-targeting 
plasmid in transposition reaction. All of the four Mly I sites (249, 2334, 2836 and 3322) 
were removed from pGFPUV by site-directed mutagenesis (see Appendix III for primer 
FF1 
(remove one codon) 
FF2 
(remove two codons) 
FR1 
(deliver one codon) 
FR2 
(deliver two codons) 
One codon deletion 
one codon substitution 
One codon substitution 
One codon substitution 
one codon insertion 
Two codon substitution 
Choice of  
forward primer 









Figure 2.29. Generation of libraries containing random deletions, insertions and 
substitutions using CSM. A) Examples of libraries resulting from combined primer 
pairs. B) Generation of random deletions, insertions and substitutions in a single library.  
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sequences). The GFPUV protein expressed from this vector contains a 24 amino acid N-
terminal fusion tag. 
The MuDel transposon bearing chloramphenicol selection marker was PCR amplified 
as previously described (25). The PCR product was cloned into pCR2.1 TOPO vector 
(Invitrogen, Carlsbad, CA). Transposon DNA was released from this vector by Bgl II 
digestion and then gel-purified. The transposition reaction contained 570 ng of pGFPuv 
vector, 140 ng of transposon DNA, 1 unit of HyperMu MuA transposase (Epicentre 
Biotechnologies, Madison, WI), 50 mM Tris-acetate (pH 7.5), 150 mM potassium 
acetate, 10 mM magnesium acetate and 4 mM spermidine in a 20 L solution. The 
reaction was kept at 30 °C for 4 h and then stopped by addition of SDS to 0.1% followed 
by heat-inactivation at 70 °C for 10 min. The reaction product (1 L) was transformed 
into 50 μL of chemically competent GeneHogs Escherichia coli cells. The cells were 
recovered in SOC at 37 °C for 1 h and plated on LB agar containing 100 g/mL 
ampicillin (Amp100) and 35 g/mL chloramphenicol (Chl35) to select for the pGFPUV 
vector with transposon insertions. In total, 38,000 colonies were collected to build the 
pGFPUV-MuDel library. These colonies were sufficient to ensure the full coverage of 
library diversity (78). The library DNA was extracted and digested by EcoR I/Kpn I 
(Fermentas, Glen Burnie, MD). As transposon could insert both in and outside of the 
GFPUV gene, EcoR I/Kpn I digestion generated four DNA fragments: GFPUV, 
GFPUV+transposon, vector backbone, vector backbone+transposon (Figure 2.7B). The 
2.0 kb band (GFPUV + transposon) and and 2.6 kb band (vector backbone) were re-ligated 
to isolate those transposon insertions in the GFPUV gene. The ligation product was 
transformed into chemically competent GeneHogs E.coli cells. The plasmid DNA of the 
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cleaned transposon library was extracted and then digested by Mly I (Fermentas) as 
follows: 1.5 g DNA, 10 unit of Mly I (New England Biolabs, Ipswich, MA), 100 g/mL 
of BSA, 20 mM Tris-acetate (pH 7.9), 50 mM potassium acetate, 10 mM magnesium 
acetate and 1 mM DTT in a 100 L reaction. The reaction was kept at 37 ºC for 3 h and 
then gel-purified to isolate the linearized pGFPUV plasmid with random triplet nucleotide 
deletion. The gel-purified product was subjected to a blunt-end intramolecular ligation in 
a 20 L reaction containing 300 ng DNA, 400 cohesive end units of T4 DNA ligase 
(NEB), 50 mM Tris-HCl (pH7.5), 10 mM MgCl2, 10 mM DTT and 0.5 mM ATP. The 
ligation was performed at 16 ºC for 16 h. This product was transformed into chemically 
competent GeneHogs E. coli cells. In total, 10,000 transformants were collected as the 
deletion library. 
2.4.1.2 Screening of deletion mutants 
The plasmid DNA of the deletion library was transformed into GeneHogs E. coli cells 
and then plated on LB agar (Amp100) at a density of ~500 colonies/plate. These plates 
were grown at either 37 ºC for 14 h or 23 ºC for 30 h. Screening of the fluorescent and 
non-fluorescent mutants was accomplished using a TC312E UV transilluminator (310 nm 
wavelength) (Spectronics, Westbury, New York) by visual inspection. In total, 40 
fluorescent colonies were picked from the plates grown at either 37 ºC or 23 ºC and 24 
non-fluorescent colonies were picked from the 23 ºC plates. All the picked clones were 
verified by digestion and then sequenced at DNA Analysis Facility at Yale University 
(New Haven, CT). 
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2.4.1.3 Liquid culture whole-cell fluorescence 
Plasmid DNAs of wtGFPUV and deletion mutants were transformed into GeneHogs E. 
coli cells and plated on LB agar (Amp100) at a density of ~200 colonies/plate. Single 
colonies with a diameter of ~0.5 mm were inoculated into 2 mL of liquid LB media 
(Amp100). Three replicates of each sample were grown at 37 ºC, 30 ºC and 23 ºC for 14, 
18 and 25 h, respectively. The E. coli cells of each sample were harvested by 
centrifugation, washed with 500 L of TNG buffer (100 mM Tris-HCl, pH 7.5, 150 mM 
NaCl and 10% glycerol) (72) and then resuspended in 100 L TNG buffer. A fraction of 
the resuspended cell solution was adjusted to an OD600 of 0.150 ± 0.003 for fluorescence 
assay. The rest cell solution was stored at -20 ºC for further experiments. Whole-cell 
fluorescence assay was performed using a model F4500 fluorescence spectrophotometer 
(Hitachi, Tokyo, Japan) with 397 nm for excitation wavelength and 509 nm for the 
emission wavelength. The background of empty GeneHogs cells was subtracted from 
each reading. The fluorescence of each deletion mutant was normalized to that of 
wtGFPUV grown under the same temperatures. 
2.4.1.4 Expression level and fraction soluble analyzed by SDS-PAGE 
The resuspended cells of wtGFPUV and deletion mutants were adjusted to an OD600 of 
0.100 with TNG buffer. For each sample, 300 L of such cell solution was forced to two 
sequences of 10 pulse sonication with an interval of 3 min using a model 450 sonicator 
(Branson Ultrasonics, Danbury, CT) equipped with a 1/2 inch horn and a 1/8 inch tip 
with 50% power output and 50% duty time. The gel loading sample was prepared by 
mixing 15 L sonicant (crude cell lysis) with 15 g BSA protein (Sigma, St. Louis, MO) 
which served as an internal standard to quantify the GFP expression. The protein samples 
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were resolved in 12% acrylamide SDS-PAGE gels and analyzed by Image J 
(http://rsbweb.nih.gov/ij/). The overall GFP expression was quantified based on the 
density ratio of GFP band and BSA band on the protein gels as previously described (72) 
(Figure 2.9A). To calculate the soluble fraction of GFP, 15 L sonicant was clarified by 
centrifugation and the supernatant was mixed with 15 g BSA protein. The same analysis 
was performed as above to obtain the soluble GFP expression. The fraction soluble of 
each sample was the ratio of soluble GFP expression and overall GFP expression. Three 
individual replicates were performed for each protein sample. 
2.4.1.5 Protein expression and purification 
wtGFPUV and the five mutants with internal deletions (C48, P75, P75/D76H, E172, 
S175/V176F) were cloned into pET28b(+) vector (EMD Chemicals, San Diego, CA) 
using primers GFPUV_FWD and GFPUV_REV (Appendix III). The recombinant DNAs 
were transformed into (DE3) E. coli cells (Stratagene, La Jolla, CA). A single colony was 
inoculated into 100 mL 2×YT media, induced with 1 mM of IPTG at OD600 of 0.6 and 
then grown at 20 ºC for 12 h. The cells were centrifuged, washed twice with binding 
buffer (100 mM HEPES, pH 7.5, 10 mM imidazole) and then resuspended in 30 mL 
binding buffer supplemented with 1 mM PMSF. The resuspended cells were sonicated 
and then centrifuged at 12,000 for 15 min to isolate the soluble fractions. The soluble 
proteins were run through Promega HisLink resins (Promega, Madison, WI), washed 
with wash buffer (100 mM HEPES, pH 7.5, 50 mM imidazole) and then eluted with 
elution buffer (100 mM HEPES, pH 7.5, 500 mM imidazole). The eluted proteins were 
dialyzed into two successive 200-fold TNG buffer. Each sample was purified to >90% 
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homogenity and the concentration was determined using Pierce BCA Protein Assay kit 
(Thermo Fisher Scientific, Rockford, IL). 
2.4.1.6 Characterization of purified deletion mutants 
The excitation and emission spectra were scanned using 6 g/mL of purified proteins in 
TNG buffer. The emission wavelength for the excitation scan was 509 nm. The emission 
scan was recorded using excitation wavelengths of both 397 nm and 495 nm. 
The concentration of proteins containing matured chromophore was determined using 
the “base-denatured” method (75). Briefly, 7 M of purified proteins were denatured in 
0.1 M NaOH (pH 13) for 5 min at 25 ºC. Absorption spectra from 300 nm to 600 nm 
were scanned using Cary 50 Bio UV-visible spectrophotometer (Varian, Palo Alto, CA). 
The concentrations of matured proteins were calculated using Beer-Lambert Law: 
A = c·l· 
where A is the experimentally determined absorbance at 447 nm, c is the concentration of 
matured protein that is to be obtained, l is the path length of the cuvette and  is pre-





) (75). The efficiency of chromophore maturation (Echromphore) or fraction 
of matured protein was calculated using the following equation: 
Echromphore = c matured/ c overall 
where c matured is the concentration of matured protein pre-determined using “base-
denatured” method as above and c overall equals 7 M in this experiment. Three 
measurements of the same protein preparation were performed with an estimated 
instrumental error of 2%. 
The 397 and 495 of wtGFPUV and mutants were determined using Beer-Lambert Law: 
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A = c·l· 
where A was the experimentally determined absorbance at corresponding wavelengths 
(397 nm or 495 nm), c is the concentration of matured GFP (as the efficiency of 
chromophore maturation is pre-determined, the concentration of matured protein can be 
calculated if the overall protein concentration is known) and l is the path length of the 
cuvette. 
To determine the quantum yield of each mutant, protein samples were adjusted to an 
absorbance of 0.100 at 397 nm and then diluted 100 fold with water. The emission from 
450 nm to 600 nm using an excitation wavelength of 397 nm were integrated and then 
compared to the integrated emission of wtGPFUV, for which a quantum yield of 0.79 has 
been reported (76). 
2.4.1.7 Fluorescence rescue by folding-enhancing mutations F64L and S30R 
The central mutation F64L (77) and distant mutation S30R (72) were introduced into 
wtGFPUV and deletion mutants by site-directed mutagenesis (see Appendix III for the 
primer sequences). The whole-cell fluorescence of F64L- or S30R-rescued mutants at 37 
ºC was assayed as above. The fluorescence of deletion mutants with F64L or S30R 
mutations was normalized to that of GFPUV-F64L or GFPUV-S30R, respectively. Mutants 
with double internal deletions were constructed using site-directed mutagenesis (see 
Appendix III for the primer sequences). Mutations F64L and S30R were then introduced 
into the double deletion mutants. The rescued whole-cell fluorescence of double deletion 




2.4.2 Codon deletion mutagenesis of GFPUV using MuCDM transposon  
2.4.2.1 Construction of MuCDM transposon and transposon-targeting plasmid 
The asymmetric Mu transposon for codon deletion mutagenesis (MuCDM) was 




CGAAAATGAGTAAACGCGGTCTGACTC-3' (Bgl II site underlined, the four 
nucleotide difference highlighted in red and MuA transposase recognition sites in 
shadow). The PCR was performed using Taq DNA polymerase and the following PCR 
cycling conditions: 95 ºC for 3 min, 11 cycles of 95 ºC for 30 s, 66 ºC (-1 ºC/cycle) for 30 
s and 72 ºC for 2 min, followed by 20 cycles of 95 ºC for 30 s, 66 ºC for 30 s and 72 ºC 
for 2 min and final extension at 72 ºC for 10 min. The PCR product was first cloned into 
pCR2.1 TOPO vector (Invitrogen) using TA-end cloning (easy cloning process). This 
PCR product was then transferred into the Hind III and Xba I site of pUC18 vector for 
long-term storage purpose. The MuCDM transposon was released from pUC18 vector by 
Bgl II digestion and then gel-purified using the QIAquick purification (Qiagen, Valencia, 
CA) prior to transposition reaction. 
The plasmid pTTGFPUV was constructed by cloning the GFPUV gene (Clontech) into 
the previously described intein-targeting plasmid pIT (49). GFPUV was fused downstream 
to the Tat signal peptide and vacuolar membrane ATPase (VMA) intein N-terminal 
domain (VMAI-N) (see Appendix IV for the full sequence). The GFPUV insert sequence 
was confirmed by sequencing at Yale. 
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2.4.2.2 Transposition reaction 
The transposition reaction was performed in a 10 L reaction containing 420 ng of 
pTTGFPUV, 125 ng of gel-purified MuCDM transposon, 1 unit of HyperMu MuA 
transposase (Epicentre), 50 mM Tris-acetate (pH 7.5), 150 mM potassium acetate, 10 
mM magnesium acetate and 4 mM spermidine. The molar ratio of transposon DNA to 
target plasmid was approximately 1.5. The transposition reaction was incubated at 30 ºC 
for 4 h and then stopped by 0.1% SDS followed by heat-inactivation at 70 °C for 10 min. 
The reaction was then cooled on ice and 2 L of the product was transformed into 200 
lL electro-competent GeneHogs E. coli cells. The transformants were plated on LB agar 
supplemented with 50 g/mL kanamycin (Kan50) and 40 g/mL ampicillin (Amp40) and 
grown at 30 °C overnight. In total, 3,000 colonies were resulted and collected as the 
pTTGFPUV-MuCDM library. Twenty random colonies were digested with EcoR I and 
FastDigest Mly I (Fermentas) to verify the randomness of transposon insertions. 
2.4.2.3 Enzymatic inverse PCR (EI-PCR) 
In this study, five deletion libraries were constructed, containing one to five codon 
deletions, respectively. The pTTGFPUV-MuCDM library was used as the template in the 
EI-PCR. As the starting and ending position of the PCR product were randomly 
distributed in the GFPUV gene (depending on the position of transposon insertions), the 
“head” of a PCR product could overlap with the “tail” of another product, resulting in 
“side product” with extended size (see Figure 2.16 for condition test of template 
concentrations). To avoid this type of homologous recombination of the PCR products, 
reduced template concentration and cycling numbers were used (79, 84). A variety of 
template concentrations and cycling numbers were tested and the optimum values were 
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determined. For each library, PCR was accomplished in four tubes of 100 L reaction 
mixture containing 12.5 pg/L template DNA, 0.5 M of corresponding forward and 
reverse primers (see below), 0.2 mM dNTPs, 0.005 U/L of Phusion DNA polymerase 
(NEB), 1 × Phusion HF buffer (NEB, providing 1.5 mM MgCl2) and additional 2 mM 
MgSO4. The primers for each PCR were carefully designed to avoid non-specific 
annealing. The optimized primer pairs were FWD8N/REV0N, FWD8N/REV3N, 
FWD8N/REV6N, FWD8N/REV9N and FWD11N/REV9N for one, two, three, four and 
five codon deletion libraries, respectively (Table 2.2). All five PCRs were performed in a 
standardized cycling condition: initial denaturation at 98 °C for 2 min, 18 cycles of 98 °C 
for 10 s, 59 °C for 30 s and 72 °C for 2.5 min and final extension at 72 °C for 10 min. 
The 400 L PCR product of each library was pooled, purified using PCR purification kit 
(Qiagen) and eluted with 30 L of 10 mM Tris-HCl buffer, pH 8.5. 
2.4.2.4 Bsg I digestion and Klenow treatment 
The purified PCR product was digested with Bsg I in a 50 L reaction containing 
250~400 ng DNA, 0.12 U/L Bsg I (NEB), 80 M SAM, 20 mM Tris-acetate, 50 mM 
potassium acetate, 10 mM magnesium acetate and 1 mM DTT. The reaction was 
incubated at 37 °C for 4 h in a PCR thermocycler. Bsg I was then heat-inactivated at 65 
°C for 20 min. The reaction mixture was cooled to room temperature. dNTPs (Fermentas) 
were added into the reaction to a final concentration of 33 M. Thereafter, 0.5 U Klenow 
(large fragment of DNA polymerase I) (NEB) was added to each 50 L Bsg I digestion. 
The blunting reaction was incubated at 25 °C for exactly 15 min using a PCR 
thermocycler. The reaction was stopped instantly after incubation by addition of 1.1 L 
of 0.5 M EDTA, pH 8.0, followed by heat-inactivation at 75 °C for 20 min. The 50 L 
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reaction was then incubated with 4 U of Dpn I (NEB) at 37 °C for 80 min to destroy the 
template plasmid DNA (methylated). The digested DNA was gel-purified using 
QIAquick purification (Qiagen). This procedure typically resulted in 3~5 ng/L gel-
purified product. 
2.4.2.5 Intra-molecular ligation and transformation 
The blunt-end intra-molecular ligation was performed as follows: 2.5 ng/L of gel-
purified DNA, 0.1 Weiss unit/L of T4 DNA ligase (Fermentas), 40 mM Tris-HCl (pH 
7.8 at 25 °C), 10 mM MgCl2, 10 mM DTT and 0.5 mM ATP in a 10 L reaction. The 
ligation was incubated at 16 °C for 8 h and then heat-inactivated at 70 °C for 6 min. The 
ligation product (1 L) was transformed into 50 L of electro-competent GeneHogs cells 
and plated on LB agar (Kan50) at 37 °C overnight. This yielded approximately 1,000 
colonies/ L ligation product. More than 5,000 colonies were collected for each library in 
this study. In total, 24 random colonies were picked from from each library and 
sequenced for assessing the library quality. 
2.4.2.6 Screening of deletion mutants with various degree of fluorescence 
The five deletion libraries were cloned into the Hind III/ Nhe I site of pET28b(+) vector. 
The ligation products were initially transformed into GeneHogs cells and more than 
2,000 colonies were collected from each library. The plasmid DNA of each library was 
extracted from GeneHogs cells and then transformed into BL21 (DE3) cells (Stratagene 
Inc., La Jolla, CA) for analysis of fluorescence. The transformants were plated on LB 
agar (Kan50) and 1 mM IPTG and grown at 19 °C for 30 h. The screening was 
accomplished using a TC312E UV transilluminator (310 nm light) (Spectronics) by 
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visual inspection. From each library, 8 fluorescent and 8 non-fluorescent colonies were 
randomly picked for sequencing analysis. 
2.4.2.7 Determination of liquid culture whole-cell fluorescence 
Freshly transformed colonies of wtGFPUV and deletion mutants in the context of 
pET28b(+) vector were inoculated into 1 mL of liquid LB (Kan50) and grown overnight 
at 37 ºC. The overnight culture (50 L) was inoculated into 1 mL LB (Kan50) and grown 
at 37 ºC for 4 hours. The culture was then induced with 1 mM IPTG and expressed at 20 
ºC for 18 h. The cells were harvested by centrifugation, washed twice with 500 L of 
TNG buffer  (72) and then resuspended in 50 L TNG buffer. Whole-cell fluorescence 
assay was performed under an OD600 of 0.150 ± 0.003 using a model F4500 fluorescence 
spectrophotometer (Hitachi). The excitation wavelength was fixed at 395 nm and the 
fluorescence intensity at 509 nm was recorded for each sample. The BL21 (DE3) cell 
background was subtracted from each reading. The fluorescence of each mutant was 
normalized to the fluorescence of wtGFPUV. Four replicates of expression were 
performed for each sample. 
2.4.3 Codon scanning mutagenesis of sfGFP using MuCSM transposon 
2.4.3.1 Construction of MuCSM transposon and transposon-targeting plasmid 
Asymmetric transposon MuCSM were constructed by PCR amplifying the described Mly 
I TAG linker (49) using primers 5'-
AAAGGATCCTTAGCGGCGCACGAAAAACGCGAAAGCGTTTCACGATAAATGC
GAAAACGGAAGGTATTCGCAATAATCTTAAT-3'  AND 5'-
AAAAGATCTCCGACGGCGCACGAAAAACGCGAAAGCGTTTCACGATAAATG
CGAAAATGAGTAAACGCGGTCTGACTC-3' (Bgl II and BamH I sites underlined, the 
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five nucleotide difference highlighted in red and MuA transposase recognition sites in 
shadow). This PCR was performed using Taq DNA polymerase with the following cycle 
conditions: 95 °C for 3 min, 11 cycles of 95 °C for 30 s, 66 °C (-1 °C/cycle) for 30 s and 
72 °C for 2 min, followed by 20 cycles of 95 °C for 30 s, 66 °C for 30 s and 72 °C for 2 
min and final extension at 72 °C for 10 min. The PCR product was blunted and cloned 
into the pUC18 vector. Prior to transposition reactions, the transposon DNA was released 
from the vector by BamH I/Bgl II digestion, followed by gel-purification using a 
QIAquick gel-extraction kit (Qiagen, Valencia, CA). The pTTsfGFP plasmid was 
generated by cloning the sfGFP gene into the previously described intein-targeting 
plasmid pIT (49). The sfGFP gene used in this study is a synthetic gene that has been 
optimized for expression in E. coli and is devoid of the restriction sites required for the 
mutagenesis process in this study (85). Sequence details of MuCSM transposon and 
pTTsfGFP plasmid can be found in Appendix IV. 
2.4.3.2 Generation of a sfGFP library with random transposon insertions 
Transposition reactions were performed in a 20 L reaction containing 450 ng 
pTTsfGFP, 125 ng gel-purified transposon DNA, 1 unit of HyperMu MuA transposase 
(Epicentre), 50 mM Tris-acetate (pH 7.5), 150 mM potassium acetate, 10 mM 
magnesium acetate and 4 mM spermidine. The reaction was incubated at 30 °C for 4 h 
and halted by the addition of 2 L of 0.1% SDS followed by heat-inactivation at 70 °C 
for 10 min. The reaction was cooled on ice and 1 L of the solution was transformed into 
50 L electro-competent GeneHogs cells. The transformants were recovered at 37 °C for 
1 h and plated on LB agar (Kan50/Amp40). The plates were incubated at room 
temperature for 48 h. More than 10,000 colonies were resulted from the 20 L 
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transposition reaction and were collected to build the pTTsfGFP-MuCSM library. From 
this transposon library, 23 colonies were randomly picked and digested with FastDigest 
Mly I and EcoR I (Fermentas) to verify the randomness of transposon insertions. The 
library DNA was extracted and digested with Nhe I/ EcoR I (Fermentas). This yielded 
four DNA fragments (pTT backbone-transposon, pTT backbone, sfGFP-transposon and 
sfGFP). The sfGFP-transposon fragment was isolated and ligated into the Nhe I/EcoR I 
site of a modified pTrcHisA expression vector (Invitrogen) in which the Bsg I and Bpm I 
sites had been removed (see Appendix III for primer sequences). In total, 30,000 
colonies were collected from this ligation, sufficient to ensure the full coverage of library 
diversity (78). The DNA of pTrcHisA-sfGFP-MuCSM library was extracted and used as 
the template in the following EI-PCR. 
2.4.3.3 EI-PCR 
Single, di- and tri-NDT libraries were constructed using the same pTrcHisA-sfGFP-
MuCSM library DNA as the template but different primer pairs in the PCR amplification. 
The optimum template concentrations and annealing temperatures were individually 
determined for each reaction. The PCR was performed in four tubes of 100 L solution 
each containing X pg/L library DNA (see below), 0.5 M each of corresponding 
forward and reverse primers, 0.2 mM dNTPs, 0.005 U/L of Phusion DNA polymerase 
(NEB), 1×Phusion HF buffer (NEB, providing 1.5 mM MgCl2) and additional 2 mM 
MgSO4. X indicates the optimum template concentrations and was 100, 125 and 200 
pg/L for single, di- and tri-NDT library, respectively. The PCR cycle conditions were: 
initial denaturation at 98 °C for 2 min, 18 cycles of 98 °C for 10 s, Y °C for 30 s and 72 
°C for 2 min followed by a final extension at 72 °C for 10 min. Y represents the optimum 
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annealing temperatures and was 57, 59 and 65 °C for single, di- and tri-NDT library, 
respectively. The primer pairs were FF1/ FR1, FF2/ FR2 and FF2/ FR3 for single codon, 
di-codon and tri-codon libraries, respectively (Table 2.5). The PCR product was purified 
using QIAquick PCR purification kit (Qiagen).  
2.4.3.4 Bsg I or Bpm I digestion and Klenow treatment 
The purified PCR product of single NDT library was digested with Bpm I in a 50 L 
reaction containing 500 ng DNA, 1 U FastDigest BpmI (Fermentas) and 1×FastDigest 
buffer (Fermentas). The reaction was incubated at 30 °C for 4.5 h followed by heat-
inactivation at 65 °C for 20 min. The purified PCR product of di-NDT or tri-NDT library 
was digested with Bsg I in a 50 L reaction containing 500 ng DNA, 6 U Bsg I (NEB), 80 
M SAM and 1× buffer 4 (NEB). The reaction was incubated at 37 °C for 4.5 h followed 
by heat-inactivation at 65 °C for 20 min. The digestion product of each library was 
treated with Klenow fragment by adding 1.7 L of 1 mM dNTPs (NEB) and 0.5 U of 
Klenow fragment (NEB) into 50 L heat-inactivated reaction solution. The Klenow 
treatment was performed at 25 °C for 15 min and stopped by addition of 1.1 L of 0.5 M 
EDTA, pH 8.0, followed by heat-inactivation at 75 °C for 20 min. The Klenow-treated 
digestion product was then gel-purified using QIAquick gel-extraction kit (Qiagen). 
2.4.3.5 Intramolecular ligation and transformation 
The gel-purified digestion product (Klenow-treated) was subjected to an intramolecular 
ligation that contained 2.5 ng/L DNA, 0.5 Weiss unit/L T4 DNA ligase (Fermentas), 
40 mM Tris-HCl (pH 7.8 at 25 °C), 10 mM MgCl2, 10 mM DTT and 0.5 mM ATP in a 
10 L reaction. The ligation reaction was incubated at 16 °C overnight and then heat-
inactivated at 70 °C for 7 min. Several 10 L ligation reactions were performed for each 
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library, pooled and then purified by ethanol precipitation. After ethanol precipitation, the 
purified ligation product was resuspended in water and then transformed into electro-
competent GeneHogs cells. The transformants were recovered at 37 °C for 1 h and then 
plated on LB agar (Amp100). In total, 2×10
5
 colonies were collected for each library and 
the DNA was extracted to be used as the template in the second EI-PCR. 
2.4.3.6 Second round of EI-PCR, digestion and intramolecular ligation 
The conditions for the second EI-PCR were generally the same as for the first one with, 
again, individually determined optimum template concentrations and annealing 
temperatures. The template concentrations were 200, 125 and 200 pg/L for single, di- 
and tri-NDT library, respectively. The annealing temperatures were 67 °C, 63 °C and 66 
°C for single, di- and tri-NDT library, respectively. The primer pairs for single, di- and 
tri-NDT libraries were SF0/ SR, SF0/ SR and SF1/ SR, respectively (Table 2.5). The 
PCR product was purified, digested with Bsg I, treated with Klenow fragment, gel-
purified, re-ligated and transformed as described above. More than 2×10
5
 colonies were 
collected from each library and the library DNA was extracted for further 
characterization. 
2.4.3.7 Screening for spectra-shifted mutants 
From each of single, di- and tri-NDT library, 500 colonies were randomly chosen and 
inoculated into 96-well plates. Each well contained 1 mL LB media (Amp100) and 1 mM 
IPTG. The plates were grown at 37 °C for 12 h. The expression culture (50 L) from 
each well was diluted with 250 L distilled water and then loaded into 96-well 
fluorescence plates. The OD600 for each sample is generally between 0.15 and 0.2 under 
these conditions. The plates were screened using a SpectraMax M5 microplate reader 
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(Molecular Devices, Sunnyvale, CA) with 2 nm bandpass. Screening was performed 
using both 400 nm excitation wavelength with an emission range from 430 to 600 nm and 
460 nm excitation wavelength with an emission range from 490 to 540 nm. The 
background fluorescence of GeneHogs cells containing empty pTrcHisA vector was 
subtracted from each sample reading. The calibrated spectral data were then normalized 
and compared to the original sfGFP spectrum. Candidate spectra-shift mutants were 
confirmed by three replicates of the whole-cell fluorescence assay as described above. 
The spectra-shifted mutants were then diluted to an OD600 of 0.2000 ± 0.0050 and the 
whole-cell spectra were recorded using a model F4500 fluorescence spectrophotometer 
(Hitachi). The obtained excitation and emission spectra were calibrated, normalized and 
compared with the normalized spectrum of original sfGFP. These spectra-shifted mutants 




Chapter 3: Enzymatic and Nonenzymatic Assembly of PolyUb 
Chains 
3.1  Introduction 
This chapter describes how unnatural amino acid (UAA) mutagenesis technologies can 
facilitate the enzymatic and nonenzymatic synthesis of polyubiquitin (polyUb) chains. 
Two approaches have been developed for the synthesis of polyUb chains. Both of these 
two approaches relied on an orthogonal pyrrolysyl tRNA (PylT) and tRNA synthetase 
(PylRS) pair to incorporate 

N-tert-butyloxycarbonyl-L-lysine (BocLys) into a targeted 
lysine position in Ub. The first method focuses on the synthesis of homogeneous polyUb 
chain which requires a linkage-specific Ub conjugating enzyme E2 (and thus termed 
enzymatic approach). The second method utilizes a silver-based protein condensation 
technique rather than E2 enzyme and can generate polyUb chains of any linkage 
composition (and thus termed non-enzymatic approach). Also introduced in this chapter 
is a simple yet highly efficient technique for large-scale production of proteins containing 
UAAs, referred to as “condensed culture” method. 
3.1.1 Biological functions of ubiquitin and polyUb chains 
Ubiqutin (Ub) protein gets the name from its ubiquitous expression in all eukaryotic 
organisms (86). It is a 8.5 KDa regulatory protein consisting of 76 amino acids. Ub is a 
highly conserved protein among a variety of organisms. For example, human Ub is only 
three amino acid different from yeast Ub. Ub was discovery in the early 1980s by Aaron 
Ciechanover, Avram Hershko and Irwin Rose. The Nobel Prize in Chemistry 2004 was 
awarded to these three scientists “for the discovery of ubiquitin mediated protein 
degradation”. During the past three decades, collaborative efforts from researchers 
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around the world have largely expanded our understanding of Ub. Now we know that Ub 
plays important roles not only in protein degradation but also in many other cellular 
processes, including gene transcription, DNA repair, cell cycle regulation and viral 
infection (86). 
Ub carries out its biological functions by conjugating to a target protein. This 
conjugation process, referred to as ubiquitinylation or ubiquination, occurs through 
isopeptide bond formation between the -amino group of a lysine residue in a target 
protein and the C-terminal carboxyl group of Ub. Target proteins can be ubiquitinylated 
by Ub monomers (mono- or multi-Ub monomers) or polyUbs (Figure 3.1A). In polyUbs, 
Ub monomers are usually connected through isopeptide bond between the C-terminal 
carboxyl group of one Ub molecule (distal monomer) and the -amino group of one of 
the seven lysine residues of another Ub (proximal monomer). These polyUbs can have 
either the same linkage (homogeneous chains) or mixed linkages (Figure 3.2B). 
Ub contains seven lysines K6, K11, K27, K29, K33, K48 and K63 out of 76 residues. 
Much of our understand about polyUb system comes from the K48 and K63-linked 
polyUb chains, where K48 or K63 in the proximal Ub involves in the isopeptide bond 
formation (87, 88). In fact, all of the seven lysines as well as the N-terminal methionine 
can serve as the distal Ub acceptors in nature. Different polyUb chains are known to have 
distinct biological functions. For example, long (tetramer or above) K48-linked polyUb 
chains can ferry ubiquinylated proteins to the proteasome for degradation, while K63-
linked polyUb chains are generally thought to act as regulatory rather than poteolytic 
signals (89-91). However, our understanding of polyUb chains is quite fragmentary and 


















In nature, polyUb chain synthesis requires a Ub activating enzyme E1, a linkage-
specific enzyme E2 and a Ub ligase E3 (87, 92). Through an ATP-dependent mechanism, 
E1 activates the C-terminal G76 of Ub by coupling its carboxyl group to the thiol group 
of a cysteine residue of E1. This activation process yields an E1-Ub thioester 
intermediate, which will be then rendered to a conserved cysteine residue of a linkage-
specific enzyme E2 by a transthiolation step. For E3 ligases, it is generally believed that 
there exist two major superfamilies, classified according to the mechanisms of 
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Figure 3.1. Ub conjugation complex. A) A target protein conjugated with mono-, 
multi-mono-, and poly-Ubs. B) Different polyUb chains. 
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adaptor to position the E2-Ub thioester bond in close proximity to a substrate (monoUb, 
polyUb or other Ub-targeting proteins) for direct thioltranslation. The second class, 
termed HECT E3s, first accept the Ub molecule (from the E2-Ub conjugate) on to one of 
their conserved cysteine residues and then pass the Ub to a substrate. This generalization, 
however, is being challenged by the emerging experiments (93). 
Studies of the relationship between the linkage, structure and function of the polyUb 
signals requires the ability to assemble these chains with natural connectivity, controlled 
length, defined linkage composition and in sufficient quantities (milligram scale). Until 
recently, this remained a challenging problem to all researchers in the Ub field. 
Traditional methods for the polyUb chain assembly can be generally classified into two 
categories: controlled enzymatic synthesis using chain-terminating mutations (see below 
for details) (94, 95) and total chemical synthesis followed by native chemical ligation 
(NCL) (see below) (96, 97), though several variations exist within each method. Recently, 
two UAA mutagenesis-based approaches were developed for synthesis of polyUb chains 
with natural connectivity and defined linkage composition (98, 99). These two methods 
have largely expanded polyUb synthesis methodologies, though they still have inherent 
limitations. The below sections will first introduce the principles of the above approaches 
and two novel methods (100, 101) developed by our group in collaboration with Dr. 
Fushman’s group (at Department of Chemistry and Biochemistry, University of 
Maryland, College Park). 
3.1.2 Controlled enzymatic assembly of polyUb chains 
Controlled enzymatic assembly of polyUb chains relies on linkage-specific E2 
conjugating enzymes. Homogeneous K11-, K48-, or K63-linked polyUbs have been 
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successfully assembled using identified E2 enzymes Ube2S, E2-25K, and Ubc13/Mms2, 
respectively (94, 102, 103). Like any enzymatic reaction, E2-catalyzed polyUb synthesis 
reactions are highly efficient, progressive and specific. However, the drawback is that 
these enzymatic processes do not have controls of the length of products, thus yielding 
mixed products with various lengths. A partial solution to this problem is to use a “chain 
terminator”, a Ub monomer that halts further polymerization. Depending on the purpose 
of the experiments, “chain terminator” can be used for promixal, distal or both ends. 
Proximal “chain terminator” is usually a Ub mutant with two C-terminal glycine 
truncated (Ub1-74) or with one additional aspartic acid residue (UbD77). Distal chain 
terminator is usually a Ub mutant with a arginine or cysteine mutation at the lysine 
position involving in the isopeptide bond formation. For example, to synthesize K48-
linked Ub2 (K48-Ub2), Ub-K48C and UbD77 can be used in a K48-specific E2 catalyzed 
reaction such that isopeptide bond only forms between Gly76 of Ub-K48C and Lys48 of 
UbD77. The blocked ends of polyUb can be chemically or enzymatically removed for 
further polymerization (Figure 3.2). For example, distal terminator Cys can be converted 
to a lysine analogue by ethyleneimine, resulting in a distal -amino group, while proximal 
terminator Asp77 can be removed by Ub C-terminal hydrolase to free the proximal Gly76 
(Figure 3.2). This methodology, however, is limited by the non-native connectivity 
between Ub monomers and availability of linkage specific E2 enzymes. To solve these 
problems, we developed an enzymatic approach for synthesis of homogeneous polyUb 
chains and a non-enzymatic approach for synthesis of polyUb chains with any linkage 





















3.1.3 Total chemical synthesis of polyUb chains 
The limitations in controlled enzymatic synthesis have motivated several research groups 
to develop methods for total chemical synthesis of polyUb chains. The past decade has 
seen significant progress on this method (96, 97, 104-107). Ub2 and even Ub tetramers 
(Ub4) have been successfully made (30). Although variations exist within this method, 
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Figure 3.2. Controlled enzymatic synthesis of polyUb chains. Synthesis of K48-linked 
Ub2 is shown as a demonstration. Proximally or distally unblocked Ub2 can be further 


















(20~30 amino acid in length) followed by native chemical ligation (NCL) to assemble Ub 
monomer and oligomer. These methods have opened new ways to build polyUb chains 
and further expanded our understanding on how chemistries can be designed to 
accomplish enzymatically catalyzed reactions. 
    Figure 3.3 shows one approach to synthesize K48-Ub2 using -mercaptolysine (-
mercapto-Lys) as the “linker” between two Ub units (106). Two small peptides are first 
synthesized by SPSS for assembly of full-length Ub monomer. Proximal and distal Ub 
monomers share a common N-terminal peptide (Ub-N) that contains a thiolester at its C-
terminus. In C-terminal peptide (Ub-C) of both proximal and distal Ubs, the first amino 
acid (position A46 in native Ub) is mutated to cysteine residue for NCL while proximal 
Ub-C additionally contains a protected -mercapto-Lys at K48 (Figure 3.3A). Full-length 
proximal and distal Ub monomers are assembled in NCL using the common Ub-N and 
their corresponding Ub-C peptides. After deprotection of -mercapto-Lys on the 
proximal Ub, the two Un monomers werere ligated by NCL again, resulting in a Ub2 with 
native isopeptide bond (Figure 3.3B). 
However, total chemical synthesis implementation is not readily available in every 
biochemical laboratory, thus limiting its broad applications. Moreover, total chemical 
synthesis methodologies require multiple protection/deprotection steps, and iterative 
NCL processes, thus yielding a small quantity of materials. 
Due to the inherent limitations in the above two methods, UAA mutagenesis-based 
polyUb synthesis approaches have been developed  (99, 100, 108, 109). Although there is 
no “one-fits-all” method, the UAA mutagenesis-based synthesis of polyUb chains can 


























             Human Ub full sequence 
 
1                     10                     20                      30                    40                      50 
MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQL 
 
51                     60                    70             76 
EDGRTLSDYNIQKESTLHLVLRLRGG 
 
Ub-N : MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIF(thiolesterified C-terminus) 
Ub-C (distal)      : CGKQLEDGRTLSDYNIQKESTLHLVLRLRGG 
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Native isopeptide bond 
Figure 3.3. Total chemical synthesis of K48-linked Ub2. A) N- and C-terminal 
peptides synthesized by SPSS for assembly of Ub monomer. Arrow indicates the 
joint position of the two peptides. B) Assembly of Ub2 via a -mercapto-Lys linker 
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3.1.4 Synthesis of polyUbs using Ub units containing lysine analogues  
Certain methanogenic archaeal or bacterial organisms, such as Methanosarcina barkeri 
and Methanosarcina mazei, incorporate pyrrolysine into some methyltransferases in 
response to a UAG codon carried in the genes of these enzymes (29, 110, 111). Soon 
after discovery, these pyrrolysyl tRNA (PylT)/aminoacyl tRNA synthetase (PylRS) pairs 
were adapted to express proteins in E. coli. These PylT/PylRS pairs proved to be able to 
orthogonally incorporate a pyrrolysine in response to a UAG codon (112). Later, PylRS 
was evolved to incorporate lysine derivatives into proteins in E. coli (113). Recent studies 
have successfully incorporated more than 10 UAAs into proteins using PylT/PylRS pairs 
(114-116) and emerging studies are rapidly expanding this UAA list (117). 
Chin and co-workers have incorporated tert-butyloxycarbonyllysine (BocLys) into Ub 
and have developed a method to synthesize polyUb chains using Ub monomers 
containing BocLys (Ub-BocLys). This method, referred to as genetically encoded 
orthogonal protection and activated ligation (GOPAL), relies on a silver-mediated 
condensation (118) reaction to generate the isopeptide bond between two Ub monomers. 
The procedure of GOPAL is illustrated in Figure 3.4. The distal Ub is expressed from E. 
coli as a fusion protein with a C-terminal intein. Upon thiolysis of intein protein (96), a 
Ub-SR is directly obtained without further thioesterification step. The proximal Ub is 
expressed from E. coli using M. barkeri PylT/PylRS pair to incorporate BocLys at a 
target lysine position. Prior to condensation reaction, the distal monomer Ub-SR and 
proximal monomer Ub-BocLys need to be protected for free amine groups (N-terminal 
amines and side chain amines from the unprotected lysine residues). This protection is 
achieved using carboxybenzyl (Cbz) protecting group, yielding a distal Ub-SR with 8 
 
 88 
Cbz groups (Ub-SRCbz8) and a proximal Ub-BocLysCbz7 (the target lysine site is protected 
by a Boc group already). The Boc group in Ub-BocLysCbz7 is then removed by 
trifluoroacetic acid (TFA) to generate a Ub with only the target lysine unprotected 
(UbCbz7) for ligation. Remarkably, the Cbz groups in UbCbz7 are left intact as the Boc 
deprotection conditions are orthogonal to that of Cbz groups. Ub-SRCbz8 and UbCbz7 (with 
only the target lysine bearing a free -amino group) are subjected to a silver-mediated 
condensation reaction to generate an isopeptide bond between the C-terminal thioester of 
Ub-SRCbz8 and -amine of the target lysine on UbCbz7. The Cbz protecting groups are then 















Figure 3.4. Procedure of genetically encoded orthogonal protection and activated 
ligation (GOPAL). The red sphere and triangle indicate Boc- and Cbz-protected 
amines, respectively 


























GOPAL allows generation of polyUb chains of any linkage composition without the 
need of linkage-specific enzyme E2. Unlike total chemical synthesis, Ub monomers in 
GOPAL are bacterially expressed proteins, bypassing the yield problem in SPPS and 
NCL. This method, however, requires extensive protection/deprotection of Cbz groups. 
The global deprotection of bulky Cbz group occurs at 15 different positions (in the case 
of a Ub2) and does not go to completion easily in our hand even under denaturing 
conditions. This motivated us to develop a new method where the bulky Cbz group is 
substituted by a smaller allyloxycarbonyl (Alloc) group (see below). 
    In a more recent study, Chin and co-worker have evolved the M. barkeri tRNA/aaRS 
pair to directly incorporate -mercapto-Lys into a target lysine position in Ub. This Ub 
monomer can serve as the proximal unit to generate an isopeptide bond with a Ub-SR 
distal monomer. This method is advantageous over the total chemical synthesis method 
because the bacterially expressed Ub monomers can be readily produced in large quantity. 
This new method also bypasses the need of global protection/deprotection of Ubs using 
Cbz groups and thus more efficient. However, it does require a final desulfurization step 
to remove the thiol group which limits its application to ubiquitinylation of a substrate 
protein containing cysteine residues. 
3.1.5 Traceless enzymatic synthesis of polyUbs using Ub-BocLys monomers 
Traditional enzymatic synthesis of polyUb chains usually requires the conversion of a 
terminator cysteine to a lysine analogue for chain extension. This, as stated above, will 
generate a non-native isopeptide bond that may have distinct properties than the native 
isopeptide bond. To solve this problem, our group, in collaboration with Dr. Fushman’s 
lab, sought to to establish a traceless enzymatic approach to synthesize polyUb chains. 
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   This method is conceptually similar to traditional approaches, however, with the 
terminator cysteine or arginine residues replaced by a lysine analogue with removable 
protecting group. Despite that several PylRS variants have been evolved to incorporate a 
variety of lysine analogues into proteins, we chose to use the PylRS-Y384F mutant (115) 
to incorporate BocLys into Ub. PylRS-Y384F mutant can efficiently aminoacylate PylT 
with BocLys, which is a fundamental requirement for large-scale protein production. 
Moreover, Boc protecting group can be removed from a protein under mild conditions 
(2% TFA in water), leaving the Ub structure and function intact. 
    Figure 3.5 describes the rationale of traceless enzymatic synthesis of homogeneous 
polyUb chains. This method requires two building blocks: a proximal terminator and a 
Ub monomer containing BocLys (Ub-BocLys) at the desired position. The proximal 
terminator can be either UbD77 or Ub1-74. In the case of UbD77, native C-terminus (Gly76) 
can be generated by Ub hydrolase. Ub-BocLys can be prepared with high yield using the 
PylRS/PylT pair. By sequential addition of Ub-BocLys to the proximal terminator 
followed by TFA treatment, homogeneous polyUb chains can be synthesized with high 
efficiency. 
Despite the many available methods, the traceless enzymatic synthesis of polyUb 
chains is nevertheless one of the most efficient approaches to generate homogeneous 
chains. The limitation of this method, however, is that linkage-specific conjugating 
enzymes E2 are available only for K11, K48 and K63 linkage. This motivated to develop 
an E2-independent (non-enzymatic) approach to synthesize polyUb chains with any 






















3.1.6 Nonenzymatic synthesis of polyUbs using Ub-BocLys monomers 
This method was inspired by GOPAL where a silver-mediated condensation (30) is used 
to generate isopeptide bond between the distal and proximal Ub monomers. The 
procedure of Ub2 synthesis using this nonenzymatic approach is shown in Figure 3.6. 
 
Ub 
















ATP, E1, E2 
Building block #1: 
Proximal terminator 











Figure 3.5. Procedure of traceless enzymatic synthesis of homogeneous polyUb chains. 













































Figure 3.6. Generation of Ub2 and Ub3 using nonenzymatic synthesis approach. A) 
Structures of BocLys, CbzLys and AllocLys. B) Schematics of Ub2 synthesis. C) Two 
approaches to synthesize Ub3. The red spheres and triangles indicate Boc protected and 




Trimer  Distal Ub2-SR  
C. 
+  Ub-BocLys =  
Ub-BocLys 
Ub 
Proximal Ub2-BocLys  
Proximal Ub-BocLys  
Ub-SR 
Distal Ub-SR  























   To prepare the distal Ub monomer for condensation, WT Ub is first expressed from E. 
coli cells. The C-terminal carboxyl group of WT Ub is thioesterified by E1 Ub activating 
enzyme with sodium 2-mercaptoethane sulfonate (MESNA) supplemented as a thiol 
donor (119). All seven lysines as well as the N-terminal amine of this Ub-SR are then 
protected by allyloxycarbonyl (Alloc) protection group (Figure 3.6A) in the presence of 
allyloxycarbonyl oxysuccinimide (Alloc-OSu) as a Alloc group donor and N,N-
diisopropylethylamine (DIEA) as a base. This results in Ub-SRAlloc8 distal monomer for 
condensation reaction. The proximal Ub monomer for condensation reaction is prepared 
using Ub-BocLys as the template. Unprotected lysine residues as well as the N-terminal 
amine of this Ub-BocLys are protected with Alloc group as above, yielding Ub-
BocLysAlloc7. The Boc protection group of Ub-BocLysAlloc7 is then removed by TFA 
treatment, exposing a single lysine residue accessible for ligation. Importantly, all the 
Alloc groups are kept intact as the deprotection condition of Alloc is orthoganol to that of 
Boc. This results in UbAlloc7 proximal monomer for condensation reaction. Ub-SRAlloc8 
distal monomer and UbAlloc7 proximal monomer are then ligated in a silver (AgNO3)-
meditated condensation reaction. The synthesized Ub dimer contains 15 Alloc protected 
lysines. Removal of the Alloc protecting groups using a ruthenium (II)-catalyzed reaction 
results in a native Ub2. 
To synthesize Ub3 or higher polyUb chains, two strategies can be applied depending on 
the Ub2 used in the condensation reaction. The first one is to use a proximal Ub-BocLys 
monomer and a distal Ub2 that contains a thioesterified C-terminus on the proximal unit 
(Figure 3.6C). The thioesterified Ub2 can be produced using the same protocol as for the 
Ub-SR. The second strategy is to use a distal Ub-SR and a proximal Ub2 that contains a 
 
 94 
BocLys at a desired lysine position on the distal unit (Figure 3.6C). This Ub2-BocLys 
can be produced using the same protocol as for regular Ub2 if Ub-BocLys, instead of WT 
Ub, is used as the starting distal monomer. Ub4 or higher polyUb chains can be 
synthesized by either a convergent approach or a sequential approach. In the convergent 
approach, both distal and proximal unit are pre-assembled polyUb chains, for example, 
Ub2 + Ub2 = Ub4. In the sequential approach, monomer Ub is added to a preassembled 
long polyUb chains, for example, Ub4 + Ub1 = Ub5. 
The major advantage of nonenzymatic method as compared with enzymatic method 
lies in the lack of requirement for linkage-specific conjugating enzyme E2 
(nonenzymatic) and allows for the assembly of polyUb chains of any linkage 
composition. Our method has two major differences from GOPAL. First, the Ub-SR is 
generated by E1 activating enzyme, rather than by intein-mediated cleavage. In our hand, 
the E1 approach has higher efficiency than the intein approach. Furthermore, we use 
Boc/Alloc instead of Boc/Cbz as an orthogonal protecting group pair. This Alloc group is 
advantageous over Cbz because the deprotection of bulky Cbz groups in a well-folded 
protein may be more challenging than that of smaller Alloc groups. 
3.1.7 Limitation of large-scale production of proteins containing UAAs 
During the large-scale production of Ub-BocLys, it was realized that traditional methods 
for expressing proteins containing UAAs are not very efficient regarding to the usage of 
UAAs. The majority (>99%) of UAAs in the expression culture is unused. Instead, UAAs 
of high concentration (usually 2 mM) are supplemented into the culture just to ensure 
efficient cell uptake. To solve this problem, a simple yet highly efficient method was 
developed (Figure 3.7). In this method, E. coli cells are grown in regular rich media to 
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mid-log phase (OD600 of ~0.5). Prior to induction, these cells are centrifuged and 
resuspended in a smaller volume of fresh media containing inducing reagent and UAAs. 
For example, to achieve 20-fold condensation, cells grown in 1 L culture can be 
resuspended in 50 mL fresh media. This condensed culture approach was used to produce 
Ub-BocLys in large scale and turned out to be very efficient. To demonstrate the 
generality of this method, CbzLys and p-benzoylphenylalanine (pBpa) were also 











3.2  Results and Disscussion 
3.2.1 Traceless enzymatic synthesis of polyUb chains using Ub-BocLys 
3.2.1.1 Construction of PylT and PylRS plasmids for BocLys incorporation 
Two plasmid systems have been tested for incorporation of lysine analogues into Ub. The 
first one is a single plasmid system pSup plasmid (120) which carries both the tRNA and 
aaRS gene (Figure 3.8A). The second one is a double plasmid system (43) where the 
tRNA gene and the encoding gene for a target protein (myoglobin, for example) are 
carried on one plasmid pYC while the aaRS gene is encoded by another plasmid pBK 
E.coli growth                          Expression                              High yields 
Figure 3.7. Expression of proteins containing UAAs using condensed culture. 
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(Figure 3.8B). As both systems worked well (Figure 3.8C), we chose to use pSup for 
further studies because this single plasmid system is compatible with most E. coli 




















Figure 3.8. Plasmids for incorporation of BocLys into proteins. A) Double plasmid 
system. B) Single plasmid system. C) Expression tests on the two expression systems. 
A. 
B. 
C. Colony 1   Colony 2 Colony 1   Colony 2 
BocLys    -        +      -       + 







3.2.1.2 Construction of pSup plasmids for incorporation of other lysine derivatives 
Several MmPylRS variants have been developed to incorporate various lysine derivatives 
into proteins, including CbzLys (116) and photo-active amino acid o-nitrobenzyl-
oxycarbonyl-L-lysine (OnbLys) (121). At the early stage of this project, all of these three 
amino acids were tested in Ub expression to gain the information about the efficiency of 
UAA incorporation. pET3a-Ub-K48tag (where Lys48 of Ub has been changed to a TAG 
stop codon) was used as the tester expression vector. The expression results suggested 






Among these UAAs, BocLys was preferred over CbzLys as Boc deprotection 
condition is milder than that of Cbz. Moreover, BocLys had been successfully applied to 
synthesize polyUb chains (99). Ideally, if OnbLys can be incorporated into Ub with high 
fidelity, the synthesis of polyUb chains can be conducted by photochemical control. 
However, the OnbLys MmPylRS variant was developed to incorporate OnbLys into 
Colony 1  Colony 2 Colony 1   Colony 2 Colony 1  Colony 2 
BocLys   +     -      +      - CbzLys   +        -       +       - OnbLys   +      -      +      - 
MmPylRS-BocLys MmPylRS-CbzLys MmPylRS-OnbLys 
Figure 3.9. Expression tests for incorporation of BocLys, CbzLys and OnbLys into 




proteins in mammalian cells (121) and has not been demonstrated to work well for 
proteins in E. coli cells. The expression test (Figure 3.9) showed that there is little leaked 
expression (for example, aminoacylation of PylT with canonical lysine by this synthetase 
variant). However, mass spectrometry (MS) results (Figure 3.10) suggested that some of 
the Ub-OnbLys species might not have an intact caging (Onb) group. This was likely 
caused by post-translational modification, which was observed in UAA incorporation 












3.2.1.3 Construction of Ub expression plasmid pTXB1-SynUb-K48tag 
Expression of UAA-containing proteins usually has lower yield than expression of 
regular proteins. Individual factors in the expression system may need optimization to 
increase the yield of UAA-containing proteins. The previously used human Ub gene was 
first analyzed using Rare Codon Calculator (http://nihserver.mbi.ucla.edu/RACC). The 
Figure 3.10. Deconvoluted ESI-MS result of Ub containing OnbLys. The expected 





analysis result identified several rare codons for expression in E. coli cells (Figure 3.10). 
These rare codons might decrease protein yield or cause mis-incorporation of amino acids 
(as observed by NMR). A synthetic human Ub gene and homologous primers required to 
assemble this gene were designed using DNAWorks (www.helixweb.nih.gov) for 
optimum expression in E. coli cells. The DNA sequence of codon-optimized Ub is shown 













Next, expression tests were performed to determine if SynUb and PylRS variant 
Y384F could improve protein production. These expression tests were performed in the 
context of pET3a for convenient observation purpose (when expressed from pET3a, Ub 
can be well separated from background proteins when whole cell lysis is resolved on a 
protein gel). Expression tests were performed to understand 1) if the codon-optimized Ub 
gene can improve protein yield; 2) if Y384F mutation can improve the efficiency of 
Red = rare Arg codons AGG, AGA, CGA  
Green = rare Leu codon CTA  
Blue = rare Ile codon ATA  
Orange = rare Pro codon CCC  
 
Human Ub (non-optimized) 
atg cag atc ttc gtc aag acg tta acc ggt aaa acc ATA act CTA gaa gtt 
gaa cca tcc gat acc atc gaa aac gtt aag gct aaa att caa gac aag gaa 
ggc att cca cct gat caa caa AGA ttg atc ttt gcc ggt aaa cag ctc gag 
gac ggt AGA acg ctg tct gat tac aac att cag aag gag tcg acc tta cat 
ctt gtc tta AGA CTA AGA ggt ggt taa 
 
Human Ub (codon-optimized) 
atg cag ATT TTT GTG AAA ACC ctg acc GGC aaa acc ATT ACC CTG gaa GTG 
gaa CCG AGC gat acc ATT gaa AAT GTG AAA GCG aaa att CAG GAT AAA gaa 
ggc att CCG CCG gat CAG CAG CGT CTG ATT ttt GCG GGC AAA cag CTG GAA 
GAT ggt CGT ACC ctg AGC gat tac AAT att cag AAA GAA AGC acc CTG cat 
CTG GTG CTG CGT CTG CGT GGC GGC taa 
 
Figure 3.11. Codon optimization of human Ub. The changed codons in SynUb gene 
are indicated by uppercased letters. 
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BocLys incorporation; 3) if BocLys incorporation depends on the position of “TAG” 
codon. The expression results (Figure 3.12) suggest that 1) codon-optimized Ub (SynUb) 
indeed improved expression efficiency (compare Lane 1 with Lane 9 or Lane 3 with Lane 
11); 2) Y384F mutation enhanced BocLys incorporation (compare Lane 1 with Lane 3 or 
Lane 9 with Lane 11); 3) BocLys can be incorporated into K48 and K11 with equal or 
similar efficiency. It is worth mentioning that regular Ub (non-optimized) usually gives 
noisy NMR signal at rare arginine codon position due to mis-incorporation of amino 






3.2.1.4 Expression and purification of Ub-K48BocLys, N
15






-labeled Ub1-74 and N
15
-labeled Ub1-74-K48BocLys were 
expressed and purified. The whole protein molecular weight (MW) of these samples was 
confirmed by electrospray ionization mass spectrometry (ESI-MS) (Figure 3.13). 
BocLys-containing Ub showed a minor peak with a mass corresponding to Boc-
Figure 3.12. Expression tests for codon-optimized Ub (SynUb), PylRS variant Y384F 
and different “TAG” positions. 
Ub-K48tag   Ub-K11tag          SynUb-K48tag   SynUb-K11tag 
  wtPylRS    Y384F    wtPylRS   Y384F                       wtPylRS    Y384F    wtPylRS    Y384F 
 
BocLys  +      -      +    -     +      -     +     -                   +      -      +     -     +     -      +    - 
1      2     3     4    5     6     7     8                    9    10    11   12  13   14   15   16 
Ub 










deprotected Ub. This could be caused by sample handling during MS (samples were 
denatured/treated with acids prior to analysis). Leaked expression (natural lysine amino 
acid rather than BocLys had been incorporated) was unlikely the cause, because the 
expression results (Figure 3.11) suggested that the expression of Ub was strictly 












3.2.1.5 Deprotection of Boc protecting group 
To confirm that Boc protecting group can be efficiently removed by TFA treatment, the 
15
N Ub1-74-K48BocLys sample was treated by 2% TFA, analyzed by ESI-MS and then 
compared with the non-treated sample (Figure 3.13 C). The MS result suggested that 
simple TFA treatment could completely remove the Boc protecting group. It is also worth 
mentioning that TFA-treated N
15
 Ub1-74-K48BocLys is 2 Da less in mass than N
15
 Ub1-74 
because the BocLys amino acid used in this study is not 
15
N labeled. 
Figure 3.13. ESI-MS deconvolution of Ub monomer for whole-molecular weight 
determination. A) Ub-K48BocLys. B) 
15
N Ub1-74. C) 
15
N Ub1-74-K48BocLys. For 
15
N 
labeled samples, 99%.incorporation of 
15
N isotope is assumed to calculate the mass. 
Removal of the Boc group from Ub1-74-K48BocLys results in 99 Da decrease in mass. 
B. C. 
9000 8000 8500 
8549.85 8648.52 
Expected MW 











Another question is if the TFA treatment will disrupt the structure or function of Ub. 
To determine the effect of TFA treatment on the structure of Ub, TFA-treated N
15
 Ub1-74-
K48BocLys was analyzed by NMR. It is shown that the spectra of TFA-treated N
15
 Ub1–
74 K48BocLys and N
15
 Ub1–74 can be overlayed (Figure 3.14). The only difference 
between these two spectra occurs at K48 position because BocLys (which became regular 
lysine after TFA treatment) is not 
15













    The effect of TFA treatment on Ub function was examined by subjecting the TFA-
treated and non-treated Ub-K48BocLys sample to E1/E2-catalyzed polymerization 
reaction (Figure 3.15). K48BocLys mutant was first compared with the traditionally used 
distal chain terminator K48R variant. It is shown that K48BocLys can efficiently block 
chain polymerization from distal end. More importantly, TFA treated K48BocLys 




H TROSY-HSQC NMR spectra of TFA-treated Ub1–74 
K48BocLys monomer (red) and Ub1–74 monomer (blue). 
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generates a wild type-like monomer that allows chain polymerization from both distal 
and proximal ends. This suggests that TFA treatment does not impair the functionality of 












3.2.1.6 Assembly of K48-linked Ub2 and Ub3 chains 
Encouraged by the above experiments, Ub2 was assembled using N
15
 Ub1–74 (proximal 
monomer) and Ub-K48BocLys (distal monomer) (Figure 3.16, Lane 1 and 2). Removal 
of the Boc protecting group from the synthesized Ub2 allows further chain polymerization 
(Figure 3.16, Lane 4 and 5). These results indicated that Ub-K48BocLys could halt chain 
polymerization at Ub2. This Ub2 was purified and treated with TFA to remove the Boc 
protecting group. The MW of the Ub2-K48BocLys sample before and after TFA 
treatment was confirmed by ESI-MS (Figure 3.17). 
 
Figure 3.15. SDS-PAGE gels showing the corresponding polymerization reactions 
with and without E1 as controls. 
 1        2        3         4          5         6        7         8 













                                              TFA 























Although TFA treatment has been demonstrated to not disrupt the structure and 
function of Ub monomer, its influence on Ub2 remains unclear as Ub2 is a structurally 
and functionally distinct protein and might be fragile to TFA treatment. To test this, TFA-
Figure 3.17. ESI-MS deconvolution of K48-linked di-Ub comprised of the Ub-
K48BocLys monomer and 
15
N-Ub1-74 monomer before (blue) and after TFA 
treatment (black). TFA treatment is expected to result in a mass loss of 99 Da due to 
the elimination of one Boc protecting group. 
 
 
16000 17000 18000 
17100.5 
17199.7 
Expected Ub2 MW: 
Before TFA treatment: 17200 
After TFA treatment: 17101 
Mass (Da) 
Figure 3.16. Ub2 and Ub3 synthesis. Combinations of 
15
N Ub1–74 and 
15
N Ub-
K48BocLys halt polymerization at Ub2 (Lane 1 and 2). Purified Ub2-K48BocLys 
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N-P Ub2-K48BocLys (the proximal unit is 
15
N labeled Ub1-74) was purified, 
buffer-exchanged and then analyzed by NMR at pH 4.5 and pH 6.8. The obtained NMR 
spectra were overlayed with those of 
15
N Ub1-74 at pH 4.5 and pH 6.8, respectively. 
The NMR spectra of Ub2 show excellent spectral quality and chemical shift 
perturbation (CSP) (Figure 3.18), suggesting that TFA treatment did not irreversibly 
denature Ub2. Furthermore, comparison of the spectra at pH 4.5 and pH 6.8 suggest that 
the conformational properties of Ub2 are fully retained. K48-Ub2 is known to exhibit two 
properties: i) a hydrophobic Ub/Ub interface centered at residues L8, I44 and V70 (122, 
123); ii) a pH-controlled equilibrium between a closed conformation (predominant at pH 
6.8) and open conformation(s) (predominant at pH 4.5) (122, 124-126). These properties 
can be readily determined using NMR spectroscopy (122). Our NMR data (Figure 3.18) 
demonstrate that the synthesized Ub2 exhibits all of the above features. At pH 6.8, many 
residues in the proximal Ub showed significant spectral perturbations with respect to 
monomeric 
15
N Ub1–74 (Figure 3.18D). The perturbations center around the hydrophobic-
interface residues L8, I44 and V70, in strong agreement with the closed conformation of 
K48-Ub2 (122). At pH 4.5 (Figure 3.18C), significant chemical shift perturbations are 
only observed for residues near the site of the K48 isopeptide linkage. The lack of 
perturbations for residues centered around L8 and V70 indicates the absence of the 
hydrophobic interface at low pH, in full agreement with the previous observations for 
K48-linked Ub2 (122). The CSPs of the proximal Ub unit in the synthesizd Ub2 and the 
dynamic nature of Ub2 under different pH are very similar to the characteristics of K48-























This new method is preferred over the exsiting enzymatic synthesis of polyUb as it 
generates “all native” polyUb chains. Since this methodology is limited by the available 
linkage-specific E2 enzymes, an E2 enzyme-free method was also developed to assemble 
polyUb chains of any linkage composition. 




H TROSY-HSQC spectra of the 
proximal 
15
N Ub1-74 (blue) in TFA-treated Ub2-K48BocLys and monomeric 
15
N Ub1-74 
(red), obtained at pH 4.5 (A) and pH 6.8 (B). CSPs of the proximal Ub1–74 unit in Ub2 
versus Ub1–74 monomer are determined at pH 4.5 (C) and pH 6.8 (D), respectively. 
Corresponding CSPs (E) and (F) of K48-Ub2 constructed by proximal 
15
N UbD77 and 
distal Ub-K48R using traditional methods are shown as comparison. 
A.  B.  
E.  F.  
D.  C.  
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3.2.2 Nonenzymatic synthesis of polyUb chains using Ub-BocLys monomers 
3.2.2.1 Preparation of ligation precursors Ub-K11BocLys, Ub-K33BocLys and Ub-SR 
Although the efficiency of UAA incorporation into different “TAG” position may vary 
depending on the context of DNA sequence, our expression system (pSup-BocLys and 
pTXB1-SynUb) allows generation of Ub-BocLys with moderate yield (~10 mg/mL) for 
six of the seven lysine variants. The only low-yield (~3 mg/mL) construct is Ub-
K63BocLys where a considerable amount truncated protein (Ub1-63) is observed. The low 
efficiency of BocLys incorporation at position 63 is likely caused by the inefficient 
suppression of K63tag stop codon by PylT. 
Here, we focus on K11- and K33-linked polyUb chains as a demonstration for the 
nonenzymatic synthesis of polyUb chains. Ub-K11BocLys and Ub-K33BocLys were 
produced as above and confirmed by ESI-MS. These BocLys-containing Ubs will serve 
as the proximal Ub monomer. The C-terminus of the distal monomers must be first 
activated with a thioester functional group for the ligation reaction (Figure 3.6B). 
Traditionally, Ub-SR is made via intein-mediated cleavage reaction (99). Unfortunately, 
this approach is slow (each cleavage reaction takes 24~40 h), necessitates HPLC 
purification (removal of an unwanted byproduct of non-cleaved Ub), and produces Ub-
SR in low yield (only 10 mg of pure Ub-SR from expression in 2 L culture). An 
alternative approach is to react WT Ub with Ub-activating E1enzyme in the presence of 
MESNA (119). This approach turned out to be very efficient in our hand. Complete 
thioesterification of Ub C-terminus occurs after 6 h of treatment with the E1 enzyme and 
MESNA, as confirmed by ESI-MS (Figure 3.19A). Subsequent treatment with glacial 
acetic acid precipitates E1 and lowers the pH to maintain Ub-SR stability. Finally, buffer 
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exchange removes other reaction components to yield a pure Ub-SR. This method 
produces Ub-SR at high yield, because the starting protein, WT Ub, is very easy to 
express and purify in large amounts (50~100 mg from1 L culture). Importantly, the same 
procedure works nicely for activating Ub-BocLys as well as all preassembled polyUb 


















Figure 3.19. ESI-MS deconvolution to confirm thioesterification, Alloc protection 
and Boc deprotection. A) Preparation of distal monomer for condensation reaction. 
Thioesterfication of the C-termuns of WT Ub results in a 125 Da increase in mass 
for the addition of 2-mercaptoethane sulfonate (MES). Alloc protection adds 9 
Alloc groups (84 Da each) and fully protects all free amines. B) Preparation of 
proximal monomer for condensation reaction. Alloc protection of 
15
N Ub-
K11BocLys adds 8 or 9 Alloc groups. Deprotection of this 
15
N Ub-K11BocLysAlloc8 
removes the 100 Da Boc group while leaving all Alloc groups intact. 
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3.2.2.2 Alloc protection and Boc deprotection to prepare Ub monomers for 
condensation reaction 
To generate Ub2, both of distal Ub-SR and proximal Ub-BocLys need be protected by 
Alloc protecting group to produce Ub-SRAlloc8 and Ub-BocLysAlloc7. The Alloc protected 
distal and proximal monomers were analyzed by ESI-MS (Figure 3.19) and the complete 
protection of free amines in both monomers was confirmed. Interestly, one additional 
Alloc protecting group was observed in both monomers. This was presumably caused by 
the protection or partial protection of the single histidine (His68) in Ub. This 
overprotection, however, will not cause any problem in the present method as the 
deprotection of Alloc group can go to completion efficiently (see below). Ub-
BocLysAlloc7 is then Boc-deprotected to produce UbAlloc7 for condensation reaction. 
3.2.2.3 Silver-mediated condensation reaction 
Ub-SRAlloc8 and Ub-BocLysAlloc7 were subjected to a silver-mediated condensation 
reaction (118). The ligation converted ~30% of the reacting Ub monomers into Ub2 








Figure 3.20. Silver-mediated condensation reaction. A) Formation of Ub2. B) 
Purification of the Ub2 by size exclusion chromatography. 
A. B. 
Elution volume 





              TFA                    Ub-SR + 
Ub-SR  K11Boc          TFA K11BocLys 
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3.2.2.4 Global deprotection of Alloc groups and protein renaturation 
Central to the success of this method is the complete Alloc deprotection. Recently, it has 
been shown that Alloc protecting groups can be efficiently removed using relatively mild 
conditions in neutral aqueous solution using thiophenol and a ruthenium (Ru) catalyst 
chloro-pentamethylcyclopentadienylcyclooctadiene-ruthenium(II) ([Cp*Ru(cod)Cl]) 
(127). However, application of these exact conditions to Ub protein, which can have up 
to nine Alloc groups attached to it simultaneously, failed to completely remove all Alloc 
groups. To determine the correct conditions for Alloc deprotection, multiple experimental 
conditions were tested on a 
15
N-labeled sample of WT Ub (Figure 3.21). After many 
rounds of optimization, the correct amounts of Ru catalyst, thiophenol, and water to use 












Figure 3.21. Deconvoluted ESI-MS for condition optimization of Alloc deprotection 
reactions. 
15
N WT Ub is used as a test protein. Fully protected protein with nine Alloc 
groups was subjected to deprotection reactions with variable conditions. Optimal Alloc 
deprotection conditions require the use of 50% mol Ru catalyst, 50 equivalent of 
thiophenol, 30% H2O and incubation at 50 ºC for 2 h (green). If less catalyst (magenta) 
or lower temperature (sky blue) are used, the Alloc deprotection reaction does not go to 
completion, resulting in a distribution of multiple Ub species containing a variable 
number of Alloc groups. 
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    The most critical features to the success of the reaction are (i) near-stoichiometric 
amounts of Ru catalyst (50% mol) relative to the moles of amines present, (ii) at least 
30% H2O (v/v), and (iii) temperature raised to at least 50 ºC (denaturing condition). 
When any of these conditions was not met, Ub species typically still contained a variable 
number of Alloc protecting groups, as revealed by ESI-MS analysis (Figure 3.21). For 
example, lowering the amount of Ru metal in the reaction did not yield full deprotection. 
Under correct conditions, the deprotection reaction typically reached completion after a 
maximum of 2 h. Allowing reactions to proceed overnight did not change the ESI-MS 
results. 
As the Alloc deprotection is performed under denaturing conditions, the final product 
needs be renatured for further characterization. In the present study, all the synthesized 
polyUb chains could be renatured efficiently. Renatured Ub2 was characterized by ESI-
MS to verify the complete deprotection of Alloc group (Figure 3.22). Importantly, Ub2 
can be either 
15
N labeled at the distal unit (
15
N-D Ub2, Figure 3.22A) or at the proximal 
unit (
15
N-P Ub2, Figure 3.22B). The ability to label different Ub units in polyUb chains 
allows detailed NMR studies on the whole polyUb chains. Furthermore, as mentioned 
above, Ub3 or higher polyUb chains can be polymerized from Ub2 from either proximal 
end or distal end (Figure 3.6C). If Ub3 is to be polymerized from the distal end of Ub2, 
the synthesis of pre-assembled Ub2 requires using a Ub-BocLys (rather than WT Ub) 
distal monomer for thioesterification reaction, such that the final Ub2 will contain a 
BocLys at the distal Ub. It is very important to demonstrate that this BocLys is able to 
survive the Alloc protection/deprotection. ESI-MS results (Figure 3.22B) confirmed that 












3.2.2.5 Assembly and characterization of K11- and K33-linked Ub2 





N-D versions of K11- and K33-linked Ub2 were synthesized for detailed NMR 
studies. The NMR spectra of these polyUb chains revealed an excellent spectral 
dispersion of NMR resonances, indicative of a fully renatured Ub2. No minor peaks were 
observed, indicating that the chemically ligated Ub2 is free of contaminating species. 
K11-Ub2 was first synthesized because its structural properties can be easily compared 
with the enzymatically synthesized K11- Ub2 (by K11-specific E2 conjugating enzyme 
Ube2s). K11 linkages could be as abundant as K48 and K63 linkages (128) and K11-




N TROSY-HSQC (130) NMR experiments were performed on K11- Ub2 (as well as 





N amide bonds (Figure 3.23). 
 
Figure 3.22. Deconvoluted ESI-MS spectra of Ub2. A) K11-linked 
15
N-P Ub2. B) 
K11-linked 
15
N-D Ub2 containing a BocLys at K11 of the distal Ub. 
B. 
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On the distal Ub, the largest signal shifts as compared with Ub monomer are observed 
at the C-terminal residues G75 and G76 which involve in the formation of isopeptide 
bond. The K11 backbone amide signal is not present in the 
15
N-D Ub spectrum (Figure 
3.23A) because Ub-K11BocLys was used as the distal precursor to assemble this Ub2.and 




N TROSY-HSQC spectra 
of 
15
N-D Ub2 and 
15
N-P Ub2, respectively. The grey and white balls represent 
15
N-
labeled and non-labeled Ub units, respectively. C)~F) are the CSPs between each Ub2 
chains and corresponding unconjugated Ub monomer. For example, if proximal 
15
N 
UbD77 is used to assemble Ub2, 
15
N-P Ub2 will be compared with 
15
N UbD77 rather 
than 
15
N WT Ub. C) and D) are nonenzymatically synthesized 
15
N-D Ub2 and 
15
N-P 
Ub2, respectively, and E) and F) are enzymatically synthesized 
15
N-D Ub2 and 
15
N-P 







BocLys incorporated at K11 is unlabeled and thus invisible in the 
15
N NMR spectra. 




    To validate that the nonenzymatic approach itself will not change the properties of Ub2, 
the spectra of these nonenzymatically synthesized K11-Ub2 were compared with that of 
enzymatically synthesized K11-Ub2. Unfortunately, the chain-terminating mutations 
carried by the enzymatically assembled K11-Ub2 (distal Ub-K11R and proximal UbD77) 
complicate direct comparison of the spectra between the two Ub2 chains. Therefore, we 
compared each Ub unit in these Ub2 to its respective unconjugated Ub monomer. For 
example, if proximal UbD77 is used to assemble Ub2, 
15
N-P Ub2 will be compared with 
UbD77 rather than WT Ub. The remarkable similarity between the CSPs of the 
nonenzymatically and enzymatically assembled K11-Ub2 chains (compare Figure 3.22 C 
with E, and D with F) serves as a strong indicator that the two chains have identical 
structural and conformational properties. 
Notably, the two Ub units in K11-linked Ub2 show strikingly different CSP patterns 
(compare Figure 3.23 C with D). Significant CSPs are spread throughout the proximal 
Ub but almost absent in the distal Ub (except for the ligated C-terminus). This is in 
contrast with the CSP patterns observed in K48-linked (122) and K63-linked (131) Ub2 
chains. The CSP differences could be caused by 1) nonconvalent interdomain contacts, 2) 
chemical modification (isopeptide bond), or 3) a combination of both. The 3D structure 
of Ub suggests that the relatively big CSPs in the proximal Ub unit are very likely caused 
by the isopeptide formation. To test this hypothesis, we measured the CSPs between Ub-
K11BocLys and WT Ub (Figure 3.24B), where the only difference between the two 
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proteins is whether a Boc protecting group is present on the side chain of K11. Indeed, 
the results show a CSP pattern remarkably similar to that in the proximal Ub of K11-Ub2 
(compare Figure 3.23D with Figure 3.24B). This suggests that the spectral perturbations 
observed in the proximal Ub of K11-Ub2 are primarily caused by the chemical 






Encourage by the success of the synthesis of K11-linked Ub2, we next assembled 
15
N-P 
K33-Ub2 to demonstrate the generality of our method. Again, the assembled Ub2 was 







Figure 3.25. ESI-MS analysis of 
15
N-P K33-linked Ub2 
17000                              18000 
Mass (Da) 
17209.9 
Expected MW: 17210 




N TROSY-HSQC spectra of 
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    NMR characterization of the proximal Ub in K33-Ub2 revealed an excellent spectral 




H dimensions (Figure 3.26A), strongly indicating that this 
Ub unit is well folded. The K33 signal in this Ub2 chain is, again, absent due to the 
unlabeled BocLys. The CSP pattern of the proximal Ub in this K33-Ub2 is distinct from 
that in the K11-Ub2 (compare Figure 3.26C with Figure 3.23D). Interestingly, in K33-
Ub2, the CSPs are quite small for the hydrophobic patch residues L8, I44, and V70, and 
instead cluster around residues12~17 and 26~35 located close in space or adjacent to K33 
(Figure 3.26C). This suggests that the majority of the spectral perturbations observed in 
A. B. 
C. D. 




N TROSY-HSQC spectra 
of 
15
N-P K33-Ub2 and Ub-K33BocLys, respectively. C) and D) are the CSPs of the 




this Ub unit are a consequence of the chemical modification of K33 by the isopeptide 
linkage. To support this hypothesis, the spectra of Ub-K33BocLys and WT Ub were 
overlaid (Figure 3.26B) and the corresponding CSP is calculated (Figure 3.26D). Indeed, 
the CSP pattern of Ub-K33BocLys (versus WT Ub) is overall similar to that of the 
proximal unit in K33-Ub2 (versus WT Ub). This suggests that the chemical modification 
is a major, if not all, cause of the CSP observed in the proximal unit in K33-Ub2. 
3.2.2.6 Assembly and characterization of K11-linked Ub3 and K11/K33-linked Ub3 
The power of our approach lies in that pre-assembled Ub2 can be easily extended to 
produce either homogeneous or mixed linkage Ub3 or higher polyUb chains. With this 
method in hand, homogeneous K11-Ub3 and mixed linkage K11/K33-Ub3 chains were 
synthesized (Figure 3.27). In this dissertation, the nomenclature of mixed linkage polyUb 
chains follows the rule that the proximal linkages are placed in front of the distal linkages. 
Taking the K11/K33-Ub3 for example, the middle Ub unit has its K33 linked to the C-
terminus of the distal unit and its C-terminus linked to the K11 in the proximal unit. The 
yield of the condensation reaction for K11- Ub3 and K11/K33- Ub3 were 15% and 9%, 
respectively. The relatively low yields indicate that the conditions of these silver-based 
condensation reactions may require further optimization. The produced Ub3 were purified 
by size-exclusion chromatography (Figure 3.27B) and then confirmed by ESI-MS as 
above. In both of these two Ub3, the middle units were 
15
N-labeled, enabling unit-specific 
NMR studies. 





N resonances of the backbone amides (Figure 3.28) clearly indicates 
that the middle Ub is fully folded despite being tethered to two other Ub units in the 
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chain. The observed spectral differences between the middle Ub in K11-Ub3 and Ub 
monomer are a composite of the perturbations observed above in the distal and proximal 
Ub units of K11-Ub2 (Figure 3.23). This is not unexpected given that the middle Ub unit 




































Figure 3.27. Assembly of K11-Ub3 and K11/K33-Ub3. A) and C)  are coomassie-
stained SDS-PAGE gel showing the formation of K11-Ub3 and K11/K33-Ub3, 




The CSPs of the middle Ub in K11-Ub3 versus WT Ub monomer (Figure 3.28D), 
distal Ub in K11-Ub2 (Figure 3.28E), and proximal Ub in K11-Ub2 (Figure 3.28F) were 
calculated. Remarkably, the CSP of this middle unit in Ub3 versus the distal Ub in K11-
Ub2 (Figure 3.28E) is similar to the CSPs of the proximal Ub in K11-Ub2 versus WT Ub 
monomer (Figure 3.23D). Likewise, the CSP of this middle unit in K11-Ub3 versus the 
proximal Ub of K11-Ub2 (Figure 3.28F) is similar to the CSPs of the proximal Ub in 
K11-Ub2 versus WT Ub (Figure 3.23C). Again, this suggests that the oberserved CSPs 
of the middle Ub in K11-Ub3 simply reflects the additive CSPs from the proximal and the 
distal units, meaning that no additional Ub/Ub interface forms when K11-Ub2 is extended 
to K11-Ub3. Structurally, this suggests that the proximal and distal Ub units in Ub3 are 


















HSQC spectra of 
15
N-M Ub3 (red) with 
15
N WT Ub (A), 
15
N-D K11-Ub2 (B), and 
15
N-
P K11-Ub2 (C) in blue, respectively. The grey and white balls represent 
15
N-labeled 
and non-labeled Ub units, respectively. D)~F) are the CSPs of the middle unit in K11-







Perhaps one of the most interesting features of the current method is that it allows 
generation of mixed linkage polyUb chains, which can be not easily obtained using 
traditional methods. We then set up to synthesize, for the first time, a mixed-linkage Ub3 
chain comprised of K11 and K33 linkages (Figure 3.27C). As stated above, this polyUb 
construct is named as K11/K33-Ub3, designating that K11 is the first isopeptide bond 
counting from the proximal end. As above, the produced Ub3 was SEC purified, 





















HSQC spectra of 
15
N-M Ub3 (red) with 
15
N WT Ub (A) and 
15
N-P K33-Ub2 (B). The 
grey and white balls represent 
15
N-labeled and non-labeled Ub units, respectively. C) 






    The nicely spread NMR signals of the middle Ub in K11/K3-Ub3 chain strongly 
indicate that the structure of this Ub unit is intact. Similar to the middle Ub in K11-Ub3, 
the spectral perturbations observed in the middle Ub of K11/K3 Ub3 are roughly the 
additon of the perturbations in the respective Ub2 constructs (proximal Ub in K33-Ub2 in 
Figure 3.26C, and distal Ub in K11-Ub2 in Figure 3.23C). This suggests that no 
additional inter-domain interaction exists in K11/K33-Ub3. 
    As a proof of principle, we also assembled K11-Ub4 using the pre-assembled Ub3 as 
the distal unit precursor (to be thiolesterified) and a proximal Ub-K11BocLys. Shown in 














AgNO3    N/A            N/A           -               +                          MW (KDa) 






Figure 3.30. Coomassie-stained SDS-PAGE gel, showing the formation of K11-Ub4. 
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    Overall, the non-enzymatic approach described here is capable of assembling polyUb 
chains of any linkage composition and isotopic labeling scheme. polyUb chains up to 
trimer were successfully synthesized and characterized. With further optimized reaction 
conditions, tetramer or higher polyUb chain may be readily obtained. One limitation, 
however, is that large-scale production of polyUb chains requires a lot of Ub monomers 
containing BocLys incorporated at a desired lysine position. Traditional methods for 
expressing proteins containing UAAs require unnecessarily large amount of UAAs. This 
may prevent the large-scale production of Ub-BocLys in a cost-efficient way. Below is 
introduced a simple yet highly efficiently technique to solve this problem. 
3.2.3 Condensed E. coli cultures for highly efficient production of proteins containing 
UAAs 
3.2.3.1 Determination of optimum ratio for condensation 
Condensed culture strategies have been used previously to minimize the cost associated 
with isotopic labeling of protein samples for NMR studies (132, 133). To test if the same 
strategy can be applied to express proteins containing UAAs, a 2 L E. coli culture was 
grown to express Ub-BocLys from pET3a vector. When the culture reached mid-log 
phase, the cells were harvested by low-speed centrifugation, resuspended in 80 mL (25-
fold condensation) fresh media supplemented with corresponding antibiotics, inducing 
reagent and BocLys to induce the expression. The Ub-BocLys expression was analyzed 
on a gel. Robust expression was observed (Figure 3.31). 
    To demonstrate the generality of this methodology, two different UAA incorporation 
systems were tested for this condensed culture approach. In the first system, tester protein 
Ub was expressed from pET3a vector under the control of T7 promoter, and CbzLys was 
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site-specifically incorporated into K48 by MbPylT/MmPylRS variant (115). In the second 
system, sfGFP was expressed from pTrcHisA vector under the control of pTrc promoter, 
and p-benzoylphenylalanine (pBpa) was site-specifically incorporated into V150 by 
Methanococcus jannaschii tyrosyl tRNA/aaRS variant (MjTyrT/MjTyrRS) (134). Various 
condensation ratios ranging from 1× (normal cell concentration) to 100× have been 








In the case of Ub, clear protein expression can be seen in all samples except 100× at 
which point the condensation experiment reaches a point of diminishing returns. This 
indicates that UAA can be added to cells at the time of induction and be utilized for 
protein expression at high cell densities. The lack of protein production in the absence of 
UAA indicates that the fidelity of amber codon suppression and incorporation is not 
affected by changes to culture density. We performed these analyses in triplicate and used 
the presence of a BSA internal standard (10 g) to quantify protein yields and the relative 
efficiency of UAA usage under each scenario (Table 3.1). Using Ub-K48CbzLys as an 
example, we observed that the optimum protein production per unit amino acid occurs 
when cultures are condensed by a factor of 25 (Table 3.1). Under 25-fold condensation, 
Figure 3.31. Production of Ub-K48BocLys using condensed culture, with 2 mM BocLys. 
Ub-K48BocLys 




1.8 mg of Ub-K48CbzLys was produced from a 2 mL expression, representing a 
significant improvement in yield. Importantly, ~93% less UAA is needed. When 
expression cultures are not condensed (1×), it is evident from the cell density and the 
observed protein quantities that there was some continued cell growth after IPTG 





















Figure 3.32. Determination of optimal condensation ratios. A) Structures of CbzLys 
and pBpa. B) Ub expression. C) sfGFP expression 
CbzLys 
pBpa 
+     -    +    -     +     -    +    -          +     -    +     -    +     -   CbzLys 
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In the case of sfGFP expression, there was very little protein observed by SDS–PAGE 
in condensation experiments above 10×. The reduced consumption of pBpa under 10× 
and 5×, however, is very evident from the calculation (Table 3.1). The lower levels of 
production observed can be ascribed to an overall lower productivity of this tRNA 
synthetase/tRNA pair, the relative lower expression of sfGFP in comparison to Ub, 
and/or less expression efficiency of pTrcHisA/ pTrc promoter as compared to pET/ T7 
promoter. In addition, while we do not observe target protein production at the highest 
condensation ratios, it is possible that there is a low level of production, that is, not seen 


















from 2 mL 
culture (g) 
Protein production 




Ub-K48CbzLys    
100× ND ND ND 
50× 1.3 ± 0.3 1300 38 
25× 3.6 ± 0.5 1800 53 
18× 4.0 ± 0.7 1400 41 
10× 6.3 ± 1.7 1300 38 
5× 7.4 ± 1.8 740 22 
1× 3.6 ± 0.7 140 4.1 
sfGFP-K150pBpa    
100× ND ND ND 
50× ND ND ND 
25× ND ND ND 
18× 0.7 ± 0.1 250 2.3 
10× 2.5 ± 0.5 500 4.6 
5× 3.8 ± 0.5 380 3.5 
1× 2.1 ± 0.2 170 1.6 
Table 3.1. Protein production per unit UAAs using condensed cultures 
Note: [a] For 2 mL cultures, 4 mol UAAs were used (final concentration 2 mM) 
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    3.2.3.2 Characterization of purified proteins 
Finally, “large scale” purifications of both Ub and sfGFP were conducted using the 
optimal condensed formats such that we could verify UAA incorporation by mass 
spectrometry. The condensed culture allowed us to induce 1 L of production cultures of 
Ub and sfGFP in 40 mL (25×) and 100 mL (10×) of media, respectively. These proteins 
were purified to >90% homogeneity resulting in large amounts of protein (>25 mg), a 
sample of which was subjected to in-gel tryptic digests and the resulting peptides 
analyzed by mass spectrometry. Upon examining the mass data we observed clear site-
specific incorporation of CbzLys and pBpa into the correct tryptic fragments of Ub and 
sfGFP, respectively (Figure 3.33). Importantly we do not see incorporation of any 
endogenous amino acids at those positions, indicating again that suppression fidelity 
remains intact under very high cell density conditions. 
In summary, the methodology presented here represents a simple yet effective way of 
maximizing the efficiency of UAA mutagenesis studies. This method requires no major 
changes to experimental conditions and is compatible with standing cell lines and 
plasmids. The observed improvement using this protocol varies with target protein, 
expression vector and UAA used. While it is sufficient to conserve UAA by culture 
condensation, it might be further enhanced when coupled with codon optimized genes. 
Ideally researchers will test a range of condensation conditions with a protein of interest 












Figure 3.33. Mass spectral analyzes of purified proteins from condensed culture, 
showing the incorporation of UAAs. A) Ub-K48CbzLys. B) sfGFP-V150pBpa. 
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3.3  Conclusion and Future Applications 
3.3.1 Traceless enzymatic synthesis of polyUb chains using Ub-BocLys 
Enzymatic synthesis of polyUb chains using Ub-BocLys is advantageous over traditional 
methods as removal of Boc protecting group can result in a natural lysine residue which 
allows the subsequent formation of a natural isopeptide bond. Using this method, we 
successfully synthesized and characterized K48-linked Ub2 and have demonstrated that 
synthesis of Ub3 or higher polyUb chains is possible. Intriguingly, while many of the E2 
enzymes remain uncharacterized, a growing number have been shown to be highly 
promiscuous and capable of targeting different lysine residues (135). Moreover it has 
been shown that the lysine-targeting preferences can be amplified by using blocked 
substrates, such as arginine mutants (135). 
    Using the strategy described here it might be possible to capitalize on promiscuous E2 
enzymes and block multiple lysines simultaneously to direct the synthesis of atypical Ub 
linkages. For example, UBE2C has been determined to have conjugating activity toward 
both K11 and K48 linkages. Double blocking of K11 and K48 using Boc group and chain 
terminating mutations (Arg or Cys), followed by selective unblocking, could potentially 
direct UBE2C to produce polyUb chains of desired linkage composition (Figure 3.34). 
This strategy, however, may not result in polyUb chains with native residues because of 
the need of chain terminating mutations. The advantage of this “double blocking” 
strategy is that iterative protection/deprotection chemistries are not required and thus, a 

















3.3.2 Nonenzymatic synthesis of polyUb chains using Ub-BocLys monomers 
The dearth of native polyUb chains of any defined length, linkage composition, and 
isotopic labeling scheme has been a major hindrance to the ubiquitin field. To address 
this challenge, we have developed an affordable and widely accessible method for 
controlled, iterative nonenzymatic assembly of completely natural polyUb chains using 
recombinant monomers as the primary building blocks. Using this method, we 
synthesized homogeneously K11-Ub2, Ub3, and Ub4, and K33-Ub2, as well as a mixed 
linkage K11/K33-Ub3. With this chain-assembly method in hand, it is now possible to 
generate and study essentially any polyUb chain, both homogeneously linked and with 
mixed linkages, to uncover the structure and receptor recognition of the polyUb signal 
and its processing by linkage-specific deubiquitinases. Importantly, our method can be 
UbD77-K48BocLys 
UbD77 




















Figure 3.34. Proposed scheme of making K11-, K48-mixed linkage polyUb chains 
using a “double blocking” strategy by both chain terminating mutations and Boc group.  
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extended to (poly)ubiquitinate a target protein, with no need for specific E2 and E3 
enzymes, and could also be used to form an isopeptide bond between Ub and virtually 
any two proteins. 
    Perhaps one of the most interesting experiments that can be accomplished with these 
atypical polyUb chains is to identify naturally occurring proteins that are involved in 
ubiquitination or deubiquitination processes. One possible approach is to capture 
potential target proteins by running phage displayed (136) human protein library through 
a desired polyUb chain that has been immobilized on a resin. Following MS proteomic 
analysis or DNA sequencing analysis the bound proteins or gene sequences will be 



















human protein library 
Figure 3.35. Identification of natural ligand proteins of polyUb chains from phage-
displayed human protein library. Phage-displayed human proteins are shown in green. 
Enriched genes 
encoding ligand proteins 
DNA sequencing to 
identify ligand proteins 
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3.3.3 Condensed E. coli cultures for highly efficient production of proteins containing 
UAAs 
We have domenstrated that by using condensed culture method, protein production per 
unit UAAs can be increased by up to 10 fold. This will be particularly useful when the 
UAAs to be incorporated into proteins are not readily available. Appendix I includes one 
such example where condensed culture method was used to produce proteins containing 
o-nitrobenzyl thiol tyrosine (OnbSTyr). In addition to regular protein production, it is 
possible that condensed E. coli cultures could be used in genetic selections of novel 
aminoacyl-tRNA synthetase variants. Reporter proteins could be expressed in small 
volumes and then the cells diluted and selected. In the past such selections have been 
notorious for consuming large quantities of UAAs. Ultimately we believe that this 
approach will become standard practice in laboratories that are applying UAAs to solve 
biophysical problems, particularly in situations where the UAA in use must be 
chemically synthesized. 
 
3.4  Materials and Methods 
3.4.1 Traceless enzymatic synthesis of polyUb chains using Ub-BocLys 
3.4.1.1 Construction of PylT and PylRS plasmids for BocLys incorporation 
The Methanosarcina barkeri pyrrolysyl tRNA (MbPylT) encoding DNA (see Apendix 
IV for full sequence) was assembled using primers PylT#1~#6 (Apendix III). In this 
synthetic gene, PylT transcription is under the control of a upstream proK promoter (137), 
which has been reported to enhance the in vivo expression of tRNA (120). This proK-
PylT fusion gene was PCR amplified using primers pSup_PylT_FWD and 
pSup_PylT_REV (Appendix III). The PCR product was digested with ApaL I/Xho I, gel-
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purified, and ligated into pSup vector (120) cut with the same restriction enzymes to 
replace the original tRNA region. This new plasmid was named as pSup-PylT. The gene 
encoding Methanosarcina mazei pyrrolysyl tRNA synthetase (MmPylRS) (see Apendix 
IV for full sequence) is PCR amplified from M. mazei genomic DNA (ATCC catalog 
number BAA-159D-5) using primers PylRS_FWD and PylRS_REV (Appendix III). The 
PCR product was digested with Nde I/Nsi I, gel-purified and ligated into pSup-PylT 
plasmid pre-treated with Nde I/Pst I (MmPylRS encoding gene contains Pst I site. 
Therefore, Nsi I was used in primer to create a Pst I compatible end on the MmPylRS 
PCR product). The recombinant plasmid was named as pSup-Pyl and was confirmed by 
DNA sequencing. A single mutation Y384F, which is known to enhance PylRS activity 
toward BocLys (116), was introduced into pSup-Pyl by site-directed mutagenesis using 
primers PylRS_Y384F_FWD and PylRS_Y384F_REV (Appendix III). The resultant 
plasmid was renamed as pSup-BocLys. 
As a backup plan, the MbPylT and MmPylRS were also cloned into a double plasmid 
system. To clone the proK_PylT gene into pYC vector (43), pSup-BocLys was PCR 
amplified using primers pYC_PylT_FWD and pYC_PylT_REV (Appendix III). The 
PCR product was digested with Pst I/Not I, gel-purified and ligated into the Pst I/Not I 
site of pYC vector to replace the original tRNA. This new plasmid is named as pYC-
PylT-Myo4tag, which also bears a myoglobin gene containing a “TAG” stop codon at 
amino acid position 4. To clone PylRS into pBK vector, pSup-BocLys vector was PCR 
amplified using primers PylRS_FWD and PylRS_REV (Appendix III). The PCR 
product was digested with Nde I/Nsi I, gel-purified and ligated into pBK vector pre-cut 
with Nde I/Pst I. The recombinant plasmid was named as pBK-BocLys 
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To confirm that the MbPylT and MmPylRS were functional in the new plasmids, 
expression tests were run to incorporate BocLys into proteins using the newly constructed 
plasmids. For the double plasmid system, the “tester” protein was the myoglobin carried 
by pYC-PylT-Myo4tag plasmid. For the single plasmid system, the “tester” protein was 
sfGFP from pTrcHisA-sfGFP150tag plasmid (138). This sfGFP gene was generated by 
overlapping PCR using synthetic primers (Appendix III). Val150 mutation was 
introduced by site-directed mutagenesis using primers sfGFP_V150tag_FWD and 
sfGFP_V150tag_FWD (Appendix III). pYC-PylT-Myo4tag/pBK-BocLys and pSup-
BocLys/pTrcHisA-sfGFP150tag pairs were co-transformed into GeneHogs E. coli cells. 
pYC-PylT-Myo4tag/pBK-BocLys cells were plated on LB agar with 15 g/mL 
tetracycline (Tet15) and Kan50. pSup-BocLys/pTrcHisA-sfGFP150tag cells were plated 
on LB agar (Chl35/Amp100). Two single colonies were picked from each plate, grown at 
37 °C in 2×YT media with corresponding antibiotics to OD600 of ~0.5, and then induced 
with 1 mM IPTG and 2 mM 

N-Boc-L-Lysine (Chem-Impex International, Wood Dale, IL) 
and grown overnight (~16 h). The whole-cell protein expression was analyzed by 
resolving whole cell lysate from 50 L expression culture on 12.5% SDS-PAGE. 
3.4.1.2 Construction of pSup plasmids for incorporation of other lysine derivatives 
To generate MmPylRS variant for CbzLys incorporation, one additional mutation Y306A 
(116) was introduced into the PylRS gene on pSup-BocLys plasmid by site-directed 
mutagenesis using primers PylRS_Y306A_FWD and PylRS_Y306A_REV (Appendix 
III). This new plasmid bearing the MmPylRS for incorporation of CbzLys into proteins 
was named as pSup-CbzLys. To generate MmPylRS variant for OnbLys incorporation, 
three additional mutations Y306M/L309A/C348A were introduced into the PylRS gene 
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on pSup-BocLys plasmid by sequential site-directed mutagenesis using primer pairs 
PylRS_Y306M_FWD/ PylRS_Y306A_REV (for both Y306M and L309A mutations) 
and PylRS_C348A_FWD/ PylRS_C348A_REV (Appendix III). This new plasmid was 
named as pSup-OnbLys. 
To test if BocLys, CbzLys and OnbLys can be incorporated into Ub, pSup-BocLys, 
pSup-CbzLys and pSup-OnbLys were co-transformed with pET3a-Ub-K48tag plasmid 
into BL21 (DE3) E. coli cells, respectively. Two single colonies were picked from each 
plate, grown at 37 °C in 2×YT media (Amp100/Chl35) to OD600 of ~0.5 and then induced 
with 1 mM IPTG and 2 mM BocLys (Chem-Impex International), CbzLys (Acros 
Organics, Geel, Belgium) or OnbLys (see Appendix VI for synthesis details). After 
overnight expression, the cells from 100 L culture were collected, resuspended in SDS 
loading dye, boiled at 95 °C for 10 min and then resolved on 12.5% acrylamide gel. 
Expression and purification of Ub-K48OnbLys were performed using IMPACT kit (NEB) 
as described in the section 3.4.1.4. 
3.4.1.3 Construction of Ub expression plasmid pTXB1-SynUb-K48tag 
Codon-optimized human Ub gene was generated by overlap PCR using homologous 
primers SynUb #1~#6 (Appendix III). A two step PCR strategy was used, including an 
assembly PCR step and an amplification PCR step. Assembly PCR was performed in a 
50 μL solution containing 0.2 mM dNTPs, 0.5 U of Phusion DNA polymerase (NEB), 1× 
Phusion HF reaction buffer (NEB) and 2 μM of each SynUb #2 through SynUb #9 
primers. This mixture was thermal cycled as follows: initial denaturation at 98 ºC for 30 s, 
25 cycles of 98 ºC for 10 s, 58 ºC for 30 s and 72 ºC for 20 s and final extension at 72 ºC 
for 10 min. The synthetic Ub gene was then amplified in the following conditions: 0.2 
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mM dNTPs, 0.5 U of Phusion DNA polymerase (NEB), 1X Phusion HF reaction buffer 
(NEB), 1 μL of assembly PCR product and 2 μM of each SynUb #1 and SynUb #10 
primers in a 50 μL solution, under the same cycling conditions. The PCR product was 
purified using QIAquick PCR purification kit (Qiagen) and digested with Nde I/BamH I. 
The digestion product was gel-purified and ligated into the Nde I/BamH I site of pET3a 
vector (EMD Chemicals Inc., San Diego, CA). The gene was confirmed by sequencing 
and then PCR amplified from pET3a vector using primers pTXB1_FWD and 
pTXB1_REV. The PCR product was digested with Nde I/Sap I, gel-purified and ligated 
into the NdeI/SapI site of the pTXB1 vector (NEB) to generate pTXB1-SynUb plasmid. 
pTXB1-SynUb-K48tag plasmid was generated by site-directed mutagenesis using 
template plasmid pTXB1-SynUb and primers K48tag_FWD and K48tag_REV 
(Appendix III). Primers for introducing TAG codon into other lysine positions are also 
listed in Appendix III. 
To test SynUb, Y384F mutation and different TAG positions, the following eight 
double transformations were performed using BL21 (DE3) chemically competent cells 
(1~4 for regular Ub and 5~8 for SynUb):  
1) pSup-wtPylRS + pET3a-Ub-K48tag 
2) pSup-BocLys (containing PylRS Y384F mutant) + pET3a-Ub-K48tag 
3) pSup-wtPylRS + pET3a-Ub-K11tag 
4) pSup-BocLys + pET3a-Ub-K11tag 
5) pSup-wtPylRS + pET3a-SynUb-K48tag 
6) pSup-BocLys + pET3a-SynUb-K48tag 
7) pSup-wtPylRS + pET3a-SynUb-K11tag 
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8) pSup-BocLys + pET3a-SynUb-K11tag 
A single colony was picked from each plate, grown at 37 °C in 2×YT media 
(Amp100/Chl35) to OD600 of ~0.5, induced with 1 mM IPTG and 2 mM BocLys (Chem-
Impex International) and grown overnight (~16 h). After overnight expression, the cells 
from 100 L culture were collected, resuspended in 10 L 1× SDS loading dye, boiled at 
95 °C for 10 min and then resolved on 12.5% acrylamide gel. 
3.4.1.4 Expression and purificiation of Ub-K48BocLys, N
15




Ub1-74 was expressed as previously described (122). To express Ub-K48BocLys, 
plasmids pSup-BocLys and pTXB1-SynUb-K48tag were double transformed into E. coli 
BL21(DE3) chemically competent cells. Expression was induced in regular or 
“condensed” culture (see section 3.4.3). Briefly, a freshly transformed colony was grown 
in 2 L 2×YT media (Amp100/ Chl35) at 37 ºC to OD600 of 0.5. The E. coli cells were 
pelleted, resuspended in 100 mL 2×YT media (Amp100/Chl35) containing 1 mM IPTG 
and 2 mM BocLys, and grown at 30 ºC for 16 h. E. coli cells from the expression culture 
were harvested by centrifuge, washed three times with column buffer (20 mM HEPES, 
500 mM NaCl, pH 8.5) and resuspended in 60 mL of lysis buffer (20 mM HEPES, 500 
mM NaCl, 1 mM PMSF, pH 8.5). The resuspended cells were frozen and thawed three 
times, sonicated and then centrifuged to remove cell debris. Supernatant was applied to a 
column containing 35 mL of chitin-binding beads from IMPACT kit (NEB) which had 
been pre-equilibrated with 100 mL colume buffer. The beads with bound chitin-Ub 
fusion were washed with 400 mL column buffer. On-column cleavage was induced by 
flushing the column with 60 mL wash buffer containing 50 mM DTT. The column was 
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kept at 37 ºC for 24 h. Cleaved Ub-K48BocLys was eluted from the column using 60 mL 
wash buffer. Proteins were concentrated using Amicon 3K NMWL centrifugal filter 
(EMD Millipore, Billerica, MA) and SEC purified. The overall yield of expression and 
purification was 10 mg protein per liter culture. 
15
N-labeled Ub1-74 and Ub1-74-K48BocLys protein was expressed using auto-inducing 
minimal media. pET3a-Ub1-74 was transformed into BL21(DE3) cells. pTXB1-SynUb1-74-
K48tag and pSup-BocLys were double transformed into BL21 (DE3) cells. A freshly 
transformed single colony from each plate was inoculated into 4 mL 2×YT media 
(Amp100/Chl35) to grow a starter culture. Next day, this starter culture was inoculated 
into a 2 L culture of auto-inducing minimal media containing 10 mM Na2SO4, 50 mM 
KH2PO4, 50 mM Na2HPO4, 1 mM MgSO4, 18 mM 
15
NH4Cl (Acros), 0.04% ferric citrate, 
0.5% glycerol, 0.05% glucose, 0.2% lactose and 2 mM BocLys (Chem-Impex). This 2 L 
culture was grown at 30 ºC for 24 h. Purification of 
15
N Ub1-74 was performed as 
previously described (122) and purification of 
15
N Ub1-74-K48BocLys was performed 
using IMPACT kit as described above. 
The MW of purified Ub-K48BocLys, 
15
N Ub1-74 and 
15
N Ub1-74-K48BocLys samples 
were confirmed by ESI-MS at Maryland Proteomics Core Facility. High resolution MS of 
m/z 250-2500 were acquired with a JEOL AccuTOF-CS mass spectrometer in 
electrospray positive mode using flow injection. To determine the MW, spectra were 
deconvoluted using MagTran software (139) with the maximum charge set to 30. For 
dilute Ub2 and Ub3 samples, high-resolution mass spectra of m/z 400-2000 (or 600-4000 
for protein with Alloc protection group) were acquired on a Thermo Scientific LTQ 
Orbitrap XL mass spectrometer using flow injection. The resolution was 60 000 at m/z 
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400. Deconvolution was carried out using either the Xtract program in Xcalibur software 
or MagTran with a maximum charge set to 30. 
3.4.1.5 Deprotection of Boc protecting group 
The Boc protecting group of Ub-K48BocLys was removed by adding trifluoroacetic acid 
(TFA) to a final concentration of 2%, followed by incubation at 37 ºC for 4 h. The protein 
sample was then re-equilibrated to buffer containing 20 mM sodium phosphate, pH 6.8 
using a 3K NMWL concentrator (Millipore). No appreciable amount of protein was lost 
from TFA treatment.  
NMR samples of 
15
N Ub1-74 and TFA-treated 
15
N Ub1–74 K48BocLys (150 μM~ 1 mM) 
were prepared in the 20 mM sodium phosphate buffer, pH 6.8, containing 8% 
2
H2O and 
0.02% (w/v) NaN3. These and all the following NMR studies were performed on an 
Advance III 600 spectrometer equipped (Bruker Biospin, Billerica, MA) with a TXI 




H HSQC and 





N dimensions, respectively. A total of 160 t1 increments were collected with 
2048 complex points in each. Assignments for Ub1-74 and TFA-treated Ub1–74 
K48BocLys were determined by comparison with previously published spectra of human 
Ub (122). Spectra were processed using NMRPipe (140) and analyzed using Sparky 
(141). 
    Chain polymerization reactions on K48BocLys variant and TFA-treated K48BocLys 
for testing the functionality of deprotected lysine were performed as previously described 
(122) (see next section for reaction details). 
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3.4.1.6 Assembly of K48-linked Ub2 and Ub3 chains 
    Ub2 assembly reactions were performed using 10 mg each of distal Ub-K48BocLys 
and proximal 
15
N Ub1-74 in a reaction solution containing 50 mM Tris-HCl (50% base), 5 
mM MgCl2, 10 mM phosphocreatine (TCI), 4 mM ATP, 1 mM DTT, 0.6 unit/mL each of 
creatine phosphokinase and inorganic pyrophosphatase, 150 nM E1 enzyme and 10-20 
μM E2-25K enzyme. The reactions were incubated overnight at 37 ºC. The reactions 
usually went complete with little or no reactant left, as judged by a post-reaction SDS-
PAGE gel. Product was purified using both cation and SEC to > 60% yield, which is 
comparable to the yield using a reported method (95). Assembly of Ub3 followed the 
same procedure with the TFA-treated Ub2-K48BocLys being used as the proximal 
monomer and Ub-K48BocLys as the distal monomer. 
ESI-MS of TFA-treated and non-treated Ub2 was performed as above. NMR analyses 
of 
15
N Ub1-74 and Ub2-K48BocLys (with proximal Ub1-74 
15
N labeled) were performed 
under pH 4.5 and pH 6.8, respectively, using the same NMR solutions as above with the 
only difference being that 50 mM ammonium acetate buffer was used for pH 4.5 solution. 
Chemical shift perturbations (CSPs) were determined using identical buffer and 










N, respectively. CSPs are 
plotted as a function of the residue number. 
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3.4.2 Nonenzymatic synthesis of polyUb chains using Ub-BocLys monomers 
3.4.2.1 Preparation of ligation precursors Ub-K11BocLys, Ub-K33BocLys and Ub-SR 
Plasmids pTXB1-SynUb-K11tag and pTXB1-SynUb-K33tag were co-transformed with 
pSup-BocLys into E. coli BL21 (DE3) chemically competent cells as detailed above. 
15
N-
labeled WT Ub and 
15
N-labeled Ub-BocLys were expressed in E. coli using autoinducing 
minimal media with 
15
NH4Cl and were purified as described above. 
Ub variants with the thioester group at the C-terminal G76 (Ub-SR) were generated 
from respective Ub monomers (unlabeled or 
15
N labeled) using the following procedure. 
A 1 mL solution of 5 mg/mL Ub was prepared in 20 mM sodium phosphate buffer (pH 
8.0) with 10 mM ATP, 10 mM MgCl2, 100 mM sodium 2-mercaptoethane sulfonate 
(MESNA) and 250 nM of Ub-activating enzyme E1. The mixture was incubated at 37 ºC 
for 6 h and then stored at 4 ºC. The E1 enzyme was precipitated by adding a drop of 
glacial acetic acid to the solution. The protein solution was buffer- exchanged into 
distilled H2O containing 0.4% TFA and subsequently lyophilized. Ub-SR generation was 
confirmed by ESI-MS as above. 
3.4.2.2 Alloc protection and Boc deprotection to prepare Ub monomers for 
condensation reaction 
The Alloc protection reaction took place by initially dissolving 5 mg of each Ub 
monomer in 450 μL of DMSO for 15~20 min on a platform rocker. To this solution were 
added 17 μL of diisopropylethylamine (DIEA) and 75 μL of freshly made 40 mg/mL 
Alloc-OSu (TCI America, Portland, OR) solution in DMSO. The reaction was proceeded 
at least 1 h at room temperature on the platform rocker. Complete Alloc protection was 
monitored by ESI-MS. For each 100 μL of protein solution, the protein was precipitated 
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into a small white pellet by mixing with ~2 mL of ice-cold ether, vortexing for 15 s, and 
centrifuging for 10 min at 4 ºC. The top organic layer was removed after centrifugation, 
and two more rounds of ether precipitation were conducted. The pellet was then air-dried 
for 15~20 min. 
To remove the Boc protecting groups, 5 mg protein pellet from the previous step was 
dissolved in 500 μL of ice-cold 3:2 TFA/dH2O solution and left to react for 2~3 h at 4 ºC. 
Complete dissolution occurred after 15 min and can be aided by gently pipetting the 
solution. Removal of Boc group (MW loss of 100 Da) was monitored by ESI-MS. For 
every 100 μL of solution, the protein was precipitated by three rounds of extraction with 
cold ether as described above. Typically, the protein precipitated instantly after initial 
ether addition, and the resulting white pellet was air-dried for 15~20 min. 
3.4.2.3 Silver-mediated condensation reaction 
Approximately 2 mg of each of the two protected Ub monomers were dissolved in 
DMSO and then added together to a total volume of 90 μL as originally described (99). 
DIEA (4 μL), hydroxysuccinimide (H-OSu) (1 μL of fresh 390 mg/mL solution dissolved 
in DMSO), and AgNO3 (1 μL of fresh 57 mg/mL solution dissolved in DMSO) were 
added to the Ub monomers, mixed, and incubated at room temperature in the dark for at 
least 20~30 h. Formation of ligated Ub2 species was confirmed by SDS-PAGE. The 
solution was subjected to three rounds of ether precipitation as described above and then 
air-dried. The pellet typically was slightly yellowish in color. 
3.4.2.4 Global deprotection of Alloc groups and protein renaturation 
Ub was deprotected using 50 mol % chloro-pentamethylcyclopentadienyl-
cyclooctadiene-ruthenium (II) ([Cp*Ru(cod)Cl], from Sigma-Aldrich, St. Louis, MO) 
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and 50 equivent of thiophenol, relative to the number of moles of protected amines in the 
solution (counting all lysine, histidine residues and the N-terminal amine). For example, 
for 4 mg of total Ub monomer and assuring slight excess over nine amine protection sites 
on each Ub molecule, the reaction pellet was dissolved in 420 μL of DMSO to which 
were added 240 μL of H2O, 116.2 μL of 20 mM [Cp*Ru(cod)Cl] (freshly dissolved in 
DMSO), and 23.8 μL of neat thiophenol. The resulting dark-brown/black solution was 
divided into 200 μL aliquots in PCR tubes. The reactions were incubated in a thermal 
cycler at 50 ºC for 2 h. After this, the tubes were allowed to cool for 10~15 min; the 
resulting solution was typically a dark orange cloudy solution with black precipitate. 
Approximately 100 μL of each reaction tube were aliquoted into 2 mL eppendorf tubes 
for cold ether precipitation as described above. Typically, at least 10 rounds of ether 
precipitation were necessary to form a small dark-brown pellet in each of these eppendorf 
tubes. After each round of centrifugation, the top organic layer was very carefully 
removed, so as to not disturb the aqueous bottom layer. When cold ether was added, 
vigorous vortexing for 15 s was performed to ensure proper mixing of the solution. After 
pellet formation, the pellet was allowed to air-dry for 10~15 min. 
    The above protein solution from Alloc deprotection was initially dissolved in a total of 
500 μL to 1 mL of filtered denaturaton solution containing 6 M GdnHCl and 20 mM 
sodium phosphate, pH 6.8, for 10~15 min. The solution was centrifuged for 5 min to 
remove the undissolved precipitate. Renaturation solution (20 mM sodium phosphate, pH 
6.8, 130 mM NaCl) was added to the denatured protein samples stepwise in 200 μL 
aliquot with 10~15 min interval, until the solution became clear. The final volume of 
renaturation solution is 10~15 mL. The clear solution was then transferred to 3K MWCO 
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dialysis tubing and dialyzed overnight against 2 L of the renaturation buffer at 4 ºC. The 
dialyzed protein samples were concentrated to <1 mL using Amicon Ultra-15 3K MWCO 
filter (Millipore) and then SEC purified. The fractions pertaining to the desired Ub 
species were collected, concentrated, and exchanged into NMR buffer (20 mM sodium 
phosphate, pH 6.8). Purity was assessed to be >99% based on coomassie-stained SDS-
PAGE gel analysis. Typically from an input of 5 mg of Ub monomers, 0.7~1 mg of Ub2 
can be obtained. The final Ub2 was analyzed by ESI-MS to confirm the MW. 
3.4.2.5 Assembly and characterization of K11- and K33-linked Ub2 
In the current study, the K11-Ub2 was assembled using a Ub-K11BocLys distal precursor 
in the thioesterification reaction. The final Ub2 chains after Alloc deprotection were 
subjected to TFA treatment to produce native Ub2. Non-treated Ub2 with a BocLys at 
K11 was used as the proximal unit in the synthesis of Ub3 chains. The K33-Ub2 was 
assembled using WT Ub distal precursor in the thioesterification reaction. The conditions 
for individual steps are described above. 
3.4.2.6 Assembly and characterization of K11-Ub3 and K11/K33-Ub3 




N-M K11-linked Ub3), 
approximately 0.75 mg of 
15
N-D K11-Ub2-K11Boc was reacted with 1.25mg of Ub-SR. 
Both proteins were protected with Alloc groups, and K11-Ub2 was treated with TFA to 
expose the ε-amine of K11 prior to reacting with Ub-SR. Immediately prior to the 
reaction, each protein was dissolved in 45 μL of DMSO. After the proteins were mixed 
together, the remaining ingredients (DIEA, AgNO3, and H-OSu) were added. Alloc 
deprotection was performed assuming 3 mg of Ub monomer with 10 Alloc-protected 
amines per Ub. This overestimation of the amount of Ub ensured complete Alloc 
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deprotection. The reaction pellet was dissolved in 315 μL of DMSO to which were added 
180 μLof H2O, 87.2 μL of 20mM[Cp*Ru(cod)Cl] (freshly dissolved in DMSO), and 17.9 
μL of neat thiophenol. Protein was precipitated with ether, renatured, and purified as 
described above. A small aliquot (5 μL of 40 μM protein) was analyzed by ESI-MS to 
confirm that all Alloc groups on K11-Ub3 were removed. Total amount of purified Ub3 
was determined to be 0.3 mg (15% yield). 
    To assemble K11/K33-Ub3 with the middle Ub 
15
N-labeled, 0.75 mg of 
15
N-P K33-
linked Ub2 was reacted with 3mg of Ub-K11Boc. The C-terminus of K33-Ub2 was 
thioesterified using MESNA and E1 enzyme as described above. Complete 
thioesterification was verified by ESI-MS. The protein was protected with Alloc groups 
as described above, with 3-fold excess of Alloc groups, and analyzed by ESI-MS. Ub-
K11Boc protected with Alloc groups was treated with TFA as described above. Prior to 
condensation reaction, each protein was dissolved in 45 μL of DMSO. DIEA, AgNO3, 
and H-OSu were added into protein solution in DMSO in the same amounts as described 
above. Subsequent Alloc deprotection was performed assuming a total of 5 mg of Ub 
monomer with 10 Alloc-protected amines per Ub. The reaction pellet was dissolved in 
525 μL of DMSO to which were added 300 μL of H2O, 145.3 μL of 20 mM 
[Cp*Ru(cod)Cl] (freshly dissolved in DMSO), and 29.8 μL of neat thiophenol. The 
reaction was run as described above. Ub proteins were then renatured and purified. Total 
amount of K11/K33-linked Ub3 was 0.35 mg (9% yield). The apparent lower yield 
reflects the excess amount of unreacted Ub-K11Boc in the reaction. 
    K11-Ub4 was assembled using pre-assembled K11-Ub3 as the distal unit and Ub-
K11BocLys as the proximal unit. Conditions for individual steps were the same as above. 
 
 145 
3.4.3 Condensed E. coli cultures for highly efficient production of proteins containing 
UAAs 
3.4.3.1 Determination of optimum ratio for condensation 
For expression test of Ub-K48BocLys, pET3a-SynUb and pSup-BocLys were co-
transformed into E. coli BL21 (DE3). A single colony was picked to grow 5 mL of 
overnight starter culture. Next day the starter culture was inoculated into a 2 L 2×YT 
(Amp100/Chl35). This 2 L culture was grown to an OD600 of 0.5 and cells were 
centrifuged at 4,000 rpm for 10 min and then resuspended in 80 mL (25-fold 
condensation) fresh 2×YT (Amp100/Chl35) containing 1 mM IPTG and 2 mM BocLys. 
Prior to addition of BocLys, 5 mL of the culture containing no BocLys was transferred 
into a new tube and grown as a control for the UAA-dependent Ub expression. These 
cultures were grown at 30 ºC for ~16 h. For each of the samples with and without BocLys, 
the cells from 100 L culture were centrifuged, lysed, and analyzed by a 16% SDS-
PAGE gel. 
    To determine the optimum ratio of condensation, pSup-pBpa/pTrcHisA-sfGFP-
V150tag and pSup-CbzLys/pET3a-SynUb-K48tag were co-transformed into GeneHogs 
and BL21 (DE3) E. coli cells, respectively. Single colonies were picked to grow a 1 L 
2×YT culture (Amp100/Chl35). When the OD600 of the cultures reached 0.5, cells were 
centrifuged at 4,000 rpm for 10 min and resuspended in fresh 2×YT to generate a series 
of 2 mL cultures with a condensation ratio ranging from 1× to 100× (see Table 3.1). 
Antibiotics Amp100/Chl35 and inducing reagent IPTG were individually added into all 
these cultures. The 2 mL cultures were then divide into two 1 mL cultures. For one 
culture was added BocLys or pBpa, accordingly (the UAA-free cultures served as a 
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negative control). These 1 mL cultures were grown at 37 ºC overnight. Next day, the cells 
from these cultures were harvested. These cells were resuspended in 100 L water. 
Except for the 1× sample, 10 L of each resuspended cells was resolved on a 16% SDS-
PAGE gel. The cells in the 1× sample had substantial growth and only 5 L of the 
resuspended cells were run on the gel for best resolution, which was taken into 
consideration when calculation was performed on the amount of expressed proteins. A 
BSA internal standard was included in each loaded sample to quantify the expressed 
proteins. Protein quantification was performed using Image J as shown in Figure 2.9.  
3.4.3.2 MS characterizaiton of purified Ub-K48CbzLys and sfGFP-V150pBpa  
Ub-K48CbzLys was expressed as a fusion to chitin binding domain in 25× condensed 
culture (as described above) by resuspending cells from one L culture into 40 mL of 
induction media. The protein was purified according to the above purification protocol of 
Ub-BocLys construct. sfGFP-V150pBpa was expressed in a 10× condensed culture by 
resuspending cells from 1 L culture in 100 mL of induction media. sfGFP-V150pBpa was 
purified according to the protocol in Chapter 2 for His tag affinity purification. 
    For purified sfGFP and Ub proteins, about 0.5 g was digested using ~0.01 g of 
trypsin Gold (Promega) in 50 mM NH4HCO3 buffer, pH 7.8. The digestion reaction was 
incubated at 37 ºC for 4 h 30 min. MS analysis of the tryptic digested sample was 
performed at Maryland Proteomics Core Faciltiy. 
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Appendix I: Site-specific Incorporation of Photoactivable 
Tyrosine Analogues into Proteins in E. coli 
I-1  Introduction 
Tyrosine residues occur at the active sites of a wide range of proteins and are frequently 
involved in redox or radical reactions. Besides serving as catalytic centers, tyrosines can 
be also post-tranlationally modified by phosphrylation (142) or sulfation (143) to act as a 
regulatory signal. Understanding the functions of these tyrosine residues is not an easy 
task as the properties of the tyrosines, such as pKa, could be altered by surrounding 
micro-environment.  
The biological functions of specific tyrosine residues in a protein are sometimes 
investigated by mutagenesis analysis, such as mutation into an inert amino acid (alanine, 
for example) or an amino acid with distinct properties. These mutagenesis studies, 
however, are limited by the structural constrains of proteins when the newly introduced 
amino acids have significantly different structures. 
 An alternative approach is to replace the targeted tyrosines with tyrosine analogues 
that have similar structures yet distinct properties such as acidity or redox potential (144). 
Traditional methods for incorporation of tyrosine analogues include metabolic labeling or 
total chemical synthesis. In the former method, E. coli starved of tyrosine was grown in 
the presence of tyrosine analogues to force the global incorporation of tyrosine analogues 
in all E. coli proteins (145). The obvious concern of this method is the lack of the control 
of the incorporation sites. The latter method relies on the solid phase peptide synthesis 
(30) followed by expressed protein ligation (146). Although this method allows the site-
specific incorporation of tyrosine analogues, it is limited to small or medium-sized 
proteins with robust renaturating ability. 
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A more recent approach allows unnatural amino acids (UAAs) to be genetically 
encoded in a protein sequence (44). This method relies on the assignment of an UAA to 
an amber stop codon (TAG) in the gene of interest using an orthogonal tRNA and 
aminoacyl tRNA synthetase (aaRS) pair. The challenge, however, is to selectively 
incorporate tyrosine analogues while maintaining little or no incorporation of natural 
tyrosine. One strategy to overcome this problem is to “disguise” the tyrosine analogues 
with cleavable protecting groups. After the orthogonal tRNA/aaRS incorporate these 
“disguised” amino acids into proteins, the protecting groups can be removed to expose 
the desired amino acids to act as comparison probes.  
Among all the protecting groups, photoremovable groups or so-called caging groups 
represents an ideal choice. The most commonly used caging group is based on ortho-
nitrobenzyl moieties (147, 148), while other groups with improved photochemical 
properties have been also developed (149-151). These photoremovable groups have many 
advantages over other protecting group. First, caging group enables traceless protection 
of amino acids where removal of the photoremovable group or “decaging” retains the 
intact structure and function of the desired amino acids. Secondly, caging groups can 
inhibit the function of a “caged” amino acid if attached to its functional moiety. 
Subsequent decaging process restores the full function of the desired amino acids. This 
allows the spatiotemporal control of the biological functions of the proteins carrying the 
“caged” amino acids. Thirdly, light irradiation is a non-invasive technique that results in 
minimal disrruption of protein structure or cellular processes. Studies of protein functions 
in vivo or in vitro can therefore be carried out under native conditions. 
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Genetically encoded photocaged tyrosine together with photochemical control has 
been employed in many biological systems to understand or spatiotemporally control the 
functions of proteins (148, 152-159). While the photochemical control of tyrosine is a 
truly powerful biological tool, the goal of the current study is to incorporate a tyrosine 
analogue with enhanced properties as a comparison probe. In collaboration with Dr. 
Deiters research group at North Carolina State University, we have successfully 
incorporated fluorinated tyrosine into proteins in E. coli using an evolved Methanococcus 
jannaschii tyrosyl tRNA synthetase (138). Here, we intended to develop a general 
method for the incorporation of thiotyrosine into proteins in E. coli. As a thiol group is in 
close structural proximity to a hydroxyl group, it is expected to alter the activity of 
tyrosine without disturbing the structure of a host protein. 
To incorporate o-nitrobenzyl-thiotyrosine into proteins in E. coli, we first tested the 
evolved MjYRS variant E10 that is capable to selectively introduce o-nitrobenzyl-2-
fluorotyrosine (OnbFTyr) (138). This E10 synthetase was identified from a MjYRS 
mutant library that contain random or selectively diversified mutations at seven active-
site residues (Y32, L65, H70, F108,D158, I159, and Ll62) (160). This library was then 
applied in a double-sieve selection experiment, based on suppression of a stop codon in 
the gene encoding chloramphenicol acetyl transferase (CAT) (positive selection) and 
barnase (negative selection). This selection resulted in variant synthetase that can 
incorporate OnbFTyr but not natural tyrosine into proteins in E. coli. Subsequent 




Test of this E10 synthetase with OnbSTyr for the current study indeed resulted in a 
moderate OnbSTyr-dependent protein production. However, MS results suggested that 
the caging group in the produced proteins had been reduced (see next section). Although 
the detailed reason of this modification in vivo is unknown, we speculated that it might be 
caused by the low-fidelity incorporation of UAAs by MjYRS. Recent studies have 
suggested that PylT/PylRS could selectively incorporate tyrosine deratives such as o-
benzyltyrosine into proteins in E. coli. The possibility of incorporaton of OnbSTyr using 
PylT/PylRS (or variants) is currently under investigation. 
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I-2  Preliminary Results 
I-2-1 Expression, purification and MS characterization of OnbSTyr-containing sfGFP 
and Ub produced by MjYRS variant E10 
Ub-K48OnbSTyr was purified using IMPACT kit (Figure I-1) and then analyzed by ESI-
MS for MW determination. The expected mass of Ub-K48OnbSTyr is 8750 Da. However, 
the MS results revealed a major peak at 8720, which had 30 Da less than the expected 
mass (Figure I-2). This 30 Da mass loss was very likely due to the reduction of the o-
nitro group (NO2) to amine group (NH2) as the Ub protein had been incubated with high 














Figure I-1. Purificaiton of Ub-K48OnbSTyr. 
OnbSTyr           +          -       







    To solve the potential nitroreduction problem, regular affinity tag expression and 
purification method were used where DTT is no longer a necessary component. We 
cloned SynUb-K48tag gene into pET11a vector to express Ub with a C-terminal His6 tag. 
A pTrcHisA-sfGFP-Y66tag plasmid was also constructed. Ub-His-K48OnbSTyr and 
sfGFP-Y66OnbSTyr were purified using His tag affinity purification and then analyzed 
by SDS-PAGE gels (Figure I-3). Interestingly, a truncated sfGFP1-66 was co-purified due 
to inefficient suppression of TAG codon and the N-terminal His tag. ESI-MS analysis of 

















OnbSTyr    +   -         +     -       
Figure I-3. Purificaiton of Ub-His-K48OnbSTyr and sfGFP-Y66 OnbSTyr. 




I-2-2 Protein expression in the presence of nitroreductase inhibitor and incorporation of 
o-aminobenzyl-thiotyrosine (OabSTyr) into Ub 
The above experiment indicated that nitroreduction may not be caused by the DTT-
mediated protein purification process. Instead, this problem may occur in vivo, likely 
caused by endogeneous nitroreductases. To solve this problem, we sought to test protein 
expression in the presence of a wide-range nitroreductase inhibitor dicoumarol (161, 162). 
Cell growth curve in the absence and presence of dicoumarol was first recorded to 
confirm that the supplement of dicoumarol would not affect cell growth (Figure I-5). 
Purification of Ub-His-K48OnbSTyr in the presence of dicoumarol, however, did not 




The nitroreduction, if at all, could happen at either pre-translational or post-translational 
stage. In the former case, OnbSTyr gets reduced before being incorporated into proteins. 
That said, o-aminobenzyl-thiotyrosine (OabSTyr) needs to be a substrate of the E10 
synthetase. If the reduction occurs at the post-translational level, OnbSTyr amino acid 
gets reduced after its incorporation into proteins. To test this hypothesis, OabSTyr was 
Figure I-5. Cell growth curve in the absence and presence of 500 M dicoumarol. 
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synthesized and incorporated into Ub protein. The expression results suggested that 
OabSTyr was, indeed, a substrate of E10 synthetase (Figure I-6). Therefore, the observed 
nitroreduction problem could be explained as that OnbSTyr was first reduced to OabSTyr 
by E. coli cellular components and this reduce amino acid was then incorporated into 
proteins by E10 synthetase. This result also suggests that E10 synthetase has relatively 










I-2-3 Incorporation of OnbSTyr into proteins using PylT/PylRS pair 
As E10 synthetase (MjYRS variant) seemed to have low-fidelity toward OnbSTyr, it may 
be advisable to test other tRNA/aaRS pairs. Recently, PylT/PylRS pair has been 
demonstrated to be able to incorporate a wide range of UAAs, including o-benzyl-
tyrosine, into proteins in E. coli when PylRS contained two promiscuous mutations 
N346A/C348A (117). Several reported PylRS variants have been tested for their activity 
toward OnbSTyr, including WT PylRS, Y384F (BocLys) (115), Y306A/Y384F (CbzLys) 
(115), Y306M/L309A/C348A/Y384F (OnbLys) (121) and Y306M/L309A/Y384F 
Ub-His 
UAA            1       2       3       4 
Lane 1: no UAA 
Lane 2: OnbTyr 
Lane 3: OnbSTyr 
Lane 4: OabSTyr 




(referred to as Interm PylRS) which is an intermediate construct when OnbLys PylRS 
was generated from BocLys PylRS by introducing additional mutations. The two reported 
promiscuious mutations were also introduced into each of the above variants to test if 
they can enhance the activity of these synthetases. The PylRS variants with incorporated 
N346A/C348A mutations were named after the original variants with “+” suffixes (for 
example, BocLys+ stands for PylRS BocLys variant incorporated with the double 







306 309 346 348 384 
1 WT Y L N C Y 
2 BocLys Y L N C F 
3 CbzLys A L N C F 
4 OnbLys M A N A F 
5 Interm
[b]
 M A N C F 
6 WT+ Y L A A Y 
7 BocLys+ Y L A A F 
8 CbzLys+ A L A A F 
9 OnbLys+
[c]
 M A A A F 
10 Interm+
[c]









Note: [a] N346A/C348A mutations were incorporated in the five synthetases to create the 
“+” series of constructs. 
          [b] This was an intermediate construct when OnbLys synthetase was generated 
from BocLys synthetase.  
          [c] These two variants are containing the same mutations due to incorporation of 
N346A/C348A double mutations. 
Table I-1. PylRS constructs tested for activities toward OnbSTyr 
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I-2-4 Scanning PylRS constructs for selective incorporation of OnbSTyr 
The in-plate fluorescence of these PylRS constructed was monitored under UV light to 
determine their activities toward OnbSTyr. Interestingly, synthetases OnbLys+ (#9) and 
Interm+ (#10) that carry the same mutations showed different fluorescence intensity 
(Figure I-7). This was likely due to some unexpected mutations in the synthetase gene, 
which can be verified easily by sequencing. Synthetases Interm (#5) and Interm+ (#10) 











Figure I-7. Plate fluorescence of the constructed synthetases, showing their activities 
toward OnbSTyr. A) and B) were taken with light filter on camera and C) and D) were 
taken without filter. In A) and C), the LB agar plates contained 1 mM IPTG, but no 
UAA; in B) and D), the LB agar plates contained 1 mM OnbSTyr. The numbers 











I-3  Ongoing/Future Experiments 
1. Purification of proteins containing OnbSTyr using synthetases #5 and #10 
2. MS confirmation of the MW of the purified protein 
3. Decaging experiments 
I-4  Materials and Methods 
I-4-1 Construction of plasmids for UAA incorporation 
pTrcHisA-sfGFP-Y66tag was constructed by performing site-directed mutagenesis on 
previously reported pTrcHisA-sfGFP plasmid using primers sfGFP_Y66tag_FWD and 
sfGFP_Y66tag_REV (Appendix III). pTrcHisA-sfGFP-V151tag was constructed as 
above using primers sfGFP_V151tag_FWD and sfGFP_V151tag_REV (Appendix III). 
To clone SynUb gene into pET11a, SynUb gene was amplified by PCR using primers 
SynUb #1 and SynUb_pET11a_REV (Appendix III). The PCR product was digested 
with Nde I/Nhe I and then ligated into the pET11a vector treated with the same restriction 
enzymes. The Ub protein expressed from this pET vector contained a C-terminal His tag. 
    A series of pSup-PylRS constructs containing N346A/C348A double mutations (117) 
were generated by site-directed mutagenesis using primers PylRS_N346A/C348A _FWD 
and PylRS_ N346A/C348A _REV (Appendix III). These two mutations were 
incorporated into the following PylRS constructs: WT PylRS, Y384F (BocLys) (115), 
Y306A/Y384F (CbzLys) (115), Y306M/L309A/C348A/Y384F (OnbLys) (121) and 
Y306M/L309A/Y384F (Interm PylRS). 
I-4-2 Expression and purification of Ub and sfGFP containing OnbSTyr 
pSup-E10 (138) was co-transformed with pTXB1-SynUb-K48tag (100), pET11a-SynUb-
His or pTrcHisA-sfGFP-Y66tag into BL21 (DE3) cells, respectively. A single colony 
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was picked from each plate to grow a 5 mL overnight starter culture. This starter culture 
was then inoculated into 100 mL 2×YT (Amp100/Chl35). The 50 mL culture was grown 
to an OD600 of 0.5, centrifuged, and resuspended in 10 mL fresh 2×YT media (10-fold 
condensation). The condensed culture was supplemented with Amp100/Chl35, 1 mM 
IPTG and corresponding UAAs to induce the expression. Ub-K48OnbSTyr was purified 
using IMPACT kit (NEB) as described (100). Ub-His-K48OnbSTyr and sfGFP-
Y66OnbSTyr were purified using His tag affinity purification resins (Promega). The 
purified proteins were concentrated to 100 L and then confirmed by SDS-PAGE gel. 
Ub-K48OnbSTyr expressed from pTXB1 vector was analyzed by ESI-MS at Maryland 
Proteomics Core Facility. Ub-His-K48OnbSTyr expressed from pET11a vector was 
analyzed by ESI-MS at Virginia Commonwealth University Proteomics Facility. 
I-4-3 Scanning PylRS variants for activities toward OnbSTyr 
To test the activities of the above PylRS variants toward OnbSTyr, pSup plasmids 
carrying these PylRSvariants were co-transformed with pTrcHisA-sfGFP-V151tag into 
GeneHogs cells and plated on LB agar (Amp100/Chl35). A single colony was picked 
from each plate and grown to OD600 of 0.8. The culture (50 L) of each variant was 
plated on two LB agar plates (Amp100/Chl35) containing 1 mM IPTG, no UAAs or 




Appendix II: Evolution of Aminoacyl tRNA Synthetases Using 
In Vitro Compartmentalization 
II-1  Introduction 
In vivo evolution of tRNA synthetase is usually laborious and notorious for consumption 
of a large amount of UAAs. Furthermore, tRNA synthetases can not be evolved in vivo to 
incorporate cytotoxic or cell-impermeable UAAs into proteins. To overcome these 
limitations, we intended to develop an in vitro system for evolving synthetase functions. 
This project is still being developed. Introduced below are the rationale of the proposed 
experiments and some preliminary results. 
II-2  Rationale 
This experiment relies on in vitro compartmentalization technique, or so-called “water-
in-oil”. Water-in-oil emulsions are created by mixing aqueous and oil phase solutions 
with the help of surfactant. The aqueous phase is cell-free transcription/translation system 
containing the DNA template. The ratio of genes to droplets is controlled such that most 
droplets contain no more than a single gene statistically. 
    To evolve the substrate specificity of tRNA synthetases, a DNA construct is designed 
to carry the gene library of a target synthetase and the ORF of streptavidin (STA) which 
bears an amber stop codon (TAG). During in vitro translation, only the functional 
synthetase can suppress the stop codon in STA gene and result in a full-length STA, 
which will bind to the biotinylated DNA template. This way, the functional synthetase 
gene is linked to STA protein that contains an affinity tag for purification thereafter. 



























II-3  Preliminary Results 
II-3-1 IVC construct 
The DNA template (IVC construct) used in the selection is a PCR product, amplified 
from a plasmid pIVC using biotinylated primers. The IVC construct contains the gene or 
gene library of a desired synthetase and STA gene that bears a stop codon. This linear 
DNA contains a single T7 promoter sequence but separate ribosome binding sites (RBS) 
such that a single messenger RNA (mRNA) will be used to translate two different 
proteins (see Appendix IV for DNA sequence of pIVC). 
II-3-2 Cell-free translation using plasmid DNA 
Three different cell-free translation systems have been tested: 1) NEB PURE kit which 







Full-length STA Functional synthetase 
Synthetase STA 
Enrich functional gene-protein 





Figure II-1. Proposed experiment for in vitro evolution of synthetases. 
 
 161 
Yield S30 Extract which is the E. coli cell extract optimized for expression of proteins 
under the control of T7 promoter 3) home-made S30 extract. 
 






















Figure II-2. In vitro sfGFP expression using NEB PURE kit. Lane 1: no DNA; Lane 2: 
10 ng/L dihydrofolate reductase (DHFR) containing plasmid, as a positive control; 
Lane 3: 10 ng/L pRSET-sfGFP. The reactions were incubated at 37 ºC for 2 h. 
1        2        3 
Figure II-3. In vitro expression of synthetases from pIVC constructs using NEB PURE 
kit, 5 L reactions. Lane 1: no DNA; Lane 2~4: 10 ng/L of pIVC-MjYRS(WT)-STA, 
pIVC-MmPylRS(BocLys)-STA(1TAG) and pIVC-MmPylRS(BocLys)-STA(2TAG), 
respectively. STA expression was not observed due to the overlapping of protein bands. 

















Interestingly, this kit did not work for linear DNA as shown by later experiments.  
 
Home-made S30 
The home-made S30 reactions were tested using both sfGFP reporter (Figure II-5) and 









Figure II-5. In vitro expression of sfGFP using home-made S30, with 16 g/mL 
pRSET-sfGFP plasmid and 0.17 mg/mL tRNA. The reactions (300 L) were incubated 
at 37 ºC for 2 h. 
Figure II-4. In vitro expression of sfGFP, using Promega T7 High Yield S30 kit. Test, 
20 g/mL pRSET-sfGFP plasmid; negative control, no DNA. The reactions (10 L) 
were incubated at 37 ºC for 2 h. The GFP fluorescence was monitored on a fluorimeter 



















II-3-3 Cell-free translation using linear DNA and emulsified reactions 
As our experimental design requires the cell-free translation to be performed on 
biotinylated PCR product in emulsified condition, it is advisible to examine if linear 
DNA or “water-in-oil” has any effect on the translation reation. These experimental tests 
were performed using home-made S30 cell extract. It was evident that the home-made 
S30 reaction worked for both linear DNA template and emulsified reaction. However, 
both of these conditions decreased the translation efficiency by ~50%. 
Figure II-6. In vitro expression of Renilla luciferase using home-made S30. Sample 1, 
no DNA; sample 2, 13 g/mL Renilla luciferase control plasmid (Promega). The 
reactions (300 L) were incubated at 37 ºC for 2 h. The luminescence assay was 
monitored with a ~5 s delay and an integration time of 10 s. 
Figure II-7. Optimization of tRNA concentration in home-made S30 reaction, using 13 
g/mL Renilla luciferase control plasmid (Promega). Sample 1, no tRNA; Sample 2, 
0.17 mg/mL total tRNA; Sample 3, 0.85 mg/mL total tRNA. Three replicates were 












II-3-4 Isolation of E. coli total tRNA 
We first focused on production of proteins containing UAAs using PylRS/PylT pairs. The 
PylT tRNA was prepared by two different methods: 1) isolation of total tRNA from an E. 














Figure II-8. Cell-free translation using linear DNA (6.7 g/mL PCR product T7-sfGFP) 
and emulsified translation reactions (fluorescence assayed after ether extraction). 
Figure II-9. Isolated total E. coli tRNA. Lane 1, 0.4 g of commercial total E. coli 
tRNA (Sigma); Lane 2, 1.85 g of home-made total E. coli tRNA. 
1         2 
Figure II-10. Run-off transcription. Lane 1, with 5 mM NTPs; Lane 2, no NTPs. 
















    NEB PURE kit gave promising results. However, Promega S30 and home-made S30 
did not show evident production of proteins containing UAAs. 
 
II-3-6 Examination of binding specificities of nickel resins and antibodies 
In the IVC experiment, the basis of the selection is that the functional (full-length) STA 
captures the biotinylated template DNA, and this DNA-protein fusion is enriched by His 
tag affinity purification after breaking emulsion (in the presence of excess free biotin to 
prevent the binding between excess functional STA and non-functional DNA). We were 
concerned that the functional DNA-protein fusion may be difficult to enrich by 
traditionally used nickel resin-based His tag purification as the negative charges on DNA 
may interefere with the positively charged resins. 
Figure II-11. In vitro expression of sfGFP containing BocLys at position 151, using 
NEB PURE reaction (10 L). Positive control, 5 ng/L pRSET-sfGFP (without stop 
codon); negative control, 5 ng/L pRSET-sfGFP-V151tag, 73 ng/L MbPylT total 
tRNA, 5 ng/L pIVC- MmPylRS(BocLys)-STA(1TAG); test, the same as negative 
control, supplemented with 2 mM BocLys amino acid. 
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    To test this possibility, linear PCR product of IVC-MjYRS(WT)-STA and IVC-
MmPylRS(BocLys)-STA(2TAG) (1:1 molar ratio) were incubated with nickel resins 
under varying NaCl concentrations. The resins were washed and then applied in PCR 
reactions to amplify any residing DNAs (Figure II-12). The results suggested that 1) 
high concentration of NaCl inhibits PCR reaction (from Lane 3 and 4) and that 2) nickel 









We then intended to examine if non-specific binding also existed between anti-His 
antibodies and DNA templates. The binding between antibodies and His6 tag is more 
specific as it is selective not only for charges but also the structure of the His6 tag. We 
expected that antibody could solve the problem of non-specific binding. The antibody 
selection system was based on rabbit antibodies and protein A immobilized on magnetic 
beads that could bind IgG antibodies. Two different antibodies, anti-His tag and anti-
FLAG tag, were examined. The results suggested that there were not many DNA residing 
on the Protein A magnetic beads. However, it was not clear if the antibody could bind to 
the protein A beads properly. Futher experiments are required. 
Figure II-12. PCR tests of non-specific binding between nickel resins and DNA 
templates, under varying NaCl concentrations. Lane 1~4: starting solution (prior to 
binding with resins); Lane 5~8: binding flow-through; Lane 9~12, eluted solution from 
resin. The NaCl concentrations are: Lane 1, 5 and 9, 50 mM; Lane 2, 6 and 10, 200 
mM; Lane 3, 7 and11, 500 mM; Lane 4, 8, 12, 1 M. 


















II-3-7 IVC Model selection 
Before the IVC is used for the evolution of synthetases, we set up control experiments to 
model the selection process. Functional gene (PCR product IVC-MjYRS(WT)-STA) and 
non-functional gene (PCR product IVC-MmPylRS(BocLys)-STA(2TAG)) were used in 
1:1 ratio as the starting template in emulsified NEB PURE translation reactions. The 
functional gene has plain STA and thus can produce full-length STA which can capture 
the biotinylated PCR product. The non-functional DNA cannot produce full-length STA. 
Ideally, the functional gene-STA fusion should be readily enriched by His tag affinity 
purification. In our experiment, a 5-fold enrichment was indeed observed, as determined 
by Image J (Figure II-14). However, the conditions may need further optimizations 
because 1) there were non-specific PCR products and 2) fold enrichment was insufficient 
as compared with the 50-fold enrichment reported in previous study (163). 
Figure II-13. PCR tests of non-specific binding between antibodies and DNA 
templates. Lane 1, wash solution, anti-His tag antibody; Lane 2, wash solution, anti-
FLAG tag antibody; Lane 3, protein A beads, anti-His; Lane 4, protein Abeads, anti-
FLAG. 
















II-4  Ongoing/Future Experiments 
1. Repeat the in vitro expression of sfGFP-V151BocLys using NEB PURE kit 
2. Optimization of IVC selection conditions (to achieve >10-fold enrichment) 
3. Construct synthetase library using overlapping PCR 
4. Selection of functional synthetase gene using IVC 
 
II-5  Materials and Methods 
II-5-1 Construction of pIVC plasmids containing synthetases and STA genes 
WT MjYRS and STA gene bearing no stop codon was amplified then cloned into pET24a 
vector. The WT MjYRS gene in this plasmid has been replaced by MjYRS variant for 
pBpa incorporation and PylRS Y384F variant for BocLys incorporation. To clone the 
MjYRS-pBpa gene, PCR was performed on pSup-pBpa plasmid (138) using primers 
MjYRS_pIVC_FWD and MjYRS_pIVC_REV. The PCR product was digested with Nde 
Figure II-14. IVC model selection. Lane 1, binding flow-through; Lane 2~5, wash 
1~4, respectively; Lane 6, protein A beads bound with protein-DNA fusion. 







I/Pst I and ligated with the pIVC-MjYRS(WT)-STA treated witht the same restriction 
enzymes. For PylRS(BocLys) synthetase, pSup-BocLys plasmid was PCR amplified 
using primers PylRS_FWD and PylRS_REV. The PCR product was digested by Nde 
I/Nsi I and then cloned into pIVC construct pre-cut with Nde I/Pst I. To introduce the 
TAG stop codons into STA gene, site-directed mutagenesis was performed on pIVC 
plasmids using primers STA_TAG_REV and STA_one TAG_FWD (for one stop codon) 
or STA_two TAG_FWD (Appendix III). In summary, the following plasmids were 
constructed: pIVC-MjYRS(WT)-STA, pIVC-MjYRS(pBpa)-STA, pIVC-
MmPylRS(BocLys)-STA, pIVC-MjYRS(WT)-STA(1TAG), MjYRS(pBpa)-STA(1TAG), 
pIVC-MmPylRS(BocLys)-STA(1TAG), pIVC-MjYRS(WT)-STA(2TAG), pIVC-
MjYRS(pBpa)-STA(2TAG) and pIVC-MmPylRS(BocLys)-STA(2TAG). 
II-5-2 Cell-free translation reactions using commercial kits 
To test the efficiency of different translation systems, sfGFP reporter gene was cloned 
into pRSET vector to create pRSET-sfGFP tester plasmid.To create reporter gene for 
UAA incorporation, stop codon was introduced into V151 of sfGFP by PCR 
amplification of pRSET-sfGFP plasmid using primers sfGFP_V151tag_FWD and 
sfGFP_V151tag_REV. 
For translation reaction using NEB PURE kit, 50 g pRSET-sfGFP was added into 5 
L reaction solution containing 2 L solution A and 1.5 L solution B. The reaction was 
incubated at 37 ºC on a PCR thermocycler for 2 h and the fluorescence was monitored by 
Cary Eclipse fluorescence spectrophotometer (Varian Inc., Palo Alto, CA). To test the 
expression of synthetases from pIVC constructs, 50 g of pIVC-MjYRS(WT)-STA, 
pIVC-MmPylRS(BocLys)-STA(1TAG) and pIVC-MmPylRS(BocLys)-STA(2TAG) were 
 
 170 
added to 5L of reaction solution, respectively. The production of synthetases was 
monitored by SDS-PAGE gel. 
For translation reaction using Promega T7 S30 kit, 100 g pRSET-sfGFP was added 
into 10 L reaction solution containing 4 L premix solution and 3.6 L S30 extract. The 
reaction was incubated at 37 ºC on a shaker for 2 h. The fluorescence was monitored. 
II-5-3 Preparation of home-made E. coli S30 cell extract 
The homemade E. coli S30 extract was produced using the reported protocols (164, 
165). Freshly transformed BL21 (DE3) cells were grown in 2×YT media to an OD600 of 
0.8. The cells were then harvested by centrifugation at 5,000 rpm for 10 min at 4 ºC. The 
cell pellet was washed twice with S30 buffer (10 mM Tris-acetate, pH 8.2, 60 mM 
potassium glutamate, 14 mM magnesium acetate, 1 mM DTT). The cell pellet was then 
weighed and stored at -80 ºC for further application. To lyze the cells, 1 mL of S30 buffer 
was added per gram of cells. The cells were resuspended and then transferred to the 15 
mL chamber of bead beater (Biospec Products, Bartlesville, OK) pre-filled to half way 
with cold 0.1 mm glass beads (Biospec). The outside chamber was filled with ice. The 
cells were lyzed by applying 20 pulses of 30 s vibration. The cell lysis were transferred 
into a centrifugation tube and then clarified by centrifugation at 30,000 g for 30 min 
twice. The supernatant was transferred into a new tube. To this supernatant was added 0.2 
volume of pre-incubation solution containing 370 mM Tris-acetate, pH 8.2, 11.1 mM 
magnesium acetate, 5.5 mM DTT, 16.5 mM ATP (MP Biomedicals, Solon, OH), 50 M 
each of the 20 natural amino acids (Acros), 105 mM phosphoenolpyruvate (Alfa Aesar, 
Ward Hill, MA) and 8.4 U/mL Calbiochem rabbit muscle pyruvate kinase (EMD 
Millipore, Rockland, MA). This solution was incubated at 37 ºC for 80 min in dark to 
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consume all the endogenous mRNA. The solution became cloudy after incubation and 
was dialyzed using MWCO 6,000~8,000 dialysis tubing (Fisher Scientific, Pittsburgh, 
PA) against 100 volumes of S30 buffer for 40 min at 4 ºC. The dialyzed solution was 
centrifuged at 3,000 g for 10 min at 4 ºC. The supernatant was transferred into a new tube, 
aliquoted into 200 L solution/tube and then flash-freezed. These cell extracts were kept 
at -80 ºC. 
II-5-4 Cell-free translation reactions using home-made S30 cell extract 
The homemade S30 reaction contained 55 mM HEPES, pH 7.5, 1.7 mM DTT, 27.5 
mM ammonium acetate, 208 mM potassium glutamate, 19.3 mM magnesium acetate, 3.5 
mM each of the 20 natural amino acids, 68 M folinic acid, 1.2 mM ATP, 0.85 mM each 
of GTP, CTP and UTP, 0.64 mM 3', 5'-cyclic adenosine monophosphate (cAMP), 0.25 
mg/mL of creatine phosphokinase, 80 mM creatine phosphate, 0.17 mg/mL of E. coli 
total tRNA (Roche Applied Science, Indianapolis, IN), 0.1 mg/mL T7 RNA polymerase, 
25% (v:v) of cell extract and 16 g/mL DNAs. The reaction was incubated on a shaker at 
37 ºC for 4 h. For sfGFP reporter, the fluorescence was monitored directly after reaction. 
For luciferase reporter, 100 L Renilla luciferase assay solution (99 L assay buffer + 1 
L substrate) (Promega) was added to 50 mL S30 reaction and the luminescence was 
monitored on a luminometer. 
To successfully perform this S30 reaction, the following stock solutions were prepared 
and added in the order as below: 1) nuclease-free water 2) 10× reaction buffer (550 mM 
HEPES, pH 7.5, 17 mM DTT, 275 mM ammonium acetate, 2.05 M potassium glutamate, 
193 mM magnesium acetate); 3) 50 mM water soluble amino acid mix (Ala, Arg, Gly, 
His, Lys, Pro, Ser, Thr and Val), dissolved in water; 4) 50 mM of base soluble amino acid 
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mix (Ile and Phe), dissolved in 1 M NaOH; 5) 50 mM of acid soluble amino acid mix 
(Asp, Asn, Cys, Glu, Gln, Leu, Met, Trp and Tyr), dissolved in 1 M HCl; 6) 64 mM 
cAMP (100×), dissolved in water by dropwise addition of 1 M NaOH; 7) 6.8 mM folinic 
acid (100×), dissolved in water; 8) NTP mix containing 120 mM ATP and 85 mM each 
of GTP, CTP and UTP (100×), dissolved in water; 9) 1.6 M creatine phosphate (20×), 
dissolved in water; 10) 25 mg/mL creatine phosphate kinase (100×), dissolved in water; 
11) 5 mg/mL home-purified T7 RNA polymerase (50×), in storage buffer (50 mM Tris-
HCl, pH 7.9, 100 mM NaCl, 20 mM 2-mercaptoethanol, 1 mM EDTA, 50% Glycerol and 
0.1% Triton X-100); 12) S30 cell extract, pre-thawed on ice (may take up to 1 h); 13) 
DNA template of high quality and cocentration, dissolved in nuclease-free water; 14) 
commercial or home-made E. coli total tRNA. 
II-5-5 Cell-free translation using linear DNA and emulsified reactions 
Home-made S30 was used for testing linear DNA template and emulsified reactions. For 
reactions with linear DNA, 6.7 mg/mL sfGFP PCR product (generated using primers 
IVC_FWD and IVC_REV, with T7 promoter and terminator) was used in translation 
reaction with other conditions the same as above. For emulsified S30 reaction, 16 g/mL 
pRSET-sfGFP was used as template and the reaction was emulsified (see details below in 
Section II-5-9). The reaction was incubated as usual and the emulsion was removed by 
ether extraction (see Section II-5-9). The fluorescence of the ether-extracted solution was 
monitored. 
II-5-6 Isolation of total tRNA 
Total E. coli tRNA isolation was performed as reported (166). This protocol can be used 
for most E. coli strains including those containing suppressor tRNAs. A culture from the 
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desired strain was grown in 2×YT to an OD600 of 0.8 and then harvested by centrifugation. 
The cell paste was washed with distilled water for twice. To 10 g cell were added 17.5 
mL 1% (w/v) NaCl and 23.75 mL water-saturated phenol (dissolve crystal phenol in 
distilled water; acidic pH is critical to keep DNA in the organic phase). This solution was 
incubated at room temperature with shaking for 30 min. To this cell lysis was added 
2.375 mL chloroform. The mixture was incubated at room temperature with shaking for 
15 min and cleared by centrifugation at 27,000 g for 30 min. The upper aqueous phase 
was transferred into new tubes (under acidic pH, DNA is protonated and more soluble in 
organic phase. RNAs which in general have lower pKa than DNA due to the 2' hydroxyl 
group will be more soluble in aqueous phase). This aqueous solution was ethanol 
precipitated by adding 0.1 volume of 3 M sodium acetate, pH 5.2 and 2 volume of cold 
ethanol. Ethanol precipitation was performed at -20 ºC for at least 2 h (overnight for best 
result). The precipitates were collected by centrifugation at 5,000 rpm for 20 min. The 
cell pellet was washed twice with 75% cold ethanol, air-dried until becoming transparent 
and then dissolved in 4 mL of 0.3 M sodium acetate, pH 7.0. To this dissolved pellet was 
added 6.5 mL isopropanol. This solution was kept on ice for 30 min and then centrifuged 
at 12,000 rpm for 10 min. The supernatant was transferred into a new tube (mRNA and 
rRNA are less soluble than tRNA. However, there might be low level 5 S rRNA 
contaminations). To this supernatant was added 5.56 mL isopropanol. The precipitates 
were collected by centrifugation at 12,000 rpm for 10 min, air-dried and then dissolved in 
640 L nuclease-free water (less volume can be used to increase the concentration of 
tRNA). The tRNA solution was aliquoted and stored at -20 ºC. The quality of the 
prepared tRNA was assessed by running the samples on 2% agarose gels. OD260 and 
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OD280 were determined to assess the purity and concentration (pure tRNA has an 
OD260/OD280 of ~2.0 and a concentration of 40 g/mL for OD260 of 1.0 if 1 cm path 
length is used for the measurement). 
II-5-7 In vitro transcription of tRNA (run-off reaction) 
Serine suppressor tRNA (SerU) was produced using run-off transcription. The DNA 
template was generated by overlapping PCR using primers SerU #1~3 (Appendix III). 
The PCR product was ethanol precipitated. The run-off reaction contained 40 mM 
TrisHCl, pH 7.5, 2.5 mM spermidine, 25 mM MgCl2, 10 mM DTT, 5 mM each NTPs, 
0.2 U/L RNase inhibitor, 0.005 U/L inorganic pyrophophatase, 50 g/mL T7 RNA 
polymerase, 20 ng/L SerU DNA template (~0.3 M). The reaction was incubated at 37 
ºC overnight and the product was analyzed by 2% agarose gel. 
II-5-8 In vitro production of proteins containing UAAs 
In vitro translation of proteins containing UAAs has been tested using all the three above 
cell-free translation systems. For NEB PURE kit, 10 L reactions were set up containing 
4 L solution A, 3 L solution B, 73 ng/L home-made total E. coli tRNA containing 
MbPylT. The positive control contained 5 ng/L pRSET-sfGFP DNA. Negative control 
contained 5 ng/L pRSET-sfGFP-V151tag and 5 ng/L pIVC-MmPylRS(BocLys)-
STA(1TAG). The test experiment contained the same components as in negative control, 
but is supplemented with 2 mM BocLys amino acid. Expeirments on the other two 
translation systems followed the same procedure and DNA concentrations, with 
individual conditions as described above. 
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II-5-9 Examination of binding specificities of nickel resins and antibodies 
pIVC-MjYRS(WT)-STA and pIVC-MmPylRS(BocLys)-STA(2TAG) were individually 
amplified in the PCR reactions containing 1× Phusion HF buffer (NEB), 0.2 mM dNTPs, 
0.5 M each of primers IVC_FWD and IVC_REV, and 0.01 U of Phusion DNA 
polymerase (NEB). The PCR products were biotinylated at both 5' and 3' ends. These 
PCR products were purified using QIAquick PCR purification kit (Qiagen). The 
concentrations were determined by running an agarose gel and comparing with a standard 
DNA with known concentration. 
    To test if there was non-specific binding between nickel resins and DNA, 15 ng each 
of IVC-MjYRS(WT)-STA and IVC-MmPylRS(BocLys)-STA(2TAG) linear PCR product 
(~1:1 molar ratio) were dissolved in 100 mM TrisHCl (pH 7.5) buffer containing 10 mM 
imidazole and varying concentrations of NaCl (50 mM, 200 mM, 500 mM and 1 M). 
These DNA solutions were incubated with 50 L nickel resins (Promega) at room 
temperature for 30 min with shaking. The supernatant (binding flow-through) was then 
transferred to a new tube. The resins were washed twice with 100 mM TrisHCl buffer 
(pH 7.5) containing 50 mM imidazole. The washed resins were incubated with 100 mM 
Tris buffer (pH 7.5) containing 150 mM NaCl and 500 mM imidazole to elute all the 
residing DNAs from the resins. PCR reactions (20 L) were performed on 1 L each of 
the pre-binding solution, binding flow-through and eluted solution using primers 
IVC_FWD and IVC_REV. The PCR results were resolved on 1% agarose DNA gels. 
    To test if there was non-specific binding between anti-His antibody and DNA, 15 ng 
each of IVC-MjYRS(WT)-STA and IVC-MmPylRS(BocLys)-STA(2TAG) linear PCR 
product were mixed with 0.25 mg of rabbit anti-His or anti-FLAG antibody (Genscript, 
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Piscataway, NJ) and 5 L settled Protein A magnetic beads (Genscript) in 1× phosphate 
buffer saline (PBS). The mixture was incubated at 4 ºC for 1 h with shaking. The 
supernatant (binding flow-through) was transferred into a new tube. The beads were 
washed with 500 L PBS for three times. The first wash solution (1 L) and 1 L of the 
beads were used in PCR reactions as above to detect residing DNAs. 
II-5-10 IVC Model selection 
The emulsion oil contained 95% mineral oil, 4.5% Span 80, 0.5% Tween 80 and 0.1% 
Triton X-100 as described (163, 167). This oil solution was stirred on ice for 5 min prior 
to addition of the aqueous solution. Cell-free translation reaction (10 L) was set up 
using NEB pure kit as follows: 4 L solution A, 3 L solution B, 0.9 ng of biotinylated 
IVC-MjYRS(WT)-STA PCR product, 0.8 ng of biotinylated IVC-MmPylRS(BocLys)-
STA(2TAG) PCR product and 2 L nuclease-free water. This 10 L aqueous phase 
solution was added slowly into 100 L spinning oil solution over 1 min. The mixture was 
continued stirring on ice for 5 min. Then this solution was incubated at 37 ºC for 3 h 
without shaking. To the finished reaction was added 100 L Tris buffer saline (TBS, 100 
mM TrisHCl, pH 7.5, 150 mM NaCl) containing 100 M biotin (Alfa Aesar). The free 
biotin was provided to quench the excess STA. To break the emulsion, 200 L ethyl ether 
was added and the solution was vortexed and centrifuged at 13,000 g for 5 min. The 
upper ether layer was discarded and the ether extraction was performed for additional 
three times. After the last ether extraction, the residual ether was removed by vacuum 
centrifugation. To this aqueous solution was added 100 L TBST solution (TBS 
supplemented with 0.1% Tween 20), 0.5 g rabbit anti-His antibody and 10 L settled 
protein A magnetic beads. This mixture was incubated at 4 ºC for 1 h with shaking. The 
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supernatant (binding flow-through) was removed and the beads were washed with 200 
L TBST for four times. PCR reaction (10 L) was performed as above on 1 L of 1:10 
diluted binding flow-through, 1 L each of the four washes and 1 L of the beads bound 
with DNA-protein fusion. 
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Appendix III: Primer Sequences 
Removal of Mly I sites from pGFPUV (mutation sites lowercased) 
234_FWD (CL866) TGCATGCCTGCAGGTCGAtTCTAGAGGATCC 
234_REV (CL876) TCGACCTGCAGGCATGCAAGCTTGGCGTAA 
2334_FWD (CL880) TTATCTACACGACGGGGAGcCAGGCAACTAT 
2334_REV (CL877) TCCCCGTCGTGTAGATAACTACGATACGGG 
2836_FWD (CL870) GTGTCTTACCGGGTTGGAtTCAAGACGATAG 
2836_REV (CL878) TCCAACCCGGTAAGACACGACTTATCGCCA 
3322_FWD (CL872) AACGACCGAGCGCAGCGAtTCAGTGAGCGAG 
3322_REV (CL879) TCGCTGCGCTCGGTCGTTCGGCTGCGGCGA 
 
 
Cloning GFPUV into pET28b(+) vector (restriction sites underlined) 
GFPUV_FWD (Nhe I) (CL959) CTAGCTAGCATGAGTAAAGGAGAAGAACTT  
GFPUV_REV (Hind III) (CL960) CCCAAGCTTTTATTTGTAGAGCTCATC 
 
 
Incorporation of F64L and S30R folding-mutations (mutation sites lowercased) 
F64L_FWD (CL930) GGCCAACACTTGTCACTACTcttTCTTATGGTGTT 









S30R_FWD (CL928) ATGGGCACAAATTTTCTGTCcgcGGAGAGGGTGAA 
S30R_REV (CL929) GACAGAAAATTTGTGCCCATTAACATCACCAT 
C48_FWD (CL916) AAACTTACCCTTAAATTTATCACTACTGGAAA 
C48_REV (CL917) ATAAATTTAAGGGTAAGTTTTCCGTATGTTGC 
[a] In case that two deletions/mutations are too close, a special primer including both 
deletions/mutations is designed 
 
 
Generation of mutants with double internal deletions 
P75/D76H_FWD (CL926) TCAATGCTTTTCCCGTTATCATCATATGAAAC 
P75/D76H_REV (CL927) GATAACGGGAAAAGCATTGAACACCATAAGAG 
P75_FWD (CL918)  TTCAATGCTTTTCCCGTTATGATCATATGAAA 
P75_REV (CL919)  ATAACGGGAAAAGCATTGAACACCATAAGAGA 
E172_FWD (CL920) 
TTCAAAATTCGCCACAACATAGATGGATCCGT 
















[a] In case that two deletions/mutations are too close, a special primer including both 
deletions/mutations is designed 
 
 
Removal of restriction sites from pTrcHisA (mutation sites lowercased) 
Bsg6_FWD (CL1089) TTGACAGCTTATCATCGAtTGCACGGTGCAC 
Bsg6_REV (CL1090)  TCGATGATAAGCTGTCAAACCAGATCAATT 
Bsg100_FWD (CL1091) GGAAGCTGTGGTATGGCTcTGCAGGTCGTAA 
Bsg100_REV (CL1092) AGCCATACCACAGCTTCCGATGGCTGCCTG 
Bsg3494_FWD (CL1093) CACCTCCAGTCTGGCCCTtCACGCGCCGTCG 
Bsg3494_REV (CL1094) GGCCAGACTGGAGGTGGCAACGCCAATCAG 
Bsg3694_FWD (CL1095) CATTGCTGTGGAAGCTGCgTGCACTAATGTT 
Bsg3694_REV (CL1096) GCAGCTTCCACAGCAATGGCATCCTGGTCA 
Mme2366_FWD (CL1122) TAAGTCGTGTCTTACCGGaTTGGACTCAAGA 
Mme2366_REV (CL1123) CCGGTAAGACACGACTTATCGCCACTGGCA 
Mme2550_FWD (CL1124) TATCCGGTAAGCGGCAGGaTCGGAACAGGAG 
Mme2550_REV (CL1125) CCTGCCGCTTACCGGATACCTGTCCGCCTT 
Bpm1802_FWD (CL1177) GGTTTATTGCTGATAAATCaGGAGCCGGTGAG 
Bpm1802_REV (CL1178) ATTTATCAGCAATAAACCAGCCAGCCGGAA 
Bpm3481_FWD (CL1192) TGATTGGCGTTGCCACCTCaAGTCTGGCCCTT 
Bpm3481_REV (CL1180) GTGGCAACGCCAATCAGCAACGACTGTTTG 
Bpm3970_FWD (CL1193) AGCGGAACGGGAAGGCGAtTGGAGTGCCATGT 
Bpm3970_REV (CL1182) TCGCCTTCCCGTTCCGCTATCGGCTGAATT 
Sap_FWD (CL1173)  TCAGTGAGCGAGGAAGCGGttGAGCGCCTGATG 
Sap_REV (CL1174)  CGCTTCCTCGCTCACTGACTCGCTGCGCTCGGT 
Note that only Bsg I and Bpm I sites need to be removed for this study. Other restriction 
sites (Mme I and Sap I) were removed to accommodate early tests. 
 
 























Cloning of proK_MbPylT gene into pSup vector (restriction sites underlined) 
pSup_PylT_FWD (ApaL I) (CL1128) 
AACCAAGTGCAGTGATCAAAAGCGGCCGCAAAACTAGTGGCAGCG 




Cloning of proK_MbPylT gene into pYC vector (restriction sites underlined) 
pYC_PylT_FWD (Pst I) (CL1103)  
AAAACTGCAGTTTGTCGACCAAAAAAGCCT 




Cloning of MmPylRS gene into pSup or pBK vector (restriction sites underlined) 
PylRS_FWD (Nde I) (CL609) 
AAAGCGGCCGCAAACATATGGATAAAAAACCACTAAACACTCT 




Generation of MmPylRS mutants for lysine derivatives (mutation sites lowercased) 
PylRS_Y384F_FWD (CL1114) GCGATTCCTGCATGGTCTtTGGGGATACCCT 












Generation of Codon-optimized human Ub (restriction sites underlined) 
SynUb #1 (NdeI) (CL1158) 
GGAATTCCATATGCAGATTTTTGTGAAAACCCTGACCG 
SynUb #2 (CL1159) 
ACTTCCAGGGTAATGGTTTTGCCGGTCAGGGTTTTCACAAA 
SynUb #3 (CL1160) 
AAAACCATTACCCTGGAAGTGGAACCGAGCGATACCATTGA 
SynUb #4 (CL1161) CCTGAATTTTCGCTTTCACATTTTCAATGGTATCGCTCGGT 
SynUb #5 (CL1162) 
ATGTGAAAGCGAAAATTCAGGATAAAGAAGGCATTCCGCCG 
SynUb #6 (CL1163) 
CCGCAAAAATCAGACGCTGCTGATCCGGCGGAATGCCTTCT 
SynUb #7 (CL1164) 
AGCGTCTGATTTTTGCGGGCAAACAGCTGGAAGATGGTCGT 
SynUb #8 (CL1165) 
CTGAATATTGTAATCGCTCAGGGTACGACCATCTTCCAGCT 
SynUb #9 (CL1166) 
CCTGAGCGATTACAATATTCAGAAAGAAAGCACCCTGCATC 





Cloning Ub into pTXB1 plasmid (restriction sites underlined) 





Introduction of TAG stop codons into lysine residues in Ub (mutation site underlined) 
K48tag_FWD (CL1231) CGTCTGATTTTTGCGGGCtagCAGCTGGAAGAT 
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K48tag_REV (CL1232) GCCCGCAAAAATCAGACGCTGCTGATCCGG 
K11tag_FWD (CL1212) GTGAAAACCCTGACCGGCtagACCATTACCCTG 
K11tag_REV (CL1213) GCCGGTCAGGGTTTTCACAAAAATCTGCAT 
K63tag_FWD (CL1214) AGCGATTACAATATTCAGtagGAAAGCACCCTG 
K63tag_REV (CL1215) CTGAATATTGTAATCGCTCAGGGTACGACC 
 
 
Generation of codon-optimized sfGFP (restriction sites underlined) 
sfGFP #1 (Nhe I) (CL966) 
CTAGCTAGCATGATGAGCAAAGGCGAAGAACTGTTTACCGGCGTGGTTCCG 
sfGFP #2 (CL967) 
ATCGCCATCCAGTTCCACCAGAATCGGAACCACGCCGGTAAA 
sfGFP #3 (CL968) 
GGTGGAACTGGATGGCGATGTAAATGGCCACAAGTTTAGCGT 
sfGFP #4 (CL969) 
TCGCCCTCCCCTTCCCCACGCACGCTAAACTTGTGGCCATTT 
sfGFP #5 (CL970) 
GGGAAGGGGAGGGCGATGCGACCAATGGCAAACTGACCCTGA 
sfGFP #6 (CL971) 
TTCCCGGTCGTGCAAATAAACTTCAGGGTCAGTTTGCCATTG 
sfGFP #7 (CL972) 
GTTTATTTGCACGACCGGGAAACTGCCGGTTCCTTGGCCCAC 
sfGFP #8 (CL973) 
GCCATACGTCAGGGTGGTGACAAGGGTGGGCCAAGGAACCGG 
sfGFP #9 (CL974) 
CACCACCCTGACGTATGGCGTGCAATGCTTTAGCCGTTACCC 
sfGFP #10 (CL975) 
TCATGCCGCTTCATGTGGTCCGGGTAACGGCTAAAGCATTGC 
sfGFP #11 (CL976) 
ACCACATGAAGCGGCATGACTTCTTCAAAAGCGCCATGCCTG 
sfGFP #12 (CL977) 
CGTCCGTTCCTGAACATAGCCTTCAGGCATGGCGCTTTTGAA 
sfGFP #13 (CL978) 
GCTATGTTCAGGAACGGACGATCTCGTTTAAGGATGACGGCA 
sfGFP #14 (CL979) 
CCTCCGCACGGGTCTTATAGGTGCCGTCATCCTTAAACGAGA 
sfGFP #15 (CL980) 
CTATAAGACCCGTGCGGAGGTCAAATTCGAAGGCGATACCCT 




sfGFP #17 (CL982) 
GGTGAACCGCATTGAGCTGAAGGGCATCGACTTCAAAGAGGA 
sfGFP #18 (CL983) 
TTGTGCCCCAGTATGTTGCCATCCTCTTTGAAGTCGATGCCC 
sfGFP #19 (CL984) 
GGCAACATACTGGGGCACAAGCTGGAGTACAACTTCAACAGC 
sfGFP #20 (CL985) 
GCGGTGATGTAGACGTTGTGGCTGTTGAAGTTGTACTCCAGC 
sfGFP #21 (CL986) 
CACAACGTCTACATCACCGCCGACAAGCAGAAGAACGGCATT 
sfGFP #22 (CL987) 
CCGAATCTTGAAGTTGGCCTTAATGCCGTTCTTCTGCTTGTC 
sfGFP #23 (CL988) 
AAGGCCAACTTCAAGATTCGGCACAATGTGGAGGACGGAAGC 
sfGFP #24 (CL989) 
GATAATGATCCGCCAGCTGAACGCTTCCGTCCTCCACATTGT 
sfGFP #25 (CL990) 
GTTCAGCTGGCGGATCATTATCAACAGAATACCCCCATTGGC 
sfGFP #26 (CL991) 
CCGGCAGAAGCACGGGACCGTCGCCAATGGGGGTATTCTGTT 
sfGFP #27 (CL992) 
CCCGTGCTTCTGCCGGATAATCATTACTTGAGCACCCAGAGC 
sfGFP #28 (CL993) 
ATTCGGGTCCTTGCTCAGCACGCTCTGGGTGCTCAAGTAATG 
sfGFP #29 (CL994) 
GCTGAGCAAGGACCCGAATGAGAAACGGGATCACATGGTGCT 
sfGFP #30 (CL995) 
CGCAGCGGTCACAAATTCCAGCAGCACCATGTGATCCCGTTT 
sfGFP #31 (CL996) 
GGAATTTGTGACCGCTGCGGGCATTACACATGGCATGGATGA 









sfGFP_V150tag_FWD (CL1074) TTCAACAGCCACAACtagTACATCACCGCC 
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sfGFP_V150tag_REV (CL1075) GTTGTGGCTGTTGAAGTTGTACTCCAG 
sfGFP_V151tag_FWD (CL1276) AACAGCCACAACGTCtagATCACCGCCGAC 
sfGFP_V151tag_REV (CL1277) GACGTTGTGGCTGTTGAAGTTGTACTC 
 
 
Cloning of Ub into pET11a vector (restriction sites underlined) 




Introduction of N346A/C348A double mutations into PylRS (mutation sites lowercased) 
PylRS_ N346A/C348A _FWD (CL1422) 
GAAGAGTTTACCATGCTGgccTTCgccCAGATGGGATCG 




Introduction of TAG codons into STA gene (mutation sites lowercased) 
STA_one TAG_FWD (CL1381) 
CATCATCATAGCAGCGGCATCGAAGGCCGCtagCGCTTAATT 






Cloning of synthetase genes into pIVC construct (restriction sites underlined) 
MjYRS_pIVC_FWD (Nde I) (CL1031)  
AGGAATCCCATATGGACGAATTTG 




Amplification of IVC constructs 
IVC_FWD (CL1353) GATCTCGATCCCGCGAAAT (5' biotinylated) 
IVC_REV (CL1334) GCTAGTTATTGCTCAGCGG (5' biotinylated) 
 
 
Generation of serine suppressor tRNA (SerU) 
SerU #1 (CL1385) 
tcgagatctcgatcccgcgaaattaatacgactcactataGGAGAGATGCCGGAGCGGCT 


















































































































































































































































































































































































































































































MmPylRS Y384F highlighted in red (Y384F underlined) 































































































































Highlighted in red is the ORF of sfGFP with an upstream fusion peptide. The coding 



































































































































































































































































































































































































































































































































Synthetase (shown in yellow) and STA (shown in blue) gene were cloned into pET24a 
plasmid to create pIVC construct. RBSs are indicated as lowcased letters. T7 promoter 
and terminator sequences are shown in green. 
The synthetase gene shown in the following is WT MjYRS and can be replaced by other 
synthetases as well. The STA ORF contains an N-terminal fusion peptide (including a 
His6 tag) and the core STA sequence from residues 13 to 140. One or two amber stop 
codons (TAG) are introduced into STA. The positions of TAG codons are shown by 
































































































































































The ORF for sfGFP is highlighted in red (including an N-terminal His tag and upstream 
fusion peptide). The coding region of sfGFP starts from the shaded ATG codon. 



















































































































































M. barkeri PylT 
GGGAACCTGATCATGTAGATCGAATGGACTCTAAATCCGTTCAGCCGGGTTA
GATTCCCGGGGTTTCCGCCA 
Note: M barkeri PylT (MbPylT) has one nucleotide difference from M. mazei PylT 
(MmPylT) (highlighted in red). In MmPylT, position 42 is a T instead of C. Both MbPylT 
and MmPylT can be readily aminoacylated by M. mazei tRNA synthetase. 
 
































Codon-optimized Ub (SynUb) for expression in E. coli 
 



























Appendix V: Sequencing Results from Transposon 
Mutagenesis 























G4  11 
E5/E6E 3 
F8/T9S 1 
C48  1 
P75/D76H 1 
P75  1 
E172  1 
S175/V176F 1 
A226/A227A 2 





G10  1 
D21  2 
G24  1 
E34  3 
P58  1 
P89/E90Q 1 
T203  1 
Unexpected 
No deletions 
stop codon mutations 
4 bp deletions 
21 
Table S-1. Sequencing results of fluorescent and non-fluorescent clones 
Note: [a] If occurred in two neighboring codons, the 3-bp deletions 
can result in unexpected mutations 
[b] Many mutants have more than one possibility for the 
deletion positions. The numbers indicate the positions in 
the DNA sequence of GFPUV gene. 
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Library characterization of CDM 
Table S-2. Deletions in the 104 sequenced clones 










20 2 -27(3), -17  
D21 (2), G33, G35, T49, N105 (2), L125, 





21 1 -35 
G10 (2), D19 (3), D21 (2), G24 (2), G33 (3), 





21 2 - 
T9 (4), D19 (2), N23 (1), G33 (2), P89, G103 





20 1 -59 
F8 (2), L18 (3), F71 (2), M88, F114 (2), 






-59, -56,  
-40(2), -27 
S2, F8, V12, L18, V22 (2), E34, F71, R80, 
K101, D102, R122, I136, H181, I229 
Note: 
a
 In case of multiple codon deletions, only the first codons are shown 
b 
The C-terminal residue of the leading peptide, which is adjacent to GFPUV, is numbered 
as -1. 
c
 The number of identical clones is indicated in parentheses. 
 
Library characterization of CSM 
Table S-3. Correct mutations in the 104 sequenced clones 
Codon libraries Correct mutations 
One 
D21L, D21G, E32S, Q69L, N149H, N149D, N149R, N149G, 
Y151R, S205H 
Two 
V11H/V12N, V11H/V12H, V22H/N23R, S28N/V29S, 
Y74R/P75L, F83N/F84H, G91L/Y92N, T105H/Y106R, 
N135H/I136R, I161C/K162L, S175L/V176S, S205H/V206L, 
G232S/M233D 
Three 
G10H/V11R/V12H, G10H/V11R/V12H G10Y/V11H/V12R, 
G10G/V11D/V12C, G10Y/V11C/V12V, G10H/V11V/V12Y, 







Appendix VI: Synthesis of UAAs 
Synthesis of OnbLys 
Step 1: synthesis of N-tert-butoxycarbonyl-

N-o-nitrobenzyloxycarbonyl-L-lysine 
First, 1g (4.060 mmol) of N-Boc-L-lysine was dissolved in 6 mL of tetrahydrofuran (THF) 
(0.67 M). The solution was cooled to 0 ºC in an ice bath and then was added 13 mL of 1 
M NaOH. The solution was left stirring for 5 min at the same temperature and then was 
added slowly 900 mg (4.18 mmol; 1.03 eq) of o-nitrobenzyloxychloride over a period of 
10 min. The reaction mixture was left stirring 12 h at room temperature and then cooled 
down to 0 ºC with an ice bath. The prechilled solution was acidified by the addition of 10 
mL of 1 M HCl. The acidified reaction mixture was extracted with 5 mL ether three 
times. The organic phase was discarded. The aqueous phase was extracted with 10 mL 
ethyl acetate for three times, and dried by anhydrous Na2SO4 and finally purified by 
column chromatography (60:30:10 for hexane/ethyl acetate/acetic acid). In total, 0.740 g 




N-OnbLys) was isolated as 
white crystals (Rf: 0.60). The purified product was characterized by NMR and MS. The 
compound signals were consistent with previous study (121). 





N-OnbLys from last step was dissolved in 2 mL of dioxane (0.87M). Then 
was added, under argon atmosphere, 10 mL of 4 M HCl-dioxane (0.04 mol; 23 eq) by 
syringe. The reaction mixture was left stirring under argon and at room temperature over 
2 h. Finally, the solvent was removed by reducing pressure and triturating with ether for 4 
h. Finally, 0.400 g (57% yield) of OnbLys was isolated as the HCl salt and characterized 
by NMR and MS. The compound signals were consistent with previous study (121). 
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Synthesis of OnbSTyr and OabSTyr 
Scheme 1: Structure and synthesis of o-nitrobenzyl thiotyrosine (OnbSTyr) and o-amino 




The synthesis of o-nitrobenzyl thiotyrosine hydrochloride 6 and its reduced analogue o-
amino benzyl tyrosine hydrochloride 7 was started from the known disulfide ester 1 
which was synthesized in two steps starting from toluene disulfide as reported in 
literature (168). Reduction of disulfide bond of 1 in the presence of NaBH4 followed by 
alkylation with o-nitrobenzylbromide 2 or Boc protected aminobenzyl bromide 3  in a 
THF/EtOH mixture (1:1) at room temperature furnished corresponding sulfides 4 (yield 
82%) or 5 (yield 40%). Boc protected aminobenzyl bromide 3 was synthesized from 
commercial product aminobenzyl alcohol in two steps according to the reported 
procedure (169). Finally, acetamidomalonate 4 or 5 was refluxed in a mixture of aqueous 
6 M HCl and acetic acid (1:1) to obtain corresponding amino acid hydrochlorides 6 (yield 
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